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ABTRACT 
Restless Legs Syndrome is a sensorimotor disorder that is also classed as a type of sleep disorder 
due to the RLS motor and sensory symptoms interfering with sleep.  Over the last 20 years research 
investigating RLS has demonstrated that there is an association with depression or an increase in 
depressive symptoms. The purpose of this review is to critically assess the methods used to 
measure RLS severity and depression in the research literature and investigate the impact they have 
on the research findings.  A number of important factors were identified: sampling; objective 
versus subjective measures; primary versus secondary RLS; reliability of measures; and 
responsiveness to potential confounds. These factors contributed to a quality rating scale devised to 
assess the quality of each of the papers included in the review. Following searches of electronic 
databases and key journals, 18 papers met inclusion criteria; nine epidemiological studies and nine 
clinical studies. The studies were reviewed in detail with respect to the methods they used and how 
these methods affected the level of association found between RLS and depression.  The majority 
of studies utilised mainly subjective measures of RLS severity, sleep quality and mood. The 
reliability of the measure of depression was questionable in many studies. Factors which appeared 
to influence the association between RLS and depression were the methodology (e.g. subjective 
versus objective), the measure of depression, the RLS diagnostic criteria used, and the population 
participants were recruited from. It was unclear from the current literature how other factors such 
as medication and periodic leg movements during sleep influenced the level of association found.  
Recommendations for future research were then proposed.  
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Introduction 
Professor Karl Ekbom first coined the term Restless Legs Syndrome (RLS) in 1944.1 The 
International Classification of Sleep Disorders (ICSD-R) produced by the American Academy of 
Sleep Medicine (AASM) 2 classified RLS as a type of dyssomnia, which causes either excessive 
sleepiness or difficulties in initiating or maintaining sleep. RLS is categorized further as an intrinsic 
sleep disorder recognising that the difficulties in initiating or maintaining sleep are due to factors 
arising from within the body. RLS is more common in women than in men and age of onset is 
typically between 30-40years old, with increasing symptom frequency and intensity with age. The 
prevalence in western populations, such as Europe and America, is estimated between 5 and 15%. 3 
 
The essential features of RLS are uncomfortable sensations in the legs, usually occurring in the 
evening and when at rest, accompanied by an irresistible urge to move the legs. The ICSD 
highlights the characteristic feature of partial or complete relief from symptoms upon leg 
movement and return of the symptoms when legs movements stop.2 The feelings usually occur in 
both legs between the ankle and knee, although, in some cases RLS can also present in the feet, 
thighs or arms. The symptoms can last for a few minutes or several hours prior to sleep and 
therefore can disturb sleep onset. Most people with RLS are usually able to sleep for several hours 
and generally do not complain of excessive daytime sleepiness.2  However, RLS does appear to be 
associated with emotional distress and in the last 20 years there have been numerous studies 
investigating the impact of RLS on psychological functioning.  
 
Association with Depression 
In severe cases, RLS is associated with significant anxiety and depression. People have attributed 
negative psychosocial outcomes, such as divorce, to their RLS. One study showed that as many as 
38% of RLS patients had suicidal thoughts in relation to their RLS. 4  
 
A review of the literature by Picchietti & Winkelman (2005)5 found that depression symptoms are 
common in adults with RLS. However the relationship between RLS and depression is a complex 
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one. As many of the diagnostic criteria for RLS and depression overlap1, this increases the 
importance of the methods used in studies to measure depression and RLS severity. Also 
antidepressants have been found to aggravate RLS symptoms and this creates a confound in this 
research. There have been no reviews to date that critically assess the methods used to measure 
RLS severity and depression. 
 
Standard Diagnostic criteria for RLS 
 Minimal diagnostic criteria as outlined by the International RLS Study Group in collaboration with 
the National institutes of Health were published in 2003.6 This publication is the result of a 
workshop attended by experts in RLS, epidemiology and questionnaire design. The group 
discussed and agreed upon four essential criteria for a diagnosis of RLS. Criterion1 is an urge to 
move the legs, usually accompanied or caused by uncomfortable and unpleasant sensations in the 
legs. Criterion 2 requires that the urge to move or the unpleasant sensations begin or worsen during 
periods of rest or inactivity, such as lying or sitting. Criterion 3 states that the urge to move or 
unpleasant sensations are partially or totally relieved by movement, as long as the activity 
continues. And finally, Criterion 4 stipulates that the urge to move or unpleasant sensations are 
worse in the evening or night than during the day or only occur in the evening or night.  
 
The participants in the above workshop also agreed upon 3 supportive clinical features which were 
not essential to a diagnosis of RLS but can help researchers and clinicians in making their decision. 
These are as follows: a family history of RLS; initial response to dopaminergic therapy; and 
periodic limb movements during sleep or wakefulness.  
 
Primary versus secondary RLS 
In order to elucidate the unique burden of RLS it is important for studies to distinguish between 
patients with primary and secondary RLS. Primary or idiopathic RLS is when the symptoms occur 
spontaneously, without an obvious medical complaint or injury that may account for the 
                                                 
1
 Of the 9 symptoms of depression listed in DSM-IV, 4 of them could be a consequence of RLS: 
insomnia/hypersomnia; fatigue; psychomotor agitation or retardation; and diminished ability to concentrate 
or indecisiveness 
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symptoms.7 Conditions such as kidney failure, diabetes, arthritis, anaemia can also cause people to 
develop RLS symptoms.3 RLS is also common in pregnancy.8 If studies do not determine whether 
the RLS is primary or secondary then they cannot state that any elevated levels of psychological 
distress are due to the RLS as they could be partly or wholly resultant from a comorbid condition. 
For example diabetes is also associated with depression.9 Similarly studies should aim to rule out 
RLS due to pregnancy (unless specifically looking at this) as this type of RLS is normally 
temporary and resolves once the mother gives birth and mineral levels return to normal.  
 
Severity (population) 
The population under investigation is understandably a significant factor in the level of severity of 
RLS reported. Studies have used a variety of methods to recruit participants. Many epidemiological 
studies recruit from random community samples. In doing so, they often include people with RLS 
who have not sought and do not intend to seek treatment. Other studies exclusively use participants 
that have been patients at a sleep centre or clinic. These participants are potentially experiencing 
symptoms at a greater frequency or increased intensity. This could introduce bias in terms of the 
impact that RLS has that may not generalise to the total RLS population. Therefore its is important 
to examine what time of sample was recruited as this will most likely have an impact on the level 
of incidence and the level of severity. This in turn may have an impact on the level of association 
with comorbid mood disorders found.  
 
Medication 
An important factor in RLS research is the involvement of pharmacological interventions for 
depression. Antidepressants, such as Selective Serotonin Reuptake Inhibitors (SSRIs), have been 
shown to aggravate RLS symptoms.10 The dopamingeric system is thought to play a role in both 
RLS and depression.11,12 SSRIs act on the serotonin neurotransmitters to increase the levels of 
Serotonin in the synapse. In the acute phase of their use they also decrease the amount of 
dopamine.13 A dopamine deficiency has been suggested as one of the biological causes of RLS. 
People with RLS nearly always show an initial positive response to either l-dopa or a dopamine-
receptor agonist at low doses, although this initial response is not always maintained.6 
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It is important that any study looking at the association between RLS and depression takes 
antidepressant use into account, particularly if as suggested, people with RLS are more likely to be 
depressed, they may also be more likely to be prescribed anti-depressant medication.  
 
PLMS and PLMD 
Periodic Leg Movements during Sleep (PLMS) are described as extensions of the big toe followed 
by dorsiflexions of the foot sometimes with flexion of the knees and hips and they occur in 80% of 
people with RLS.14,15 These movements can also be observed whilst awake during periods of 
inactivity. PLMS and periodic legs movements during wakefulness (PLMW) are usually measured 
by surface electromyogram (EMG) channels placed on the right and left anterior tibialis muscle 
during a Suggested immobilization Test (SIT).16 Not all people with RLS experience PLMS and 
PLMS are a feature of other disorders such as Periodic Limb Movement Disorder (PLMD).2 Often 
studies will combine RLS and PLMD; however PLMD does not have the same subjective 
sensations and associated urge to move. Therefore any possible psychological impact of these two 
disorders may not necessarily be a result of a common mechanism. Support for this suggestion is 
provided in a study by Inhoue et al17, which employed polysomnography (PSG) and the SIT and 
compared subjective sleep quality in RLS with PLMD. They found that scores on the Pittsburgh 
Sleep Quality Inventory (PSQI) were much higher (reflecting poorer sleep quality) in the RLS 
group than in the PLMD group (p<0.01). On the PSG variables, the PLM-arousal index was 
significantly higher in the group with both PLMS and RLS compared with the group with PLMD 
(p<0.01) despite similar PLM index values between the two groups. Consequently, it would be 
helpful for studies to measure PLMS, where they occur in conjunction with the subjective 
sensations of RLS, especially as they are classed as a supportive clinical feature of RLS.6 
 
Objective & Subjective measures of RLS Severity 
Laboratory measures, namely PSG and SIT have been used as a method of determining RLS 
severity. The PLM index during sleep (PLMs per hour of sleep) and wakefulness (PLMs during an 
hour of voluntary immobilisation) are used as indicators of RLS severity. A new method has been 
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developed to measure PLMS with actigraphy which is less intrusive to patients. This technique 
involves the patient wearing two actigraphy watches on each of their feet, at home, for a period of 
three nights and excellent sensitivity and specificity has been reported (Sensitivity, 100%; 
Specificity, 97.1%).18  
 
The IRLSSG19 have developed a rating scale to measure self-reported severity or RLS – the 
International Restless Legs Study Group Rating Scale (IRLS). Garcia-Borreguero et al20 performed 
initial validation studies of the measure and found that the IRLS correlated significantly with 
PLMS and PLMS-arousals during PSG, as well as PLMW during the SIT(all r=0.4; P<0.01). This 
promising finding adds support to the IRLS and its use in clinical trials. Ideally however, studies 
should strive to measure both objective and subjective RLS severity whenever possible.  
 
Measure of depression/ reliability of diagnosis 
Depression and in particular in relation to a specific condition such as RLS is likely to be 
multifaceted. There may also be alternative factors in the construct due to the new context of 
dealing with a motor disorder that feels out of the person’s control and has a detrimental impact on 
their sleep and social lives. Therefore it would be advantageous for studies in this area to use 
multiple modalities to assess depression.  
 
The diagnostic criteria used are also important. Some studies may use the DSM-IV (Diagnostic 
Statistical Manual, 4th Edition) whilst others may rely solely on inventories that assess the self-
report components of depression. A clinical interview by a trained clinician would be useful to 
explore whether there is an adequate correlation between the measures as you would expect if there 
are truly measuring the same construct.  
 
Depression in adults has been studied extensively using multiple modalities. Preferred methods that 
have been widely used are self-report measures such as the Beck Depression Inventory21 and 
clinician rating scales, such at the Hamilton Rating Scale for Depression22. The use of standardised 
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assessment measures has its advantages and disadvantages. Each of these measures has already 
been tested and reliability and validity are easily discovered.  
 
In any study, measures should be selected following consideration of the construct that the 
investigators are hoping to assess, the psychometric properties of a measure and the sensitivity of 
the measure to detect change. It is also an important consideration when measuring a construct such 
as adult depression is whether to use obtrusive and reactive measures, self-report inventories 
generally fall into this category, or unobtrusive measures such as medical records. The awareness 
of the participant that they are being assessed can modify their performance on a particular measure 
and is said to be reactive.23 It can help to reassure participants that their answers will remain 
anonymous and this may increase their openness about their symptoms. Unobtrusive measures 
have increased external validity as they are not based on laboratory, contrived situations, instead a 
snap shot of real-life circumstances. In particular medical records have the advantage of not being 
subjected to the bias of both the participant’s own motivations and the experimenter’s hypothesis. 
23
 
 
Aims  
The present review aims to systematically gather and evaluate the literature which investigates the 
association of depression and restless legs syndrome. There are two questions of particular interest 
given the issues outlined above:  
 
1. How does the methodology of the studies affect the reported levels of association found 
between RLS and depression? 
 
2. Do specific methodological issues have a positive effect on the level of association 
reported between RLS and depression? 
 
With a growth in the research being conducted within the area of RLS and its correlates, it is 
important to explore in more depth the evidence surrounding an increased risk of depression. 
Looking critically at the methods used should aid development of a strategy for measuring the 
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prevalence of depression in RLS, which will help to answer the questions surrounding the different 
theories that account for the association.  
 
Methods 
Search strategy 
The following databases were search electronically using the terms [Depression] or [Depressive 
symptom$] or [psychological distress] linked to [Restless legs$] or [RLS] or [Periodic leg 
movement$]: Ovid MEDLINE (R) [1980 to 2007], All EBM Reviews, CINAHL [1982 to 2007], 
EMBASE [1980 to 2007], PsycINFO [1985 to 2007], ScienceDirect [1980 to 2007]. Key journals 
were electronically searched, including Sleep Medicine Reviews and Sleep. The reference section of 
each article meeting criteria was checked for additional sources. Additionally, studies which had 
cited included studies were identified and examined.  
 
Types of Studies 
Epidemiological and clinical studies investigating the association between restless legs syndrome 
and depression or depressive symptoms were considered. Studies were selected for entry according 
to the inclusion and exclusion criteria outlined in Table 1.  
 
INSERT TABLE 1 
 
Assessment of Study Quality 
To assess the methodological quality of each study, data were extracted from each articles and 
rated on a 20-item scale (see table 2) which was devised using items adapted from the Scottish 
Intercollegiate Guidelines Network (SIGN) number 5024 and the Newcastle-Ottawa Assessment 
Scale25.  The majority of the items had a 3-point scoring system of 0, 1 or 2 which were allocated if 
studies did not meet, partially met, or did meet quality criteria respectively. The items related to the 
measurement of RLS and depression were rated separately, based on the measures and diagnostic 
criteria that were employed by the study. Each item was of equal weighting and total scores 
expressed as an integer between 0 and 1. The quality assessment process was repeated by an 
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independent reviewer and differences in ratings were resolved through discussion. The total scores 
from both reviewers were entered into a SPSS Version 15 database and the inter-rater correlation 
coefficient calculated using Spearman’s Rho (rs= .93) which indicated that inter-rater reliability 
was high.  
 
Results 
The electronic search retrieved 370 studies of which 340 were discarded based on the title and/or 
the abstract. Figure 1 illustrates the results of the study selection process. A summary of the 
excluded studies and the reasons for exclusion can be seen in Table 3.  
 
Of the remaining studies that were included in the review, nine were epidemiological studies26-34 
(see Table 4) and eight were clinical studies35-42 (see Table 5).  Of the clinical studies, only 3 were 
case-control studies. Finally there was a study by Winkelmann et al (2006)43 which reported results 
of an epidemiological survey and a sub-sample of laboratory based findings. Further breakdown of 
the quality rating scores into the areas covered in the instrument can be seen for epidemiological 
and clinical studies in Tables 6 and 7 respectively. 
 
Epidemiological studies 
The total of all samples in the epidemiological studies is 50,520 (See Table 4).  The age range of 
these studies is 18-83. Unfortunately there were insufficient data to calculate the gender 
distribution of the overall sample. The mean quality rating score for the epidemiological studies 
was .47 (range=.20-.775; see Table 6). Each of these studies will now be examined. 
 
Alattar et al26 found that in a primary care sample (n= 1943), those people suffering symptoms 
suggestive of RLS were significantly more likely to have experienced depression in the previous 10 
years (OR, 2.84; p<0.001). This study used a brief screening questionnaire aimed at categorising 
patients based on their answers into various sleep disorder symptoms. It is not clear from their 
findings how many of the patients endorsing the RLS symptoms were also endorsing symptoms 
related to other sleep disorders.  The population in this study were asked to fill in the questionnaire 
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when attending their primary care physician. Therefore this sample may have elevated levels of 
depression compared to a community sample. The study only achieved a 65.3% response rate but 
did not make comparisons between the participants and non-participants to establish their 
similarities or differences. It is not clear from the study whether they have ruled out secondary RLS 
or in fact include this within their sample of people with symptoms suggestive of RLS. Diabetes 
(17.8%) and arthritis (33.3%) are just some of the health conditions present in the sample. Thus 
some of the RLS could be secondary. The authors use a single question to assign patients to the 
RLS symptom group which only includes one of the IRLSSG’s criteria for RLS. The authors 
concluded that the study demonstrated that people with depression were at increased risk of RLS 
and should be questioned for its symptoms. However a third of the sample responded positively to 
the RLS question which is far greater than the prevalence rates found in other studies and could be 
indicative that the specificity of the measure was questionable. There is no information on the 
sensitivity and specificity of the questions employed. They use self-report of depression over the 
last 10 years which may be subject to a response bias and does not give a current measure of level 
of depression. The study does include a question related to days in the previous month were mental 
health was poor but this is not specific to depression. Table 6 shows that the study scored no points 
for the clinical or outcome measures. This study is interesting as it employed a primary care 
population in which one might expect an increase in many of the conditions they screened for but 
unfortunately the design of the study makes it impossible to isolate and sensitively classify the 
separate sleep disorders, thus only making general conclusions possible.  
 
Two studies27,28 presented in Table 4 originate from the RLS Epidemiology, Symptoms, and 
Treatment (REST) program which investigated the impact of the RLS symptoms on individuals 
who where classified as having RLS and deemed most likely to seek treatment. Both of these 
studies scored disappointingly low on the quality rating scale (See Table 4). Allen et al27 report 
their findings from a large multinational population study which used current diagnostic criteria for 
RLS. They used a panel or RLS experts to define a subset of “RLS sufferers” who were likely to 
warrant medical treatment, as those whose symptoms occurred at least twice weekly during the past 
twelve months and were reported to be moderately or extremely distressing. Using this method of 
 19 
classifying people with RLS, they identified 2.7% of the population as warranting medical 
treatment. Twenty-six percent of this subset of the sample reported a tendency to become 
“depressed/low” in mood, although only 2.6% of the sample reports this as the most troublesome 
symptom. The study obtained a very high response rate (95%) but fails to exclude secondary RLS 
and the authors do not screen for other sleep disorders such as sleep apnoea.  
 
Hening et al28 conducted the companion REST study which focuses on the impact of RLS in a 
primary care population in the same countries as the Allen et al study.  They recruited 23,052 
patients into the study from 182 primary care physicians over a two week period. Using similar 
RLS criteria as the Allen et al study they found that 59.9% of those who were presumed to require 
treatment for RLS (n=551) reported a tendency to become low or depressed. The lack of 
standardised criteria for either RLS or depression, as well as confounding factor not being 
considered in the design gives this study the lowest quality score (See Table 4). However an 
interesting addition to this study is the physician screening questionnaire. From this data they found 
that of the people presumed to have RLS, only 209 were reported to have discussed these 
symptoms to with their physician and from those consultations only 24.9% were given a diagnosis 
of RLS and 5.3% were diagnosed with depression. This indicates that some diagnoses of 
depression may in fact be due to physicians misdiagnosing RLS. This study does not separate those 
with secondary and idiopathic RLS and as a result the figure of 59.9% of depression may be 
elevated, especially given the primary care sample.  
 
The results of a National Sleep Foundation (NSF) poll conducted in the United States in 2005 was 
reported by Phillips et al29, focusing on the prevalence and correlates of RLS (see Table 4). 
Unfortunately the authors do not state the level of association that they found between RLS and 
depression. They conclude that the presence of depression was associated with the endorsement of 
RLS symptoms (p<0.05) but do not elaborate of the strength of this association. They do not use all 
the diagnostic criteria in their telephone interview, omitting the criteria related to symptoms being 
worse during periods of inactivity and being relieved by movement. This study, although a random 
sample of the general population, does not reliably give estimates of the prevalence of RLS, nor 
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does it give sufficient details of any of the correlates they investigated, accordingly the quality 
rating score for this study is low (.225) (see Table 6). A positive aspect of the study was the 
inclusion of a measure of risk of sleep apnoea but again they did not use this to isolate the RLS 
group by excluding sleep apnoea and look at the association with mental health issues.  
 
Rothdach et al30 conducted a population-based survey of older adults in Germany, using two RLS-
trained physicians to assess the prevalence of RLS in face-to-face interviews.  They found that 
older adults (66-83years) with RLS had significantly higher scores on the Center for 
Epidemiological Studies Depression Scale (CES-D) than those without RLS (11.6 vs. 7.8; p<0.01) 
(see Table 4). However, the mean scores did not reach clinical the suggested clinical cut-off of 16. 
The authors also found that there was a significant association between RLS and depression using 
the CES-D but only in men (OR, 13.06; p=0.01). The authors state that their study in the first to 
apply minimal diagnostic criteria for RLS. All of the participants in the study were given a full 
neurological examination to test for Parkinson’s Disease and information on their medical history 
was gathered. Investigators also noted use of cigarettes and alcohol, as well as BMI. However they 
do not appear to include screening items to rule out comorbid sleeping disorders which could 
confound the results. They took note of the medications that participants were prescribed and found 
that the use of medication was not significantly different between people with and without RLS.   
 
The overall sample is fairly small (n=369) with a response rate of 60% and therefore the number of 
people identified as having RLS was only thirty-six: 12 men; 24 women. These numbers are quite 
small for a population based survey, however the study scored highly on the study population 
component of the quality rating scale suggesting that this was a fairly representative sample (see 
Table 6). This sample is different from other studies though in the age of participants. Therefore the 
lack of an association of depression with RLS in females could perhaps be due to the different 
experiences of the older generation. They are not required to get up for work at a set time and 
therefore sleep disturbance caused by RLS may not have the same impact on daily functioning and 
mood. People also require less sleep as they get older and this could also be factor in the results. 
Despite only finding an association between men with RLS and depression, the authors concluded 
 21 
that RLS is a frequent syndrome in the elderly with considerable impact of self-perceived mental 
health.  
 
Another of the epidemiological studies utilised face-to-face interviews and carried out neurological 
examinations on a Turkish community sample of adults aged over 17 years. Sevim et al31 
conducted a sample size justification based on previous prevalence studies and weighted the 
randomisation according to gender, age and residence (e.g. a town or city population). They then 
employed neurologists, who were also trained in the Hamilton Rating Scale for Depression (HAM-
D) to conduct all the interviews. They achieved a high response rate (92.4%) with 3234 people out 
of the 3500 approached participating in the study. The authors give details of the reasons for non-
participation and it appears unlikely that there was any bias in the selection of the sample. The 
neurologists assessed participants for differential diagnoses such as other neurological disorders 
that can mimic the symptoms of RLS. The results of the interviews, which took place over a 
6month period, identified 103 people with RLS. An age and gender matched control group was 
taken from the same district as those diagnosed with RLS. The results on the HAM-D of these two 
groups were compared and a significant difference was found with those with RLS scoring higher 
on the scale than controls (9.27 vs. 5.88; p<0.001). This study was the highest rated on the quality 
rating scale (see Table 4) and demonstrated a medium to large effect size in comparing depression 
scores between people with RLS and healthy controls (Cohen’s d = 0.67). 44 
 
The HAM-D has been a gold standard clinician rated measure for depression since its development 
in 1960, however some have criticised the psychometric robustness of the measure, questioning its 
reliability and validity.45 Sevim and colleagues31 do not report on the inter-rater reliability for the 
HAM-D in their study. However they do report that the 4 questions based on the IRLSSG 
diagnostic criteria enjoyed excellent levels of agreement between the 4 raters (Intra-class 
Coefficient = 0.92, p<0.001). This study also used the IRLS and found a significant correlation 
with scores on the HAM-D (r= 0.201, p=0.04), which accounts for 4% of the variance. They also 
took into account co-morbid disease, such as diabetes mellitus, finding that depression scores did 
not vary with the presence of comorbid disease, or indeed smoking or socioeconomic status. The 
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quality score for this study was high indicating the strengths in design and procedure of the study. 
The authors’ conclusions state that RLS was probably the major determining factor for the 
depression scores, with higher scores correlating with more severe RLS. However despite the 
important findings of this study, the lack of data on the onset of depressive symptoms in relation to 
the onset of RLS means that they cannot make conclusive statements regarding causality.  
 
A Dutch epidemiological study by Spoormaker & van den Bout32 randomly targeted 800 homes 
throughout the Netherlands according to geographical distribution. They sent a postal survey to be 
completed by the first adult of the household. The survey consisted of: the SLEEP-50, a scale 
devised by the authors and in the preliminary stages of validation; the Dutch version of the SCL-
90; and a self-rating scale for PTSD. The SLEEP-50 was reported to have good overall sensitivity 
and specificity however they do not report the predictive validity of the measure in identifying 
those with RLS. They also do not mention whether the scale component related to RLS is based on 
the ICSD or IRLSSG criteria. The main analysis of the study is focused on the correlation of the 
various sleep problems assessed by the SLEEP-50 and the mental health complaints reported on the 
SCL-90. Unfortunately the authors do not report how many of the 402 respondents were classified 
as having RLS. The study suffered from a poor response rate (50.3%) and this limits the reliability 
of the results. The shortcomings of their sampling procedure were reflected by a low score on the 
study population component of the quality rating scale (see Table 6). No significant correlations 
were revealed between RLS and mental health complaints, including depression. Importantly, they 
do not state whether the SLEEP-50 has any items regarding medication. It appears that this has not 
been taken into account in this study and given low returns it may be that those who replied had 
already obtained a diagnosis and may have been receiving treatment. This is of course speculative 
but highlights the importance of medication in studies investigating the impact of RLS.  
 
A further epidemiological study by Sukegawa et al33 was conducted using a sample derived from 
all the elderly residents belonging to a Seniors Association in Izumo City, Japan. This study scored 
above average on the quality rating scale (see Table 6) which is attributable to the researchers 
investigating the differences between those with and without depressive symptoms. The authors do 
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not report the response rate, however only 25% (n= 2023) of the sample responded to all items on 
the questionnaires distributed, which included the Japanese versions of the PSQI and the Geriatric 
Depression Scale (GDS). They divided the respondents into two groups based on their responses to 
the GDS; the depressive group consisted of those who scored ≥11 (n= 634) and the control group 
scoring < 11 (n= 1389). The depressive group were found to be 2.5 times more likely to suffer from 
RLS (p<0.05). Following a multiple logistic regression, dividing the groups by age and gender, 
only the younger elderly men (65-74years) showed a statistically significant association of RLS 
with depression. These results are consisted with those of Rothdach et al30 . A difficulty with this 
study was the use of some but not all the criteria for classification of RLS. The respondents were 
only required to endorse one of the diagnostic criteria with an element of symptom frequency 
added. The authors attempted to manage this by saying that RLS was only “probable”. However 
this increases the likelihood that many of the people classed has having probable RLS may not in 
fact have the syndrome. They also do not rule out other health conditions that could be causing the 
symptoms, thus placing doubt over the validity of their results.  
 
The last study presented in Table 4 by Ulfberg et al34 investigated the prevalence of RLS in a 
random sample of 4000 men, aged 18-64 years, living in central Sweden. As part of their study 
they also investigated the association between RLS and neuropsychiatric and somatic disease. A 
total of 2608 men responded to the questionnaire giving them a low response rate of 66%. The 
main method involved a postal survey; however 10% of non-responders were contacted by 
telephone to determine the prevalence of RLS among them. They calculated that 5.8% of the 
sample had RLS using questions based on the ILRSSG diagnostic criteria and translated into 
Swedish. They employed a crude measure in relation to the presence or absence of depressive 
symptoms, asking the men “are you affected by depressed mood without any recognisable reason?” 
Using multivariate logistic regression they found that men responding positively to all 4 RLS 
diagnostic questions were 2.6 times more likely to report depressed mood (OR, 2.6; p<0.05). They 
also found a significant association with social isolation (OR, 2.6; p<.05). Unfortunately they did 
not screen for conditions that increase the risk of secondary RLS. Therefore it is unclear whether 
the RLS respondents were suffering from any other conditions which may cause RLS symptoms 
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and also affect their ability to cope with sleep disturbance, a common side effect, confirmed by the 
sample (problems initiating sleep OR equals 3.2). Unfortunately, like many of the other 
epidemiological studies, the authors did not take into account use of medication. They did not 
exclude another important confounding variable – the presence of sleep apnoea. However they did 
include witnessed apnoeas along with smoking and alcohol consumption in the multivariate 
analyses. Ulfberg et al34 concluded that although their high figure of depressed mood was based 
solely on self-report and not secured by an independent diagnosis, they demonstrated that RLS was 
associated with several somatic and neuropsychiatric symptoms. They avoid drawing conclusions 
specifically on the association between RLS and depression.  
 
Conclusions from epidemiological studies 
Eight out of nine of the epidemiological studies found an association between RLS and 
Depression.26-31,33,34 Examining the differences between Spoormaker et al’s32 study, which did not 
find an association, and the other studies revealed a unique difference in the way people with RLS 
were recruited to the study. The authors employed a new measure which focused on sleep disorders 
generally, lacking established reliability and validity and it is unclear whether they incorporated 
internationally recognised criteria for RLS.   
 
The two largest studies, one of a community sample27, and the other of a primary care sample28  
demonstrated using the same criteria for RLS, and marginally different measures of low mood that 
the percentage of people in the primary care RLS group reporting depressed mood was double that 
of the community RLS group. It is likely that both of these studies overestimated the level of 
depression due to the absence of a defined nosology. However the results of these studies 
demonstrate that people with RLS presenting at their primary care centres are more likely to report 
depression than a community sample. Given the same strict criteria for RLS used in both studies 
was regarded as selecting those who would be likely to require treatment, the difference in 
depression scores are unlikely to be due to a difference in severity of RLS but rather a combination 
of the other medical problems that people may affecting their quality of life.  
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Other studies failed to differentiate between primary and secondary RLS. The design and 
methodology of the majority of epidemiological studies prevented elucidation of spontaneous 
symptoms and those with a known aetiology. Only one of the studies31 carried out a neurological 
examination to test for conditions that could mimic RLS. Whilst they did not exclude people with 
relevant comorbid conditions, (e.g. diabetes, renal disease) they analysed whether the presences of 
a cormobid condition changed the level of depressive symptoms. This was not the case. There is a 
dearth of population based studies which include only primary RLS in order to discover the unique 
burden of the syndrome in a community sample. The results of the Sevim et al31 study suggests that 
there will be elevated levels of depression even when secondary RLS is excluded. This study also 
demonstrated a medium to large effect size. Further population based studies identifying those with 
primary RLS are needed. 
 
Medication was taken into account in only two out of the nine studies.28,30  However they did not 
compare results of those currently taking medication, for example psychotropic or hypnotic 
medication, with those who were medication free.  
 
Unsurprisingly none of the above population based studies applied laboratory based measures or 
actigraphy as this would almost certainly have been too expensive. It is of note here that a further 
study43 (see table 5) has used both a population based survey and selected a quasi-random subset of 
the sample to partake in laboratory assessments which provides a potential solution to the problem 
of cost. This study shall be discussed in a later section of the review. 
 
With regards to subjective RLS severity, the majority of the studies use symptom frequency as a 
measure of severity. However this says nothing about the intensity of symptoms. Only one study 
used the IRLS31 and found a positive correlation between IRLS and a standardised measure of 
depression. Although statistically significant, this association was small and the correlation 
coefficient corresponds with a below medium effect size.  The remainder of the studies do not 
directly compare severity, however measured, with the level of depressive symptoms.   
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All of the studies used obtrusive and therefore possibly reactive measures of depression/low mood. 
Just under half of the studies used standardised measures of depression. However, none of the 
measures were developed specifically for people with RLS and yet none of the studies report the 
reliability of the measures for their own data. Furthermore, they do not use more than one method 
of assessing depression and low mood. This would be impracticable in population based studies, 
although not impossible. Single measures prevent verification of the construct validity of the study. 
 
The standardised measures appear to give a more conservative estimate of depression in RLS 
groups. Studies using the CES-D found significant differences between the RLS and non RLS 
groups, yet the means of both these groups failed to reach the clinical cut off points. Single 
questions regarding mood may vastly overestimate the psychological distress in this group as they 
are often quite vague and could be misinterpreted as enquiring about normal fluctuations in mood; 
state rather than trait.  
 
Certainly from the above examination of these studies it appears that the measure of depression is 
an important factor to the level of association found between RLS and depression. The population 
recruited from is also important. It is encouraging that two studies30,33 which used similar criteria 
for RLS, and a similar sample (older adults), found a similar pattern of significance on a standard 
measure of depression. They demonstrated that the adjusted OR was only significant in men. This 
is not replicated in the adult sample (18-65yrs), which could imply that age is also a factor in the 
level of association between RLS and depression. Both women and men of working age with RLS 
are found to have elevated levels of depression, whereas in the older sample only men appear to 
have an elevated level of depression. 
  
Clinical Studies 
Together the clinical studies yield an overall sample size of 741(range of n=39-218) (See Table 5).  
Three of the clinical studies are case-control studies35,40,42, whilst the remainder are uncontrolled 
cross-sectional studies36-39,41,43. The mean quality rating scores for the case-control and uncontrolled 
clinical studies were .63(range=.55-.675) and .48(range=.275-.625) (see Table 7).  
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Case-control studies 
The first of the clinical studies presented in Table 5 by Banno et al35 compared RLS patients who 
attended a sleep clinic with 4 age, gender and socioeconomic matched controls taken from the 
Province of Manitoba Health Database. The total number of RLS patients was 218 and there were 
872 controls. The methodology of the study was reliant on an unobtrusive measure - medical 
records, thus reducing the influence of social desirability.  Patients were diagnosed with RLS 
according to the ICSD criteria. The investigators looked at all diagnoses that had been given to at 
least 4 people of each gender, giving them a total of 81 diagnoses for men and 94 women. This was 
a large number of comparisons and a Bonferroni correction was applied in the analyses. All 
diagnoses in the database were based on the ICD 9CM. The results demonstrated that male RLS 
patients were 5.3 times more likely to have a positive history of diagnosis of affective psychosis, 
depressive disorder not otherwise specified and neurotic disorder, whilst female RLS patients were 
2.9 times more likely to have the same diagnoses (both ORs were significant at the 0.001 level). 
However the inclusion of several diagnostic categories makes comparison with other studies 
difficult.   
 
An advantage to the design of this study was the access to reliable information on prescribed 
medication. Fourteen of the male RLS patients were prescribed antidepressants and thirty-one of 
the female patients were also prescribed anti-depressants.  However this was not entered into the 
analyses to see what impact if any it might have had on the results. Conversely a problem that 
arises from the design in this study is that they are unable to establish that controls are not cases. 
Given the well-documented under recognition of RLS by primary care physicians28 it could be that 
a proportion of the controls have RLS and it is yet to be diagnosed; although the use of 4 controls 
for each patient should help to circumvent this problem. The population of RLS patients in this 
study had been referred to a sleep clinic due to their sleep problems and therefore the results of the 
study may not be generalisable to other experiencing RLS at a less severe level. This problem with 
sampling is reflected in the study’s low score on the study population component of the quality 
rating scale (see Table7). In spite of this issue, Banno et al35 conclude that the results of this study 
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suggest that RLS patients are more likely to have been diagnosed with depression and that patients 
presented with depression should be have a sleep history assessment as they may require treatment 
for RLS. 
 
The second case-control study was of good quality (see Table 5), particularly in their use of 
objective laboratory measures for assessing the RLS patients. Saletu et al40 compared 33 RLS 
patients with age and sex-matched healthy controls.  All patients underwent a complete 
neuropsychiatric and general medical evaluation, including serum chemistry and laboratory tests. 
Patients were excluded is there was evidence of a medical or psychiatric disorder that might 
account for the primary complaint. Importantly, patients with sleep apnoea, signs of secondary 
RLS, pregnant woman, patients with a history of drug abuse, patients requiring psychoactive 
medication, were all excluded from the study. Therefore the patients in this study are likely to have 
the idiopathic form of the condition. They also used standard criteria for the diagnoses of RLS 
(ICSD) and a standardised measure of depression – the Zung Self-Rating Depression Scale (SDS).  
The results of the SDS scores revealed a significant difference between RLS patients and controls 
(39.9 vs. 29.6; p<0.001).  Calculations derived from these results revealed a large effect size 
(Cohen’s d = 1.5). A further part of the study involved a subset of the patients and controls who 
underwent EEG mapping techniques. An interesting finding from these investigations was that the 
greatest difference between RLS patients and normal controls occurred in those EEG measures that 
in depression showed the highest correlations to the HAM-D. They state that the EEG findings are 
characteristic of the dissociated vigilance changes described in depression. The authors fail to 
report how patients and controls were recruited therefore it is unclear whether they came from 
comparable populations and whether there were any other differences between the groups in 
relation to socioeconomic status or smoking and alcohol intake. These issues were reflected in the 
scores obtained on the quality rating scale (see Table 7). The conclusions drawn from this relative 
thorough investigation were that EEG mapping revealed neurophysiological correlates of 
depression in RLS which were further confirmed by the self-ratings on the SDS. 
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The final case-control study, conducted by Winkelmann et al42, scored very similarly to Saletu et 
al40 on the quality rating scale (see Table 7). They investigated the rates of depression and anxiety 
according to DSM-IV criteria in 130 patients with idiopathic RLS compared to controls from a 
community sample. To control for non-specific effects of somatic illness on the rates of mental 
disorder the controls were selected if they had one or more diagnoses of physical health problem. 
Controls were excluded from the study if they had any diagnoses of neurological or kidney 
problems because of the association with secondary RLS.  Telephone interviews were used to 
gather data on previous inpatients and outpatients at the Max Planck Institute Movement Disorder 
Unit. The control subjects were selected from the German National Health Interview and 
Examinations Survey, which contained the same information with regards to diagnoses on the 
DSM-IV. They found that the RLS patients reported higher 12-month rates (OR, 2.6; p<0.05) and 
higher lifetime prevalence rates (OR, 3.30; p<0.001) of any depressive disorder, suggesting that 
RLS has a greater impact that other somatic illnesses. Furthermore the study analysed age-of-onset 
of depressive disorders and found that in the majority of RLS patients, the onset of RLS preceded 
the onset of mental health problems. They also compared those in the RLS group who were 
receiving pharmacological treatment of their RLS (n=103) and those who were not (n=23) They 
did not find any significant differences in the level of depression or anxiety between these two 
groups however the authors acknowledge that their analysis was exploratory and lacks the power 
needed detect subtle changes. 
 
 A shortcoming of this study is that the patients and control samples were recruited from different 
populations and the procedure also differed for each group. The controls were not contacted for this 
study but the information was obtained from a previous population survey. They authors try to 
manage this problem by using a weighting programme to account for the differential sampling 
probabilities. They also adjusted the analyses for age and gender as these were not matched. 
Another problem stemming from the different methods of sampling is that it cannot be established 
that the control group does not also contain those with RLS. The authors balance this with their 
view that excluding the controls with a neurology or kidney problem reduced the likelihood of RLS 
symptoms being present in this group. The authors conclude that despite their strict comparisons, 
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patients with RLS have significantly higher rates of depression than others with other somatic 
disorders.  
 
Conclusion from case-control studies 
Each of the case-control studies uses a different methodology. Again these differences have an 
impact on the level of association found. However the measures of depression and whether authors 
are looking at incidence or lifetime prevalence of depression could well account for this difference. 
Saletu et al40 is the highest rated study in terms of quality and used standard self-report measures 
and EEG to confirm a diagnosis of depression (although not a standard clinical technique). Banno 
et al35 used an unobtrusive measure of previous diagnoses listed in medical records of patients and 
controls and found the highest level of association. Winkelmann et al42 used a diagnostic interview 
and found that the level of association was somewhere in the middle. Thus one could speculate that 
the reactivity of the measure contributes to the level of depression, with the more reactive measures 
estimating a lower level. However Banno et al35 also did not rule out secondary RLS which might 
create bias in the sample.  
 
Comparing any clinical sample with a healthy control group on measures of depression will 
normally produce an effect. The Winkelmann et al42 study is unusual in this area as it compares 
people with RLS to people with other somatic conditions. Despite the observed association 
between somatic illnesses and reduced quality of life, a large effect size was obtained, suggesting 
that RLS has a distinctive impact on patients. It would therefore also appear to suggest that the 
issue of primary vs. secondary RLS does not have a major influence on the levels of association 
found between RLS and depression.  
 
As with the previous section conclusions, there are a number of factors that do appear to influence 
the association between RLS and Depression; the methodology, the measures of depression, RLS 
criteria, and the population are significant. It is less clear if and how other factors, such as, 
medication, PLMS and severity of RLS affects the level of association.  
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Non-controlled clinical studies (observational studies) 
This next section of the review considers studies that are uncontrolled and employ a clinical sample 
in the form of patients attending a sleep disorder clinic. Two of these studies39,41 are looking at a 
number of other sleep disorders, of which RLS is one. The quality of the studies was variable and 
largely determined by sampling procedures and the diagnostic strength in relation to RLS (See 
Table 7). 
 
Bassetti et al36 assessed consecutive RLS patients who attended their sleep clinic over a 7year 
period. During this time only 81 out of 1284 patients received a diagnosis of RLS, however only 55 
of them, who met all four diagnostics criteria for RLS, were included in the study. Patients were 
interviewed either by telephone or during a routine clinic visit by the authors and the presence or 
absence of depression was determined by a single question, the exact wording of which was not 
provided. They divided the group into those with idiopathic RLS and symptomatic RLS. Thirty-
five percent of the idiopathic RLS group reported depression. The authors concluded that 
neuropsychiatric symptoms were relatively common in patients with RLS. This study aimed to test 
whether distinct clinical forms of the condition existed based on age of onset, presence of insomnia 
or recognised aetiology. As a result the association of RLS with depression was not looked at in 
depth. They also do not look at other covariates such as smoking and alcohol intake. Consequently 
this study scored poorly on the quality rating scale (see Table 7) and does not add substantially to 
the evidence of an association between RLS and depression.  
 
Another clinical study which took place at the University of Pennsylvania Sleep Centre was 
conducted by Cuellar et al37 (see Table 5), and employed a sample of older adults with a diagnosis 
of RLS (n=39) according to IRLSSG standard diagnostic criteria. This study was cross-sectional in 
design as they stratified the RLS group by symptom severity using the RLS severity scale19. The 
used the CES-D as a measure of depression and reported the reliability of the measure for their 
specific group was 0.76. The authors recognise that this may have been higher if they had used a 
measure that was developed specifically for older adults such as the Geriatric Depression Scale 
(GDS). Although scores in the severe RLS group were higher than those in the mild/moderate 
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group, these differences did not reach statistical significance. The data produce a medium effect 
size of 0.46, suggesting that the study was under powered to detect differences in level of 
depression between these two groups. The primary outcome measure of this study was the PSQI 
and therefore the sample size justification had been based on detecting differences in this measure. 
Nevertheless the mean scores for the CES-D did not reach the clinical caseness in either of the 
groups. They did however find a significant difference on a measure of emotional well-being 
(RLS-QLI) and concluded that severity of RLS not only affects sleep quality but also emotional 
well-being. Overall however this study does not provide strong support for an association between 
RLS and depression in older adults. 
 
Hornyak et al38 retrospectively evaluated completed self-report questionnaires of untreated, 
idiopathic RLS patients seen at their Sleep Disorders Unit. They looked at sleep quality (PSQI), 
severity of RLS (IRLS), and depressive symptoms (BDI). The level of depressive symptoms found 
is reported in Table 5. The authors excluded patients whose RLS symptoms may have been 
secondary to another medical condition and those on anti-depressants. They also reported that all 
patients underwent a physical and psychiatric examination and polysomnography; however it did 
not appear that this information was used in the analysis. The results were therefore based entirely 
on subjective self-report measures. The finding that RLS severity correlated with sleep quality 
(r=0.281, p=0.007) and not depressive symptoms (r=0.119, p=0.237) could have been due to 
patients’ reluctance to disclose mental health issues. Furthermore patients prescribed anti-
depressant medication were excluded from the study. This potentially could mean that the people 
most severely affected by their RLS were not included, underestimating the possible association 
between RLS severity and mood. An additional difficulty with this study was in the reporting of 
their findings. They report that the majority of their sample fell within the moderate to severe range 
on the IRLS however they do not give numbers or percentages. When they later report that 17% of 
the ‘moderate to severe’ RLS sample was depressed, this is misleading as they did not explicitly 
state how many of their sample this included.  
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The following two studies39,41 looked at the level of mood disorder and depressive symptoms in 
patients attending a sleep centre. They created groups based on the diagnosis of sleep disorders 
such as narcolepsy, sleep apnoea and insomnia. Both studies contain groups of people with RLS 
which were combined with people with periodic legs movements during sleep.  
 
Mosko et al39 reported on two studies, one assessing mood at presentation to the sleep disorders 
centre, and the other monitoring changes in mood as a measure of treatment outcome. From the 233 
patients attending their clinic, 12 were diagnosed with RLS. Patients underwent polysomnography, 
which included leg electromyograms of the anterior tibialis muscles.  They were also tested for 
sleep apnoea and narcolepsy. However due to the small numbers, the RLS group (n=12) was 
combined with the PLM group (n=12). The authors used the Profile of Mood States (POMS) self-
rating scale to measure mood states. One of the subscales is called Depression/Dejection. At the 
time of the study there were limited available norms for the POMS in order to enable comparison. 
However, they did tentatively report that the level of pathology in their sample was one or two 
standard deviations above a previous sample of healthy males. They also recorded the number of 
depressive symptoms that the patients reported according to the DSM-III, stating that at least four 
symptoms were required to be present for at least 2 weeks for a diagnosis of major depressive 
disorder. They found that 71% of the PLM/RLS group had four or more symptoms. However they 
did not give details regarding the nature of the symptoms they reported. These symptoms could be 
accounted for by the RLS/PLM. For example, people with RLS may complain of insomnia; 
fatigue; psychomotor retardation and diminished ability to concentrate or indecisiveness. All of 
these symptoms could be mistaken for symptoms of depression. However one could argue that 
prolonged occurrence of the above symptoms could lead to depressed mood and anhedonia.  
 
The second part of the Mosko et al39 study looked at changes in the POMS as an outcome measure 
for treatment. A subset of the RLS/PLM group from Study 1 was treated with clonazepam 
following an initial 2-week medication-free period. POMS were repeated at 4 weeks, 8 weeks, and 
again after a 4-week withdrawal period. They found that Fatigue as measured by the POMS was 
significantly less at 8weeks and increased again after withdrawal of the clonazepam. They also 
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found a significant treatment effect on the POMS factor A, which measured Anger. Anger was 
significantly increased following treatment and remained at this level even after withdrawal of the 
medication. There was no significant change on the Depression/Dejection factor after treatment 
with clonazepam in the RLS/PLM group. The authors concluded that high rates of self-reported 
depression were present in all sleep disorder patients and that their investigation indicated that the 
nature of the relationship between sleep disorder and mood disturbance was probably unique to 
each sleep disorder. This study may also suggest that it is not only the sleep disturbance that adds 
to the ratings on the depression scale, but perhaps the frustration regarding the uncontrollable urge 
to move their legs. 
 
Mosko et al39 is the oldest study considered within this review and therefore difficulties arose with 
respect to the advances that had been made in diagnostic standards for both depression and RLS. 
There have been two revisions of the DSM since their study was published and one significant 
change is that there needs to be 5 out of nine symptoms present for at least two weeks for the 
diagnosis of Major Affective Disorder. Also since Mosko et al’s study the criteria for RLS have 
been revised and agreed upon following work by the IRLSSG6. However this study was 
strengthened by the use of objective laboratory based measures in the confirmation of the diagnoses 
and scored above average on the quality rating scale (see Table 7).  
 
Vandeputte et al41 combined 154 patients from their Sleep Disorders Clinic that met ICSD criteria 
for RLS or PLMD. They assessed level of depressive symptoms with the Beck Depression 
Inventory (BDI) completed by the patients between two nights of PSG recordings in their own 
home. They found that 53% of those with the RLS/PLMD diagnosis had some form of depression 
(using a clinical cut-off score of <10). They pointed out that as they excluded all patients with a 
primary diagnosis of depression, these results are indicative of depressive feelings that are 
secondary to the sleep problems. It is unclear from their description of the sample how many of the 
RLS/PLMD group were on antidepressants, they also did not give details of which other 
pharmacological interventions this group were receiving. They did not report information on 
smoking, alcohol intake or BMI which are important confounding factors. Also combining PLMD 
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and RLS made it difficult to draw conclusions about how each of these disorders is related to mood 
disturbance. There could be different factors in the aetiology of mood disturbance in these two 
distinct groups. For example people with only PLMD do not experience the creeping-crawly 
tingling sensations accompanied with the uncontrollable urge to move their legs. RLS could have a 
very different psychological impact in view of this different subjective experience.  These issues 
were reflected in the low scores on components of the quality rating instrument dealing with 
sampling and potential confounds, however this study did score relatively highly on the clinical 
measurement aspect of the scale (See Table7). 
 
The final study is both an epidemiological study and clinic based (see Table 5). Winkelmann et al43 
utilised data from the prospective Wisconsin Sleep Cohort study in order to assess prevalence of 
RLS and to determine associations with mental and physical heath, daytime sleepiness, and specific 
medical conditions. From the initial sample (n=2821) a prevalence rate of 10.6% was found for 
RLS symptoms of at least weekly frequency. A subset of the sample (n=898) were invited to the 
laboratory for PSG assessments within a two year timeframe from the original survey. Data on 
Mood, daytime sleepiness and cardiac problems was collected during the laboratory visit. The 
authors coded those with a score <50 on the 20-item Zung Depression Scale (SDS) and those 
currently taking anti-depressant medication as depressed. Although this subset of participants had 
undergone PSG the authors did not report the results of these tests. However they did take into 
account possible confounding variables such as age, gender, BMI smoking, diabetes and sleep 
apnoea and included them as covariates in the analysis. They found that people with Daily RLS 
symptoms (OR, 2.17; 95%CI=1.20-3.95) and Frequent RLS symptoms (OR, 1.80; 95%CI=1.00-
3.24) were more likely to be depressed than those with no RLS symptoms.  
 
However there were several limitations that must be considered. The way in which this study 
encoded people as depressed, may lead to an artificially elevated level of people with depression. 
The use of antidepressants could be due to doctors misdiagnosing the RLS symptoms as 
depression. The authors did indicate that they have analysed the data to check that rates of 
depression remain elevated in the RLS symptom group after controlling for hypnotic 
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antidepressants and taking away the questions on the SDS that relate to sleep and motor 
restlessness.  Unfortunately they did not report the results of this analysis but stated that levels of 
depression do in fact remain elevated. Another limitation of the study is that the data on mood and 
RLS symptoms were gathered at different times which, as the authors conceded, may have 
introduced bias into the associations between RLS symptoms and this measure. This study also did 
not use the standard criteria for RLS. Instead of a requirement of symptoms to worsen at night, in 
order for people to be classed as having RLS symptoms they had to report problems of sleep 
disturbance related to the RLS. This may have actually underestimated the rate of RLS present in 
the sample as this latter symptom would only be found in those with a severe form of the disorder. 
The authors inferred that there were elevated levels of depression in individuals with RLS but also 
stated that it is impossible to elucidate from their data whether there is a causal link between them.  
 
Conclusions from uncontrolled clinical studies  
The highest levels of association between RLS and depression or depressive symptoms were found 
in studies that did not separate RLS and PLMD. Both of these studies39,41 looked at all patients 
attending a sleep disorder clinic and therefore RLS was not a specific focus of their work. As 
previously discussed these are two distinct disorders with some overlapping symptoms. The 
difference in subjective experience of these disorders could be crucial and therefore future studies 
should aim to separate them. These studies might also therefore suggest that the presence of PLMS 
could increase the likelihood of mood disturbance. 
 
Unfortunately although two-thirds of the clinical studies discussed in the above section of the 
review included the use of objective measures such as 24-hour PSG, none of them used these 
findings in the analysis. Therefore it remains unclear the impact of the presence of PLMS on levels 
of association found between RLS and depression. As this could be a mediating factor it is essential 
that researchers who have the means (i.e. availability of equipment) include this in their design in 
order to help explain how RLS impacts on mood.  
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Cuellar et al37 and Hornyak et al38 both utilised the IRLS as a subjective measure of RLS severity. 
Apart from the aforementioned difficulties with reporting in the Hornyak study, these studies can 
also not be compared due to the fact that they categorised the samples differently. Hornyak et al38 
create a ‘moderate to severe” RLS category whilst Cuellar et al37 break the sample up into 
‘mild/moderate’ and ‘severe/very severe’. Cuellar et al37 did not find any significant differences in 
the depressive symptoms of their two groups and breaking the sample up further was out of the 
question. Further studies with greater numbers are needed so that the level of subjective severity 
and its impact can be investigated more thoroughly.   
 
Hornyak et al38 was the only uncontrolled clinical study to investigate a solely idiopathic RLS 
sample. They found no association between RLS severity and depression. However, perhaps if 
PLMS play a mediating role then measures of subjective severity would not detect this as patients 
are not always aware that they have PLMS. Again, objective data would have been advantageous 
here.   
 
Bassetti et al36 included both people with primary and secondary RLS. However, they separated the 
two types and found that there was no significant difference in the level of depression found 
between them (35%) (See Table 5). This suggests, along with the Sevim et al31 study, that the level 
of impact of RLS on mood in primary RLS is analogous to that in secondary RLS. 
 
Although the majority of the studies detail the use of medication in the demographic of their 
samples, none of them make direct comparisons between those taking medication and those who 
are medication free.  
 
The population, measure of depression and diagnosis of RLS again all appear to play a part in the 
differences in the level of association found. However due to a dearth of studies also examining the 
effects of medication use, RLS subjective severity and objective measures – the impact of these 
methodological issues on the level of association found cannot be determined. 
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Discussion 
There appears to be strong evidence that an association exists between RLS and depression. 
However the focus of this review was to examine how the methodology of studies impacts the level 
of association found. Whilst a quantitative analysis was not possible, a qualitative evaluation of the 
included studies resulted in the above outlined conclusions. This review set out to determine how 
the methodology of the studies affects the reported levels of association found between RLS and 
depression and what factors were important to predict the association of depression with RLS. A 
number of overarching conclusions from the three types of study discussed will now be outlined. 
These conclusions are synthesised into a number of recommendations for future research. 
 
Depression Measures 
Studies employing unobtrusive measures of depression found a greater association between RLS 
and depression. Some studies looked at current incidence of depression, whilst others examined 
lifetime prevalence rates, making comparison difficult.  All of the studies used only one modality 
to assess level of depression and the majority of studies only used self-report measures. None of the 
studies employed an independent clinician assessment to diagnose depression. Nearly half of the 
population-based studies failed to use a recognised nosology. 
 
 
Research Agenda: 
Future studies should try to use medical records/independent clinical assessment where possible. 
They should include a standardised measure of symptom severity and have a question regarding 
symptom onset. 
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RLS Diagnosis 
Studies which did not use recognised diagnostic criteria or adapted criteria from the ICSD or 
IRLSSG, did not find a strong association between RLS and mental health problems. Subjective 
severity of RLS was not routinely measured in a standardised way. Whilst many of the clinical 
studies employed objective measures such as PSG, these were only used to confirm diagnoses and 
the PLM index was not reported. 
 
 
Research Agenda: 
Future studies should use IRLSSG criteria and have a subjective measure of severity such as the 
IRLS. Clinical studies should report PLMS parameters and examine whether these should be added 
to the statistical analysis as a covariate. Where possible, studies should measure subjective sleep 
quality, SIT and (PSG) PLMS. Not only will this help to categorise RLS and rule out other sleep 
disorders but it will also bring us closer to understanding the link between RLS and Depression and 
the influence of sleep disturbance on this association. 
 
 
Population 
Population based studies have shown that the association between RLS and depression is greater in 
primary care than community samples. However these studies lacked standardised measures of 
depression. There was tentative evidence that the presence or absence of comorbid conditions such 
as diabetes or kidney disease do not impact the level of association found between RLS and 
depression. Whilst it appears that the presence of comorbid medical conditions may not have a 
great influence, the impact of sleep disturbance could be investigated further. Studies of older adult 
populations have found that the association between RLS and depression exists only in men and the 
only clinic-based study37 did not find high levels of depression in a sample of older adults attending 
a sleep clinic. There was a dearth of case-control studies investigating older adult samples. 
However it appears that the age of the sample did have a bearing on the level of association found. 
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Research Agenda: 
Follow-up research should be carried out using a control group consisting of people with psycho-
physiological insomnia to control for the effects of sleep disturbance. Further studies of older adult 
samples are required and control groups would be helpful to control for the social and 
environmental circumstances of the elderly.  
 
 
Medication 
It remains unclear the impact that pharmacological treatment for RLS has on the level of depressive 
symptomatology.  
 
 
Research Agenda: 
Studies should include in the design a measure of pharmacological treatments and investigate the 
impact these have on the level of depression found in those receiving treatment.  
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Table 1. Inclusion and exclusion criteria 
 
 
 
Inclusion Criteria Exclusion Criteria 
• Studies that measure RLS and level of 
depression (or other related mental 
health problems). 
• Studies that measure sleep 
disturbance and PLMS or PLMW in 
RLS 
• Outcome studies investigating the 
effects of pharmacological treatment of 
restless legs syndrome on measures 
of psychological distress. 
• Epidemiological and clinical studies 
• Studies including adults 
• Studies written in English 
 
• Studies with people < 18 years 
• Studies looking at secondary RLS, 
for e.g. uraemia, pregnancy and 
peripheral nerve injuries 
• Studies grouping RLS with co-morbid 
sleep disorders (e.g. OSA) 
 
• Non English language studies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RLS: Restless legs syndrome; PLMS: Periodic leg movements during sleep; PLMW: 
Periodic leg movements during wakefulness; OSA: Obstructive Sleep Apnoea. 
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Table 2. Quality Rating Scale  
 
Quality of Methodology Checklist 
 
Reviewer:     Article No:    Score:    
 
Study design: _______________________ 
 
    Cohort, prospective 
    Cohort, retrospective 
    Cross-sectional 
    Case-control 
    Case reports or case series 
 
Possible responses to Questions 1-10 & 14-19:  YES (=2) PARTIAL (=1) NO (=0) N/A  
Study Question: 
1. Was the study question sufficiently described?___ 
 
Study population 
2. Were participants appropriate to the study question?____ 
3. Were control participants used? ____ 
4. Were participants and controls taken from comparable populations? ____ 
5. The same exclusion criteria are used for both cases and controls?____ 
6. Comparison is made between participants and non-participants to establish their similarities or differences? 
____ 
7. Cases are clearly defined and differentiated from controls? ____ 
8. It is clearly established that controls are non-cases? ____ 
   
Demographic details: 
9. Were demographic details of participants reported? ____ 
10. The main potential confounders are identified and taken into  account in the design and analysis? ____ 
 
Clinical Characteristics: 
11. How was RLS diagnosis ascertained? 
a. Independent assessment (Objective measures: EMG, PSG, Actigraphy)(= 2)____ 
b. Medical Records (= 1)____ 
c. Clinical interview(= 1)____ 
d. Self report (e.g. IRLSSG rating scale)(= 0) ____ 
e. No description(= 0)____ 
12. Were the IRLSSG diagnostic criteria used? (= 2) ____ 
 
Outcome measurement: 
13. How was level of depressive symptomatology ascertained? 
a. Independent assessment(= 2)____ 
b. Medical records(= 1)____ 
c. Clinical interview(= 1)____ 
d. Self report(= 0)____ 
e. No description(= 0)____ 
14. Was a valid assessment/screening tool used (e.g. BDI)? (= 2) ____ 
 
Statistical analysis 
15. Was there a sample size justification before the study? ____ 
16. Were post-hoc power calculations or confidence intervals reported for statistically non-significant results? ____ 
17. Were the statistical analyses appropriate? ____ 
18. Were the statistical tests stated? ____ 
19. Were the exact p values or confidence intervals reported for each test? ____ 
 
Funding or sponsorship 
20. Was this study independently funded? (i.e. not funded by a drug company) ____ 
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Table 3. Excluded Studies 
 
Study Reasons for Exclusion 
Aikens et al 1999 Not investigating RLS. 
Allen et al 2003 Report from IRLSSG conference paper  
Cuellar et al 2006 All Secondary RLS 
Dickel and Mosko 1990 Not investigating RLS 
Herraez et al 2006 Not Written in English 
Kushida et al 2004 Looking at RLS Quality of life 
Kushida et al 2007 Looking more generally at Quality of life 
Philips et al 2000 No specific measure of mental health problems or depression 
Picchietti & Winkelmann 
2005 Review Article  
Rodrigues et al 2007 Not Written in English 
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Table 4. Population based studies examining the prevalence and correlates of RLS 
Study Type of Study 
Quality 
score 
Population 
& 
appropriate 
control 
group 
Sample 
size Main methods RLS criteria 
Depression 
measure 
Mx Analysis 
Level of 
Depressive 
symptoms 
found 
Limitations Authors Conclusions 
Allattar 
et al. 
2007 
Cross-
sectional 
0.425 Patients 
attending their 
Primary Care 
Practices in 
North 
Carolina, 
USA. 
 
n= 1934 Questionnaire; 
either self-
report or via 
interview. 
Screened by 
question: “At 
night, how 
often do you 
feel 
unpleasant, 
tingling, 
creeping, or 
restless 
feelings in 
your legs 
while trying to 
sleep?  
Question 
related to 
health 
problems 
experienced 
over previous 
10 year 
period. 
NS ODDS 
RATIO 
(adjusted 
for race, 
age and 
gender) 
2.84 times 
more likely to 
have 
suffered 
depression in 
last 10 years.  
Do not use 
IRLSSG 
criteria; No 
measure of 
Depressive 
symptom 
severity;  
Mental 
disorders 
were 
significantly 
associated 
with sleep 
disorders.  
Allen et 
al. 2005 
Cross-
sectional 
0.275 Randomly 
selected 
population 
based sample 
in UK; France; 
Germany: 
Italy; Spain; 
USA. 
n= 
15,391 
Telephone or 
face-to-face 
interview.  
4 questions 
addressing  
IRLSSG 
diagnostic 
criteria & 
questions 
regarding 
frequency of 
symptoms. 
RLS sufferers 
were defined 
as those 
whose 
symptoms 
occurred at 
least twice 
weekly in last 
12 months 
Percentage 
reporting 
tendency to 
become 
“depressed/ 
low” 
NS None 26.2 % 
reported 
tendency to 
become 
depressed 
Do not use 
valid 
measure of 
Depression. 
Do not rule 
out other 
sleep 
disorders.  
Clinically 
significant 
RLS is 
common, is 
under 
diagnosed 
and 
significantly 
affects sleep 
and quality of 
life. 
 RLS Criteria: The diagnostic clinical criteria employed; Mx: Whether medication taken into account - NS: Not stated; Y: Yes; 
free: participants were all medication free; RLS: Restless legs syndrome; PLMD: Periodic limb movement disorder. 
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Table 4 cont. Population based studies examining the prevalence and correlates of RLS 
Study Type of 
Study 
Quality 
score 
Population 
& 
appropriate 
control 
group 
Sample 
size 
Main 
methods 
RLS criteria Depression 
measure 
Mx Analysis Level of 
Depressive 
symptoms 
found 
limitations Authors 
conclusions 
Hening 
et al. 
2004 
Cross-
sectional 
0.2 Primary care 
sample in UK; 
France; 
Germany: 
Italy; Spain; 
USA. 
N= 
23053 
 
RLS n= 
551 
(likely to 
require 
tx) 
Screening 
questionnaire 
completed by 
patient and 
physician 
during 2 week 
enrolment 
period 
Same as the 
Allen et al 
study 
Question 
related to 
impact of 
RLS 
symptoms 
Y Chi-
squared 
for 
categorica
l data; t-
tests for 
quantative 
data 
59.9% of 
reported 
tendency to 
become low/ 
depressed. 
Primary 
care sample 
will have 
elevated 
levels of 
comorbid 
health 
conditions. 
Do not 
separate 
primary & 
secondary 
RLS. Do not 
use 
standard 
methods for 
RLS 
diagnosis. 
Do not have 
a measure 
of 
depression. 
RLS 
significantly 
impairs 
patients’ lives, 
often by 
severely 
disrupting 
sleep. 
Philips 
et al. 
2006 
Cross-
sectional 
0.225 USA adults n=1506 Telephone 
survey 
Standard 
question 
developed by 
IRLSSG 
Self-report of 
previous 
diagnosis by 
doctor of 
Depression 
NS Stepwise 
multiple 
logistic 
regression 
models  
NS  
(Significant 
association 
found but no 
details of 
level) 
Not all 
IRLSSG 
criteria are 
used.  
Did not 
exclude 
people with 
comorbid 
Sleep 
apnoea 
from 
analysis 
RLS is 
significantly 
associated 
with medical 
and 
psychiatric 
conditions.  
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Table 4 cont. Population based studies examining the prevalence and correlates of RLS 
Study Type of 
Study 
Quality 
score 
Population 
& 
appropriate 
control 
group 
Sample 
size 
Main 
methods 
RLS criteria Depression 
measure 
Mx Analysis Level of 
Depressive 
symptoms 
found 
limitations Authors 
conclusions 
Rothdach 
et al. 
2000 
Cross-
sectional 
0.750 Germany; 
Older Adults 
aged 65-83 
years. 
n=369 Face-to-face 
interviews 
Questions 
using the 
IRLSSG 
standard 
diagnostic 
criteria 
The Center 
for 
Epidemiologi
c Studies 
Depression 
(CES-D).  
 
Y T-test and 
logistic 
regression
. 
RLS 
positives 
have 
significantly 
higher  
CES-D 
scores(11.6 
vs 7.8; 
p=0.01). 
Significant 
association 
between RLS 
and 
depression 
for males 
only (OR, 
13.06; 
p=0.01) 
Did not use 
objective 
laboratory 
based 
measures to 
confirm 
diagnosis of 
RLS. 
Does not 
rule out 
other sleep 
disorders. 
RLS is a 
frequent 
syndrome in 
the elderly 
with 
considerable 
impact of self-
perceived 
mental health 
Sevim 
et al 
2004 
Cross-
sectional 
& case-
control 
0.775 Community 
sample of 
adults aged 
over 17years; 
Mersin; 
Turkey. 
N = 
3234 
RLS n = 
103 
Face-to-face 
interview, 
neurological 
examination, 
questionnaires 
IRLSSG 
Criteria 
Hamilton 
Rating Scale 
for 
Depression 
(HAM-
D)(Turkish 
Version) 
ns t-test and 
correlation
. 
Significant 
difference 
between RLS 
and controls 
on HAM-D; A 
positive 
correlation 
between 
depression 
and RLS 
severity 
(r=0.201; 
p=0.04) 
Higher rate 
of smokers 
in RLS 
group. 
Issues with 
the HAM-D 
scoring and 
classificatio
n due to 
modification 
by authors.  
RLS more 
anxious & 
depressed 
than controls. 
HAM-D scores 
were directly 
related to 
increased 
IRLSSGRS 
scores. Taken 
together RLS 
was probably 
the major 
determining 
factor for dep 
scores, with 
higher scores 
correlating with 
more severe 
RLS. 
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Table 4 cont. Population based studies examining the prevalence and correlates of RLS 
Study Type of Study 
Quality 
score 
Population 
& 
appropriate 
control 
group 
Sample 
size Main methods RLS criteria 
Depression 
measure 
Mx Analysis 
Level of 
Depressive 
symptoms 
found 
Limitations Authors Conclusions 
Spoor-
maker et 
al. 2005 
Cross-
sectional 
0.35 Community 
sample of 
adults over 18 
years old. 
Netherlands. 
N= 402 Postal survey SLEEP-50 
which 
provides 
subscales for 
the impact of 
sleep 
complaints on 
daily 
functioning. 
Dutch 
version of the 
SCL-90 
NS Correlation RLS did not 
correlate with 
any mental 
health 
complaints 
Low 
response 
rate 
(50.25%). 
Response 
bias 
present. 
Reliability of 
SLEEP-50 
unclear. 
Authors do 
not mention 
RLS in 
discussion. 
Do conclude 
that other 
sleep 
complaints 
are related to 
depression 
and anxiety 
Suke-
gawa et 
al. 2003 
Cross-
sectional 
0.575 Elderly 
residents in 
Seniors 
Association 
(age <65 
years): Izumo 
City; Japan 
N=2023, 
sub-
divided 
by 
scores of 
depressi
on 
measure 
DEP 
group 
n=634, 
control 
group 
n=1389 
Self-report 
questionnaires 
Questions 
based on 
IRLSSG 
diagnostic 
criteria with 
also 
measures of 
symptom 
frequency. 
Geriatric 
Depression 
Scale (GDS) 
NS Χ2 test for 
association 
of variables 
with the 
depressive 
group & 
Logistic 
Regression 
OR, 2.5 
(p<0.05) in 
total sample. 
i.e. 
Depressed 
group 2.5x 
more likely to 
have RLS. In 
younger 
males 
Adjusted OR, 
3.9 (P<0.05) 
Not all 
Criteria 
needed e.g. 
RLS 
“probable”. 
Failed to 
rule out or 
take 
account of 
co-morbid 
disorders in 
either 
group. 
Restless legs 
syndrome was 
significantly 
associated 
with 
depression in 
younger men. 
Ulfberg 
et al. 
2001 
Cross-
sectional 
 
Epidemiol
ogical 
0.65 Random 
sample of 
male 
population 
aged 18-64 
years: 
Sweden 
N = 
2608, 
RLS = 
181. 
Postal survey, 
followed by 
telephone 
contact of 10% 
of non-
responders 
Questions 
devised and 
translated 
using the 
IRLSSG 
standard 
diagnostic 
criteria. 
Yes/no 
question: 
“are you 
affected by 
depressed 
mood without 
any 
recognisable 
reason”. 
NS Multivariate 
logistic 
regression. 
RLS 
responders 
were more 
likely to 
report 
depressed 
mood (OR, 
2.6; 95% CI, 
1.8-3.8) 
Do not report 
demo-
graphics. Do 
not rule out 
secondary 
causes (e.g. 
primary vs. 
secondary 
RLS). Low 
response 
rate. 
It is 
hypothesized 
that RLS may 
be associated 
with several 
somatic and 
neuro-
psychiatric 
symptoms. 
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Table 5. Clinic-based studies examining the association between RLS and Mood Disorder 
Study Type of 
Study 
Quality 
score 
Population 
& 
appropriate 
control 
group 
Sample 
size 
Main 
methods 
RLS criteria Depression 
measure 
Mx Analysis Level of 
Depressive 
symptoms 
found 
limitations Authors 
conclusions 
Banno 
et al. 
2000 
Case-
control 
0.55 Patients from 
a sleep 
disorder 
center in 
Manitoba, 
Canada. 
Controls taken 
from Manitoba 
Health 
Database 
n=218 
RLS 
patients 
each 
with 4 
age & 
gender 
matched 
controls. 
Medical record 
evaluation 
ICSD criteria 
for RLS. 
Positive 
history of 
Diagnosis of 
Affective 
psychosis, 
depressive 
disorder not 
elsewhere 
classified and 
neurotic 
disorder. 
Y Mantel-
Haenszel 
χ2;  
logistic 
regression 
Bonferroni 
correction. 
OR = 5.3 for 
males 
(p<0.001) 
OR = 2.9 for 
females 
(p<0.001) 
Not clearly 
established 
that controls 
are not 
cases. No 
measure of 
symptom 
severity. 
RLS patients 
are more 
likely to have 
been 
diagnosed 
with 
depression. 
Bassetti 
et al. 
2001 
Cross-
sectional 
0.275 Patients 
diagnosed 
with RLS at 
sleep clinic; 
Switzerland. 
N = 55 Telephone 
interview 
1995 IRLSSG 
diagnostic 
criteria 
Question 
related to 
presence or 
absence of 
depressive 
symptoms 
(exact 
wording not 
given) 
Y Proportions 
reported. 
35% of those 
with 
idiopathic 
RLS (n=37) 
reported 
depression. 
Do not make 
comparison 
between 
participants 
and non-
participants.  
Do not take 
into account 
possible 
covariates 
such as 
smoking, 
alcohol intake 
and weight. 
Neuro-
psychiatric 
symptoms 
were relatively 
common in 
patients. 
 RLS Criteria: The diagnostic clinical criteria employed; Mx: Whether medication taken into account - NS: Not stated; Y: Yes; 
free: participants were all medication free; RLS: Restless legs syndrome; PLMD: Periodic limb movement disorder. 
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Table 5 cont. Clinic-based studies examining the association between RLS and Mood Disorder 
Study Type of 
Study 
Quality 
score 
Population 
& 
appropriate 
control 
group 
Sample 
size 
Main 
methods 
RLS criteria Depression 
measure 
Mx Analysis Level of 
Depressive 
symptoms 
found 
limitations Authors 
conclusions 
Cuellar 
et al. 
2007 
Cross-
sectional 
0.55 Older adults 
(aged >65) 
University of 
Pennsylvania 
Sleep Centre 
and RLS 
support 
groups in 
surrounding 
area. 
n=39 Self-report 
Questionnaires 
IRLSSG 
standard 
diagnostic 
criteria. 
Group 
stratified by 
RLS severity 
using IRLS 
The Center 
for 
Epidemiologi
c Studies 
Depression 
(CES-D).  
(Reliability 
0.90) 
Y Power 
analysis 
provided. 
 
Mean scores 
for both 
mild/moderat
e (9.2) and 
severe (13.1) 
groups did 
not reach 
clinical cut-
off. 
Small 
sample size. 
No control 
group. Not 
using the 
geriatric 
depression 
scale. 
Severity of 
RLS affects 
not only sleep 
quality but 
emotional 
well-being. 
Hornyak 
et al. 
2005 
Cross-
sectional 
0.50 Sleep 
Disorder Unit, 
Germany 
n=100 Retrospective 
evaluation of 
questionnaire 
data including 
laboratory data 
and PSG 
results. 
IRLSSG 
Standard 
diagnostic 
criteria 
Beck 
Depression 
Inventory 
(BDI) 
Y Spearman
’s 
Rho 
 
17% of RLS 
patients 
complained 
of mild to 
moderate 
depressive 
symptoms. 
Severity of 
RLS not 
correlated 
with self-
reported 
depression 
symptoms 
(r=0.119, 
p=0.237) 
Patient 
selection: 
patients on 
Anti- 
depressants 
were 
excluded. 
BDI may 
underestima
te severity. 
RLS 
associated 
with some 
depressive 
symptoms but 
not full 
spectrum of a 
depressive 
disorder. 
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Table 5 cont. Clinic-based studies examining the association between RLS and Mood Disorder 
Study Type of Study 
Quality 
score 
Population 
& 
appropriate 
control 
group 
Sample 
size Main methods RLS criteria 
Depression 
measure 
Mx Analysis 
Level of 
Depressive 
symptoms 
found 
Limitations Authors Conclusions 
Mosko 
et al. 
1989 
Cross-
sectional 
0.575 Patients at 
Sleep disorder 
Centre at the 
University of 
Califonia.  
n=233 
RLS = 
12 but 
was 
combine
d with 
PLM 
group for 
analysis 
RLS/PL
M= 35 
All night PSG 
which included 
leg electromyo-
grams; MSLT; 
self-report 
questionnaire 
Prior to 
IRLSSG 
criteria were 
published.  
Profile of 
Mood States 
(POMS); No. 
Of DSM-III 
Sx of 
Depression. 
Y One-way 
ANOVAs 
71% of those 
with 
RLS/PLM 
had 4 or 
more Dep 
Sx.  
POMS not 
well 
validated at 
time of 
publication. 
Did not rule 
out 
concomitant 
medical 
problems or 
primary 
affective 
disorders  
High 
frequency of 
self-reported 
sx of major 
depression in 
patients at 
presentation, 
irrespective of 
subsequent 
sleep 
disorders 
diagnosis.  
Saletu 
et al. 
2002 
Case-
control 
0.675 RLS & PLMD 
patients at 
Sleep centre 
and age and 
gender 
matched 
normal 
healthy 
controls; 
Vienna, 
Austria. 
RLS = 
33 
& 33 
controls 
PLMD = 
26 & 26 
controls 
EEG mapping 
and 
questionnaires 
ICSD Criteria 
For RLS 
The Zung 
Self-Rating 
Depression 
Scale (SDS) 
free Mann 
Whitney 
U-test; 
Significan
ce 
probability 
mapping 
based on 
independe
nt sample 
t-tests. 
Correction 
due to 
multiple 
tests 
Significant 
difference 
between RLS 
and Controls 
on Zung 
Depression 
Scale (39.9 
vs. 29.6) 
 
Not clear 
how 
participants 
and controls 
were 
recruited.  
EEG Mapping 
revealed 
neuro-
physiological 
correlates of 
depression in 
RLS which 
were 
confirmed by 
self ratings of 
symptoms. 
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Table 5 cont. Clinic-based studies examining the association between RLS and Mood Disorder 
Study Type of Study 
Quality 
score 
Population 
& 
appropriate 
control 
group 
Sample 
size Main methods RLS criteria 
Depression 
measure 
Mx Analysis 
Level of 
Depressive 
symptoms 
found 
Limitations Authors Conclusions 
Vandep
utte et 
al. 2003 
(Brief 
Commu
nication) 
Cross-
sectional 
0.375 Patients 
attending a 
sleep 
disorders 
clinic, 
excluding 
those with 
primary 
diagnosis of 
depression. 
Total N 
= 917 
 
PLMD/ 
RLS n = 
154 
24hr 
polysomno-
graphy 
recordings at 
home. History 
taking. Self-
report 
questionnaire 
ASDA 
international 
classification 
of sleep 
disorders. 
Beck 
Depression 
Inventory 
(BDI) 
NS Not stated 53% of those 
with RLS 
diagnosis 
had some 
form of 
depression. 
May reflect 
those 
presenting to 
a sleep clinic 
and not 
generalise to 
RLS 
population as 
a whole. 
Other info not 
reported such 
as smokers 
or alcohol 
intake, weight 
etc. 
Combines 
RLS and 
PLMD. 
In PLMD/RLS 
some form of 
depression 
occurred in 
more than half 
of patients. 
Use of a 
depression 
scale 
recommended 
for routine 
practice in 
sleep 
medicine. 
Winkel
mann et 
al. 2005 
Case-
control 
0.675 Patients of 
Movement 
Disorder Clinic 
at the Max 
Planck Institute 
of Psychiatry; 
Munich, 
Germany. 
Controls were 
selected from a 
Health 
Database, only 
subjects with 
one or more 
somatic 
diagnoses were 
included. 
Aged (18-
65years) 
RLS n = 
130, 
Controls 
n= 2265 
Telephone 
interview.  
Diagnosis of 
idiopathic 
RLS 
previously 
given. 
Methods or 
criteria used 
not stated.  
Munich-
Composite 
International 
Diagnostic 
Interview for 
DSM-IV 
Yes
1
 
 
Logistic 
regression. 
Every 
control 
subject had 
a weighting 
factor to 
account for 
differential 
sampling 
probabilities.  
RLS patients 
reported 
higher 12-
month rates of 
any 
depressive 
disorder (OR, 
2.5, 95% CI = 
1.5-4.4). 
Lifetime 
prevalence 
rates were 
also higher in 
RLS group 
(OR,3.30, 
95% CI = 2.1-
5.0)(p<0.001) 
Controls not 
clearly 
differentiated 
from patients. 
Patients with 
RLS are at 
higher risk of 
Psychiatric 
disorders than 
patients with 
other somatic 
disorders. 
                                                          
1
 Comparison between those receiving medication and those not for RLS; No significant differences were found between the groups.  
 56
 
Table 5 cont. Clinic-based studies examining the association between RLS and Mood Disorder 
Study Type of Study 
Quality 
score 
Population 
& 
appropriate 
control 
group 
Sample 
size Main methods RLS criteria 
Depression 
measure 
Mx Analysis 
Level of 
Depressive 
symptoms 
found 
Limitations Authors Conclusions 
Winkel
mann et 
al. 2006 
Cross-
sectional 
 
Epidemiol
ogical 
0.625 Community 
based 
sample; 
Wisconsin, 
USA. 
N = 
2821. 
 
N= 898 
had in-
laboratory 
tests 
Postal Survey, 
a subset 
completed 
further in-
laboratory tests 
and 
questionnaires.  
Devised own 
questions. In 
recognition 
that the 
criteria were 
not identical 
to the 
standard 
diagnostic 
criteria they 
use the term 
‘RLS 
symptoms’ 
rather than 
RLS. 
Zung Self-
rating 
Depression 
Scale (SDS) 
and those on 
Antidepressa
nts were 
coded as 
depressed. 
Y Logistic 
regression 
using ‘no 
RLS 
symptoms’ 
as the 
baseline 
group. 
People with 
Daily RLS 
symptoms 
(OR, 2.17, 
95% CI = 
1.20-3.95) 
and Frequent 
(1-6/week) 
RLS 
symptoms 
(OR,1.80, 
95%CI = 
1.00-3.24) 
were more 
likely to have 
depression. 
Primary 
diagnoses of 
Depression 
not excluded. 
Do not report 
p-value for 
significant 
OR. Data 
concerning 
depression 
symptoms 
were not 
gathered at 
the same 
time as the 
RLS 
symptoms.  
Found 
elevated 
depressions 
scores in 
individuals 
with RLS 
symptoms. It 
is unclear 
whether there 
is a causal 
link between 
RLS 
symptoms 
and 
symptoms of 
depression. 
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Table 6. Epidemiological Studies 
 
Study 
Component (maximum points 
available): 
A B C D E F G H I 
Study question (2) 2 2 2 2 2 2 2 2 2 
Study population (14) 3 4 2 2 12 11 2 10 11 
Demographic/confounding 
factors  (4) 4 1 1 1 4 3 2 1 2 
RLS Diagnosis (2) 0 0 0 0 1 1 0 0 0 
RLS standard diagnostic criteria 
used (2) 0 2 0 0 2 2 0 0 2 
Outcome measurement (2) 0 0 0 0 0 1 0 0 0 
Valid assessment/screening 
tool used (e.g. BDI-II) (2) 0 0 0 0 2 2 2 2 0 
Statistical analysis (10) 6 2 3 4 5 7 4 6 7 
Funding or sponsorship (2) 2 0 0 0 2 2 2 2 2 
Total (40) 17 11 8 9 30 31 14 23 26 
Quality Score 0.425 0.275 0.200 0.225 0.750 0.775 0.350 0.575 0.650 
 
 
A. Allattar et al 2007 
B. Allen et al 2005 
C. Hening et al 2004 
D. Phillips et al 2006 
E. Rothdach et al 2000 
F. Sevim et al 2004 
G. Spoormaker et al 2005 
H. Sukegawa et al 2003 
I. Ulfberg 
 58 
Table 7 Clinical studies 
 
Study 
Component (maximum points 
available): 
A B C D E F G H I 
Study question (2) 2 2 2 2 0 2 2 2 2 
Study population (14) 9 2 2 2 10 7 4 9 11 
Demographic/confounding 
factors  (4) 1 2 4 3 2 2 1 2 4 
RLS Diagnosis (2) 1 1 0 2 2 2 2 1 0 
RLS standard diagnostic criteria 
used (2) 2 2 2 2 0 2 2 0 0 
Outcome measurement (2) 1 0 0 0 0 0 0 1 0 
Valid assessment/screening tool 
used (e.g. BDI-II) (2) 0 0 2 2 2 2 2 2 2 
Statistical analysis (10) 4 0 8 5 5 8 0 8 4 
Funding or sponsorship (2) 2 2 2 2 2 2 2 2 2 
Total (40) 22 11 22 20 23 27 15 27 25 
Quality Score 0.550 0.275 0.550 0.500 0.575 0.675 0.375 0.675 0.625 
 
 
A. Banno et al 2000* 
B. Bassetti et al 2001 
C. Cuellar et al 2007 
D. Hornyak et al 2005 
E. Mosko et al 1989 
F. Saletu et al 2002* 
G. Vandeputte et al 2003 
H. Winkelmann et al 2005* 
I. Winkelmann et al 2006 
 
 
 
 
 * Case-control studies 
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Figure 1: Flowchart illustrating the article identification process 
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ABSTRACT 
 
 
Background: Restless legs Syndrome is a sensorimotor disorder characterised by unpleasant 
sensations in the legs when at rest and only relieved by movement. RLS is associated with 
deterioration in quality of life and depression is a common comorbid problem. 
 
Methods: The present study aimed to establish whether RLS is a risk factor for depressive 
symptoms by comparing 3 groups - RLS patients (RLS), a primary insomnia group (PI), and non-
restless good sleeper controls (NRC). Fifteen participants were recruited to each group.  To 
elucidate the mechanisms of the observed comorbidity between RLS and Depression, measures of 
mood/affect prior to, during and immediately following a Suggested Immobilization Test (SIT) 
were employed.  The BDI-II measured depressive symptoms retrospectively over the previous two-
week period. A mood visual analogue scale (VAS) was rated by participants during the SIT at 5-
minute intervals. The Positive and Negative Affect Schedule (PANAS) retrospectively measured 
affect experienced by participants during the SIT. In addition, new actigraphy techniques were 
utilised to measure Periodic Leg Movements during Sleep (PLMS) over 3 nights at home – an 
objective measure of RLS severity.  
 
Results: The groups did not differ on demographic data except for age which was added as a 
covariate to further analyses. The RLS group had higher levels of negative affect following the SIT 
than the PI and NRC groups (both p<.05). The RLS group also had higher levels of positive affect 
than the PI and NRC groups (both p<.05). The level of sensory discomfort felt in the legs during 
the SIT was strongly associated with negative affect in the RLS group (r=.853, p<.001). PLMS 
were not found to be associated with BDI-II scores.  
 
Conclusions: It appears that sleep quality and depressive symptoms as measured by the BDI-II 
were similar in the RLS and PI groups. There were some limitations of the study but tentative 
conclusions were made. The role of emotional arousal in RLS, shown by the high correlation 
between sensory discomfort and negative affect, potentially demonstrates a qualitative difference in 
the restlessness experienced by this group and further studies are required.  
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1. Introduction 
 
 “As I pass a window I peer at the outer, unfriendly impenetrable darkness. I wonder how 
many miles I’ve walked since sundown. A 26 mile marathon? I feel like it. Whatever is 
plaguing me holds tightly and does not want to let me go. What have I done to cause this? 
What is stealing my sleep every night and why? Like a slow, dreamy sleep walker, I crawl 
into bed. Tears seep from the corners of eyes. Maybe I do have witches blood in my veins 
like Jack says.”                   
 (From Wilson; 1996; p35 [1]) 
 
The above excerpt offers valuable insight into the experience of a person with a condition known as 
Restless Legs Syndrome (RLS). This qualitative account conveys the impact of RLS on this 
individual’s mood and reveals some of the negative cognitions surrounding locus of control and 
helplessness.  Those who have RLS may well identify with this account and the burgeoning 
research in this area acknowledges RLS and its consequences as having a negative impact on 
psychological, as well as physical, well-being. 
 
The first definite account of RLS came from Thomas Willis, an accomplished physician in the 17th 
Century, who described in his 1685 book a patient who would have met modern day criteria for 
RLS [2]. He noted the patient had difficulty sleeping due to discomfort in the limbs. In the 19th 
Century a German neurologist, Whittmaack, named the same set of clinical symptoms as “anxietas 
tibiarum” but it was not until 1945 that the all clinical features were defined and the phrase restless 
legs syndrome was coined by Karl Ekbom [3,4]. Ekbom emphasised the sensory element that 
accompanied the motor symptoms. Also around this time the characteristic involuntary jerking 
movements of the legs were recognised. In 1965 Coccagna and Lugaresi published the first 
polysomnographic findings showing involuntary leg movements during sleep in a patient with RLS 
[5]. Formal nosology of RLS began with the first edition of the International Classification of Sleep 
Disorders (ICSD; American Academy of Sleep Medicine)[6]. RLS was classified as a type of 
intrinsic dyssomnia in recognition of the syndrome’s interference with sleep initiation or 
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maintenance and that these difficulties originated from factors within the body. The latest edition of 
the classification system (ICSD-2) categorises RLS as a sensorimotor disorder along with other 
sleep-related movement disorders [7]. The disorder is now internationally recognised and in 2003 
the International Restless Legs Syndrome Study Group (IRLSSG) attended a National Institutes of 
Health workshop to devise an up-to-date version of the essential diagnostic criteria, plus supportive 
and associated features of the syndrome (see Table 1) [8].   
 
--------------------------------- 
INSERT TABLE 1 HERE 
--------------------------------- 
 
RLS is described by patients as creeping or tingling sensations mostly occurring deep within the 
legs, coupled with an inescapable desire to move the affected limbs. Movement brings only 
momentary relief and symptoms appear to get worse when at rest. Many people with RLS also 
complain of sleep disturbance related to the RLS symptoms occurring at night. It is usually the 
impact of the sleep disturbance that leads people to seek treatment. 
 
At present there is no cure for this condition and the aetiology has not yet been established. There 
are two types of RLS: primary and secondary. Primary or idiopathic RLS can have a childhood 
onset and slowly progresses, worsening with age. Secondary RLS usually occurs late in life and is 
linked to medical conditions, such as, renal failure, iron deficiency and pregnancy, or side-effects 
of medication [9-11]. Current treatments include improving sleep hygiene, iron supplements, and 
drug therapy such as dopamine antagonists, anti-convulsants and benzodiazepines [12]. 
 
A prevalence rate of 10% has been estimated of at least weekly RLS symptoms amongst adults in a 
population sample in North America [13]. Similarly, a study of a large multi-national primary care 
population in Europe and the US estimated a prevalence of 9.6% of weekly occurring RLS 
symptoms [14]. Nevertheless RLS remains under diagnosed. Two of the largest epidemiological 
studies concluded that the low rates of diagnosis found in each of the samples was due to 
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physicians’ low familiarity with the disorder and RLS not being recognised as a medically 
significant disorder [14,15]. However, there is growing research evidence demonstrating the 
negative impact of the condition on the person’s mental health and quality of life.  
 
As with many other physical conditions, including sleep disorders, the rate of depression is higher 
in people with RLS compared to control groups [16-22]. A recent study compared rates of 
depression between individuals with RLS and a community sample suffering from other somatic 
conditions and suggested that RLS patients are at increased risk of psychological distress [22]. This 
finding is important as it indicates that individuals with RLS could be more at risk of developing 
depressive symptomatology than individuals with other somatic conditions such as diabetes or 
cardiovascular disorders. 
 
In a clinical and neurophysiological study, Saletu and colleagues [20] identified further links 
between RLS and depression. They looked at daytime brain function in RLS and Periodic Limb 
Movement Disorder (PLMD) compared to matched-controls and also investigated objective and 
subjective sleep and awakening quality in a subset of the sample versus controls. The EEG 
mapping revealed neurophysiological correlates of depression in RLS, which were verified by self-
report data. The greatest differences between the groups occurred in the EEG measures that had 
been found to show the highest correlations to the Hamilton Rating Scale for Depression in a 
previous study investigating EEG patterns in depressed individuals. EEG mapping also revealed 
decreased sleep efficiency measured by polysomnography (PSG) in the RLS group compared to 
controls, but there was no increase in subjective daytime sleepiness suggesting that those with RLS 
compensate in some way for the reduced sleep. 
 
A further study investigated the relationship between subjective RLS symptom severity, sleep 
disturbances, and depressive symptoms [23]. Hornyak and colleagues used questionnaire data from 
100 individuals with idiopathic RLS who had attended a sleep clinic to compare self-reported sleep 
quality and depressive symptoms (measured by the PSQI and BDI respectively) with the 
International RLS Study Group Rating Scale (IRLS). They found that depressive symptoms in 
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patients with RLS seemed to be related to subjective impairment of sleep (r = 0.281, p = 0.007) 
rather than to subjective reports of RLS severity (r = 0.119, p = 0.237). However introducing a 
more objective measure of night-time RLS severity and consequently of sleep disturbance, would 
help to further explain the RLS-depression relationship. The use of a control group would also help 
to circumvent a confounding factor in the above study, of the overlapping sleep items on the BDI 
and IRLS. 
 
The reason or reasons for the observed increased comorbidity of RLS and depression is currently 
unknown. A number of possibilities have been suggested. 
 
Firstly, it could be that being depressed makes a person more sensitive to mild RLS symptoms and 
heightens the impact of RLS on the individual, but depression as a direct cause of RLS is 
questionable. More likely is that RLS is an independent risk factor for depression due to the 
consequences of disturbed sleep and in severe cases a restriction on lifestyle. This has been 
identified with other sleep disorders, such as primary insomnia and obstructive sleep apnoea 
[24,25].   
 
Another possibility is a neurological deficit that simultaneously causes both symptoms of RLS and 
depression. Dopamine deficiency has been suggested to play a part in the aetiology of both RLS 
[26,27] and depression[28].  However, as yet it is unclear whether RLS and Depression 
comorbidity is a consequence of a common pathophysiological pathway. 
 
Finally the increased comorbidity could be an artefact of differential diagnosis. The overlap in the 
symptoms of depression and RLS could lead to people being misdiagnosed. Of the nine symptoms 
of depression listed in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, 
Text Revision (DSM-IV-TR) [29], four could be a consequence of RLS: insomnia/hypersomnia; 
fatigue; psychomotor agitation or retardation; and diminished ability to concentrate or 
indecisiveness. For a diagnosis of depression to be given only depressed mood or anhedonia would 
need to be present to meet criteria. Therefore individuals with RLS may reach the clinical cut off 
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score on standardised self-report measures of depression even in the absence of a major depressive 
episode.  
 
Regardless of which mechanisms are responsible for the elevated rate of depression in RLS, a 
further problem is apparent in the clinical management of this group as antidepressants, such as 
Selective Serotonin Reuptake Inhibitors (SSRIs), [30] can aggravate restless leg symptoms. There 
is conflicting research in the literature, as well as differences in expert opinion, about the effects of 
anti-depressant medication on RLS symptom severity and the use of dopamine agonists as 
antidepressants. 
 
As discussed above there is uncertainty over the mechanisms for the increased comorbidity 
between RLS and depression and difficulties in treatment of this group. Increased understanding of 
the mechanisms may facilitate development of improved treatments. Hence this study explores the 
hypothesis that RLS is an independent risk factor for depression due to RLS-related sleep 
disturbance. In particular it considers two the specific aspects of sleep disturbance found in RLS 
outlined below as potential contributing factors to comorbid depression in RLS.  
 
One of the proposed specific mechanisms by which RLS patients’ sleep might be disturbed is the 
increasing sensory discomfort as they lie at rest in bed and the compelling urge to move their legs. 
This mechanism is analogous to the psychobiological inhibition model of insomnia which 
conceptualises insomnia as a problem with arousal down-regulation [31]. Selective attention for 
either external or internal stimuli that threaten sleep and efforts to control sleep are thought to 
inhibit the natural reduction of arousal.  Whilst individuals with psychophysiological or primary 
insomnia also complain of hyperarousal interfering with sleep onset and/or maintenance [32] this 
differs from the unique sensorimotor symptoms of RLS experienced by people with RLS prior to 
sleep onset. However it is not yet known if the impact of this restlessness or hyperarousal differs 
between these two groups. A control group consisting of individuals with primary insomnia would 
be a useful comparison to decipher whether the impact of RLS on sleep, and consequently mood, is 
similar to that found in primary insomnia, or whether the motor restlessness compounds difficulties 
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for RLS patients. The present study will therefore recruit three distinct groups: individuals with 
RLS; individuals with primary insomnia; and normal good-sleeper controls. 
 
To further our understanding of the influence of motor restlessness on psychological distress, the 
level of positive and negative feelings will be explored by comparing those with RLS to restless 
primary insomnia and non-restless good-sleeper controls during an experimental procedure 
designed to elicit symptoms. The Suggested Immobilization Test (SIT) is used as a diagnostic test 
for RLS [33]. Electromyogram (EMG) recordings are taken from both legs during a one hour 
period of voluntary immobility. RLS patients show three times more leg movements during the SIT 
than controls (76 ± 9.6 vs. 29.9 ± 16.6) [34]. In addition to being a useful assessment of the validity 
of our group allocation procedure, this test will be used to create the sensory experience of RLS in 
our participants in order to observe the direct impact on affect. 
 
Another of the proposed mechanisms by which RLS disturbs sleep is that Periodic Leg Movements 
during Sleep (PLMS) may reduce the quality of sleep in RLS patients by causing micro-arousals 
which reduce the amount of deep sleep. PLMS are described as extensions of the big toe followed 
by dorsiflexions of the foot sometimes with flexion of the knees and hips and occur in 80% of 
people with RLS [35,36]. PLMS occur repetitively during sleep, last 0.5-5 seconds and have an 
intermovement interval (IMI) of between 4 and 90 seconds.   
 
Millman and colleagues [37] found that obstructive sleep apnoea (OSA) can produce symptoms of 
depression and these appear to be related to the severity of the underlying apnoeas. This is an 
important potentially confounding factor, as many people with OSA have also been found to have 
elevated levels of depression and PLMS [25]. The focus of the present study is related to the 
influence of PLMS on levels of depression in RLS and therefore people suffering from OSA will 
be excluded.  
 
By objectively measuring the PLMS in individuals with RLS we can explore what impact this has 
on subjective quality of sleep and level of depressive symptomatology. Hornyak et al [38] 
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investigated whether PLMS, measured by PSG, were associated with subjective quality of sleep in 
people with RLS, primary insomnia and secondary insomnia. They found a negative correlation 
between PLMS and subjective sleep quality in those with RLS (n=33) on the first night (r= -.464, 
p<.01). This correlation was not found on the second night and the authors concluded that the first 
night result may be due to more superficial sleep as a result of being in the laboratory environment. 
However the night-to-night variability of the PLMS index has been well-documented [36]. 
Monitoring PLMS over more than 2 nights and within the person’s home environment may reveal 
whether an association exists between subjective sleep quality and PLMS.  
 
The present study measured participants’ PLMS at home over three nights using actigraphy. This is 
now possible due to new actigraph technology which allows PLMS to be measured in a person’s 
home environment. A new technique has been developed by Cambridge Neurotechnology Ltd that 
measures Periodic Limb Movements (PLM) in both legs simultaneously by an Actiwatch™ device 
on each foot, which is then combined to give an index of PLM (PLM per hour). This gives a direct 
objective measurement of movement in the lower limbs. Using actigraphy as apposed to PSG and 
EMG means that measurements can be obtained over a longer period of time, allowing for the 
assessment of the night-to-night variability of PLMS, without the need for lengthy inpatient 
investigation.  
 
In summary, in order to elucidate further the link between RLS and depressive symptoms this study 
will investigate the levels of positive and negative affect experienced during a Suggested 
Immobilization Test (SIT) and how this differs between the groups. Assuming that sleep 
disturbance does mediate the level of depression in people with RLS, this study will also consider 
the hypothesis that PLMS are responsible for sleep disruption in  RLS patients and are therefore 
associated with a reduction in self-reported sleep quality and an increase in depressive symptoms.  
 
1.1 Aims and Hypotheses  
The aim of the present study was to compare levels of depressive symptoms, and positive and 
negative affect in three groups: a RLS group (RLS), a restless primary insomnia group (PI) and a 
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non-restless control group (NRC) to establish whether RLS is an independent risk factor for 
depression, taking into account PLMS, which may influence the level of sleep disturbance. The 
main hypothesis postulated that the groups would differ in levels of positive and negative affect 
following a SIT. The RLS group was expected to have higher levels of negative affect than the PI 
and NRC groups. The NRC group was predicted to have higher levels of positive affect than the 
RLS and PI groups. There were a number of secondary hypotheses: a) higher PLMS index scores 
would be positively related to the level of depression reported on the BDI-II in the RLS group; b) 
the mean level of sensory discomfort score (MDS) during the SIT would be highest in the RLS 
group and lowest in the NRC group and positively correlated with the level of negative affect in the 
RLS group; c) participants with RLS would have the greatest SIT PLM and PLMS index followed 
by the PIs and then NRCs; and d) the PLMS index would be negatively correlated with subjective 
reports of sleep quality in the RLS group. 
 
2. Methods 
2.1 Design 
The study employed a between-groups design comparing three groups: a RLS group (RLS), a 
primary insomnia group as a clinical control (PI) and a non-restless, good-sleeper, control group 
(NRC). The independent variables were the presence or absence (depending on the group) of: (1) 
sleep disturbance, (2) “Restlessness”, (3) motor disorder, and (4) depressive symptoms. There were 
three dependent variables, namely, three different measures of psychological distress over different 
time periods: a retrospective measure, the Beck Depression Inventory, Second Edition (BDI-
II)[39], was used as a standard measure of depressive symptomatology over the previous two 
weeks; a concurrent measure of mood, a visual analogue scale, taken throughout the SIT; and an 
attributional measure, the Positive and Negative Affectivity Scale (PANAS)[40], assessed the 
emotional reaction to the SIT as a whole. Of these measures the PANAS was the primary 
dependent variable.  
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2.2 Participants 
 Participants were recruited from the general population by advertisements in newspapers, radio 
and GP surgery waiting rooms (press cuttings and poster are presented in Appendix 2.2). Seventy-
four potential participants were screened (see below for details of screening procedure). A number 
of participants were excluded from the study at this stage based on the following exclusion criteria 
age, <18years old or >80years old (n=2); diagnosis of major depression or bipolar disorder; 
prescribed medication to aid sleep; sleep apnoea (n=2), kidney disease(n=1); and pregnancy(n=2). 
A further 18 participants who were screened for the study declined to take part. Forty-nine 
volunteers who provided written informed consent entered the study and were allocated to one of 
the three groups based on the outcome of the face-to-face interview and their responses to the 
screening questionnaires. Four individuals where excluded at this stage due to presence of PLMD 
without RLS (n=1); cardiovascular problems (n=1); and a diagnosis of Major Depression (n=2). 
Those in the PI group complained of restlessness that affected the quality of their sleep but did not 
fulfil criteria for RLS (verified by a high score on the Pre-Sleep Arousal Scale, PSAS, [41]). The 
NRC group have no sleep-related motor problems or movement disorder or clinically significant 
insomnia as indicated by a score < 8 on the Insomnia Severity Index (ISI) [42]. A subset of the 
sample was randomly selected by a computer programme for review by the Director of the 
University of Glasgow Sleep Research Centre to ensure that the grouping allocation was reliable. 
Findings from the interview, screening questionnaires and results of the SIT and actigraphy assisted 
clinical decision making. In addition, in order to resolve any diagnostic uncertainties, participants 
were discussed with the Director of the Sleep Centre to confirm whether they had been correctly 
classified.   
 
2.2.1 Sample Size Estimation 
Given that the relationship between SIT-PLM (as a measure of RLS severity) and psychological 
distress has not been directly compared in previous studies an expected effect size was not readily 
identifiable. The power of the present study was increased by strict adherence to the grouping 
protocol in order to reduce within-group variability. Using data from the study by Saletu et al [20], 
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a large effect size was found (ƒ = 0.602) for the difference between RLS, PLMD and controls on a 
self-report measure of depression (See Appendix 2.3 for calculation). A priori sample size 
calculations for a one-way ANOVA design, using an effect size of 0.6, significance level set at 0.05 
and standard power of 0.8, suggested a sample size of 10 per group. These numbers were similar to 
another study which recruited 16 individuals with RLS with 16 age-matched controls, and detected 
a significant difference in SIT PLM (28.4 vs. 5.0; p< 0.01) and PLMS index (76.1 vs. 26.9; p 
<0.001) [34]. Therefore it was proposed that at least 15 participants should be recruited to each of 
the three groups.  
 
2.3 Measures 
2.3.1 Demographic, screening and clinical measures 
Participants were screened via telephone interviews prior to being invited to the Sleep Centre. 
Information gathered included: age; weekly alcohol intake; current smoking status; medical 
history; psychiatric history; medication use; and Body Mass Index (BMI).  
 
The essential diagnostic criteria for RLS as defined by the IRLSSG were incorporated into 
telephone screening questions. These questions were based on the recommendations from the 
restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health 
[8] and are listed in Table 2.  Screening questions based on the IRLSSG criteria have been shown 
to have between 87.5%-100% sensitivity and 96% specificity for RLS diagnosis [8,43].  
 
          -------------------------------- 
INSERT TABLE 2 HERE 
-------------------------------- 
 
Subjective RLS symptom severity was assessed by the International Restless Legs Syndrome Study 
Group Rating Scale (IRLS) [44].  This measure is a reliable 10-item self-report questionnaire 
which has high levels of internal consistency (Cronbach’s α = 0.95) and good test-retest reliability 
                                                 
2
 Cohen’s [ref] conventional value for an operationally defined large effect size for the one-way ANOVA is ƒ 
=0.4. 
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(r = 0.87). This measure was used to ensure adequate severity of the RLS symptoms in those 
meeting the diagnostic criteria and a cut-off value of above 10 indicated the presence of RLS 
symptoms.  
 
The Pre-Sleep Arousal Scale (PSAS) [41] was employed and is a reliable self-report instrument, 
commonly used in insomnia research studies, which describes the intensity of cognitive and 
somatic symptoms of arousal just as the individual is falling asleep. There are two subscales, 
Cognitive and Somatic, each with 8 items. Internal consistency of both the Cognitive and Somatic 
subscales are satisfactory (Cronbach’s α = 0.88 and 0.79 respectively). 
 
The Insomnia Severity Index (ISI) [42] was also used which is a brief 7-item self-report measure 
which targets subjective symptoms and perceived consequences of insomnia and level of distress 
caused by those difficulties. Investigations of the ISI’s psychometric properties indicate adequate 
internal consistency (Cronbach’s α = 0.74).  There is also preliminary evidence of its concurrent, 
predictive, convergent and content validity [45].  
 
Further questions based on a suggested outline of a Sleep History Assessment [32] were asked 
during interview to rule out other sleep-related problems such as sleep apnoea and to facilitate 
categorisation of the volunteers into appropriate groups. The Epworth Sleepiness scale (ESS) [46] 
was also administered as a self-report measure of daytime sleepiness. It provides a useful indicator 
of the presence of various sleep related disorders such as sleep apnoea, narcolepsy and idiopathic 
hypersomnia. The ESS has demonstrated good internal consistency and test-retest reliability 
(Cronbach’s α = 0.88 and r = 0.82) [47]. 
 
Subjective sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI) [48]. The 
PSQI was developed to provide a reliable, standardised measure of sleep quality and to 
discriminate between good and poor sleepers. There are 7 component scores targeting a variety of 
areas of sleep quality and these combine to give a global score ranging from 0-21. A PSQI global 
score >5 was shown to have 89.6% sensitivity and 86.5% specificity for distinguishing good and 
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poor sleepers. In addition a score >5 indicates that an individual is having severe difficulty in at 
least two areas, or moderate difficulty in more than three areas. A score greater than 5 on the PSQI 
confirmed the presence of a sleep disturbance in the RLS and PI groups.  
 
Participants were required to fill out a sleep diary, adapted from Morin & Espie [32], in 
conjunction with the actigraphy. A copy of the sleep diary is shown in Appendix 2.4. The sleep 
diary has been established as a useful and reliable measure of sleep latency, wakefulness, sleep 
time and sleep efficiency and is commonly used in sleep research and clinical practice [32].   
 
Quality of life was also measured using the Short-Form 36 Health Survey (Version 2.0) (SF-36v2) 
[49]. There are eight components: Physical Function; Role limitations due to physical health; 
Bodily Pain; General Health; Mental Health; Role limitations due to mental health; Vitality; and 
Social Functioning. A physical health component summary score (PCS) is derived from the first 
four scales and a mental health component summary score (MCS) derived from the latter four 
scales. The components have been found to have good internal consistency in a UK sample 
(Cronbach’s α = 0.80-0.95)[50]. 
 
The Beck Depression Inventory Second Edition (BDI-II) [39] is a 21-item self-report questionnaire 
which gives a total score (range 0-63) relating to the level of depressive symptoms. Internal 
consistency is high in both psychiatric and non-psychiatric populations (Cronbach’s α = 0.92 and 
0.93 respectively) [39]. Test retest reliability is also high at r = 0.93. The BDI-II has demonstrated 
good construct, convergent and discriminant validity [39]. Although the BDI has a strong somatic 
component, it has been commonly used in studies of chronic and acute health conditions.  For the 
present study it was employed as a secondary measure, with the PANAS being the primary 
measure. 
 
2.3.2. Prospective experimental measures  
2.3.2.1. Suggested Immobilisation Test 
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Participants were asked to complete a daytime Suggested Immobilization test (SIT) in which they 
were instructed to sit on a bed at a 45º angle and not to voluntarily move their legs for a period of 
one hour. Periodic Leg Movements (PLM) were measured using electromyogram channels attached 
to the anterior tibialis muscles of both legs. The SIT PLM index was calculated in accordance with 
recent criteria defined by Michaud et al [35]. Criteria for scoring PLMS are appropriate for the SIT 
except for leg movement duration which has been increased from 0.5-5s to 0.5-10s. A cut-off score 
for SIT PLM  of 12 was found to have a sensitivity of 62% and a specificity of 84% and is 
recommend when testing individuals with varying levels of symptom severity[51].  
 
Two Visual Analogue Scales (VAS) measured perception of sensory discomfort in the participants’ 
legs during the SIT and their mood throughout the test at 5 minute intervals. The sensory 
discomfort scale was constructed with a 100mm horizontal line with the descriptors “no 
discomfort” on the left to “extreme discomfort” on the right taken from an established VAS, 
developed as an addition to the SIT procedure [33]. The 12 discomfort scores were then averaged 
to give a mean discomfort score (MDS). An MDS >11 has been found to correctly classify 82.7% 
of all subjects in a RLS group and a control group with sensitivity of 82% and a specificity of 84% 
[51] and was adopted for this study. The mood VAS, similarly a 100mm horizontal line, had the 
descriptors “worst ever” on the left to “best ever” on the right. A mean mood score was derived 
from the 12 scores.  
 
2.3.2.2. PANAS 
The level of positive and negative affect experienced during the SIT was measured using the 
Positive and Negative Affectivity Schedule (PANAS) [40]. The internal consistency reliabilities are 
high for both positive and negative affect scales (Cronbach’s α = 0.89 and 0.85 respectively for 
moment timescale instructions). Both scales have a range of 10 - 50. The test-retest reliability of 
the positive and negative scales are r = 0.54 and 0.45 respectively at the “moment” timescale which 
is explained by the measure tapping into state rather than trait affect.  
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2.3.2.3. Actigraphy 
The participants’ periodic leg movements during sleep (PLMS) were measured at home using 
Actiwatches, produced by Cambridge Neurotechnology, which were taped to each foot at the base 
of the big toe.  The analysis software allows movements that occur in both legs to be scored 
simultaneously. The adaptations made by Moorish and colleagues [52] to the American Sleep 
Disorders Association (ASDA) criteria for scoring PLMS, normally measured by EMG during 
PSG, were used in the present study in order to reduce the chance of artificially inflating the 
number of PLMS due to the lowest epoch being two seconds. Participants were given instructions 
to wear the Actiwatch™ devices on both feet for three nights and to fill out a sleep diary each 
morning. A PLMS index > 5 was adopted as this indicates the presence of Periodic Limb 
Movement Disorder (PLMD) according to the International Classification of Sleep Disorders –
Revised (ICSD) [6], however whilst this is found in around 80%-90% of people with RLS its 
presence is not essential [8].  
 
2.4 Procedure 
Following screening, potential participants who did not meet any of the exclusion criteria were sent 
participant information sheets and invited to attend the University of Glasgow Sleep Centre.  
Participants provided informed written consent before proceeding to the next stage - a face-to-face 
interview with the researcher and completion the self-report measures. Participants in all three 
groups were required to complete the SIT.  The researcher set up the EMG equipment and carried 
out the necessary biocalibration procedure before beginning the SIT (See Appendix 2.5 for 
biocalibration). The researcher had received prior training from the Sleep Centre’s Clinical 
Physiologist. Participants rated their sensory discomfort and mood on a visual analogue scale every 
5 minutes throughout the 1-hour duration of the test. After the test they were asked to rate their 
affect during the SIT using the PANAS [40]. If data from the self-report questionnaires indicated 
that the participant did not meet criteria for their allocated group, they were reallocated or excluded 
from the study. Following the SIT, participants were given both verbal and written instructions 
regarding the use of the Actiwatches (See appendix 2.6 for the written instructions). Once the 3-
nights of actigraphy recording had been completed, participants posted their Actiwatches and sleep 
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diary to the Sleep Centre.  The Actiwatch data was electronically summed using specialist 
software. The average PLM index for each participant was calculated from all three nights’ data. 
Participants were then sent a report of the results of testing.  
 
2.5. Equipment 
The equipment required for the SIT procedure was as follows. Two self-adhesive electrodes 
(Ambu® Neuroline 720 EMG electrodes manufactured by Ambu) were positioned on each leg 
above the anterior tibialis muscle, and two electrodes (also Ambu® Neuroline 720) for the baseline, 
were placed on the forehead (see Figure 1). The electrodes were attached to a Trackit 24 device 
(manufactured by Lifelines Ltd) and signals relayed via a Bluetooth module back to the control 
room where the researcher watched the signals live on a PC monitor. The data was stored on a flash 
memory card and downloaded and analysed using Stellate Harmonie Version 6 software 
(manufactured by Stellate Systems Incorporated). The traces from each SIT procedure were then 
scored manually (see Figure 2 for a sample of an EMG trace).  
 
----------------------------------- 
INSERT FIGURE 1 & 2 HERE 
----------------------------------- 
 
The actigraphy utilised two AW4 Actiwatches from Cambridge Neurotechnology Ltd (CNT) for 
each participant. The Actiwatches were taped to each foot using low allergy tape to avoid skin 
irritation. The exact positioning of the Actiwatch™ is illustrated in Figure 3. The Actiwatch data 
was downloaded using an Actiwatch reader, connected by serial port to the PC and analysed using 
the first version of PLMS Software®, also manufactured by CNT.  
 
--------------------------------- 
INSERT FIGURE 3 HERE 
--------------------------------- 
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2.6 Data Analysis 
Preliminary analysis was conducted on the demographic data to ensure that the groups were 
similar. Differences between the groups in demographic data were added as covariates in the main 
analysis. Confirmatory analyses were carried out on the screening measures to verify that groups 
differed appropriately on each of the variables. Prior to formal data analysis, data were inspected to 
ensure that assumptions for parametric tests were met. All of the data, except PANAS negative and 
PLMS index scores, were normally distributed as indicated by Kolmorogov-Smirnov tests. Where 
variances were heterogeneous, as indicated by Levene’s Test for the Homogeneity of Variances, 
data were transformed using appropriate techniques [53] (See appendix 2.7). However, given the 
robustness of the F-test and post-hoc Tukey Tests and the equal sample sizes the untransformed 
data and analyses were reported [54,53]. The main hypotheses were tested by analysing the 
differences between the groups using one-way analysis of variance (ANOVA) for each of the 
dependent variables. The analysis was then repeated using analysis of covariance (ANCOVA) to 
investigate the impact of adding covariates (see appendix 2.8). However, non-normality and 
heterogeneous variances could not be rectified for PANAS Negative and PLMS index and 
therefore non-parametric tests were employed where appropriate. In addition, correlational analyses 
of the PLMS index and subjective sleep quality, RLS severity and depression were performed 
using Pearson’s product moment correlation coefficient unless non-parametric tests were indicated, 
in which case Spearman’s rank order correlation coefficient was utilised.  All analyses were carried 
out using Statistical Package for Social Sciences Version 15. Significance tests were 2-tailed and a 
significance threshold of p<.05 implemented.  
 
2.7. Ethical approval 
Ethical approval for the project was granted from the Greater Glasgow & Clyde Primary Care 
Community & Mental Health Research Ethics Committee (See Appendix 3.2 for a copy of the 
approval letter).  
 
3. Results 
3.1. Participant Characteristics 
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The mean age across all participants was 34.7 years (SD = 10.8 years), with a total of 26 females 
and 19 males. The average BMI of participants was 24.3 (SD = 3.6) and 8 (17.8%) of the overall 
sample were smokers. The average units of alcohol consumed per week was 5.9 units (SD = 8.5 
units).  In total, 13 (28.9%) of the participants reported that they snored. Table 3 shows the 
demographic characteristics by group. With regards to group differences in demographic data, 
ANOVA and Tukey’s post-hoc Test demonstrated that the RLS group was significantly older than 
the non-restless controls (NRC) (p= 0.014). Given this finding, each of the subsequent analyses of 
group differences were performed first without a covariate and then again with an analysis of 
covariance (ANCOVA), with age as a covariate. 
 
-------------------------------- 
INSERT TABLE 3 HERE 
-------------------------------- 
 
3.2. Screening and clinical measures 
The mean scores and standard deviations for each of the screening and clinical measures are 
presented in Table 4. As expected on the measures relating to sleep, those in the NRC group scored 
significantly lower than the PI and RLS groups on the ISI, PSQI and the physical subscale of the 
PSAS, confirming that they were good sleepers. The PI group scored significantly higher on the 
cognitive subscale of the PSAS compared to the NRC but not the RLS group. The RLS group and 
the PI group did not significantly differ on any of the sleep related measures, confirming that both 
of these groups are characterized by the presence of a sleep disorder. No significant differences 
were found between any of the groups on the ESS. The IRLS scores were compared for the RLS 
and PI groups by Student t-test and the difference between the means was found to be significant 
(t(28) = 7.6; p<.001), confirming the presence of a motor disorder in addition to a sleep disorder in 
the RLS group. With regard to sleep diary data (see Table 4 for data), this confirmed that the NRC 
comprised good sleepers and had significantly higher Sleep Efficiency scores than the RLS group 
(P<.001) and PI group (p =.003). Similar to the sleep-related questionnaire measures, the sleep 
diary data also confirmed the presence of a sleep disorder in both the RLS and PI groups. The 
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groups differed in reported quality of life measured by the SF36v2, the RLS group reported poorer 
physical health than the PI and NRC groups. The quality of life mental health component score 
only significantly differed between the RLS group and the NRC group with the RLS group 
reporting poorer mental health. There was no significant difference between the RLS and PI group 
on the mental health component of the SF36v2. The RLS group scored significantly higher than the 
NRC group on the BDI-II but not the PI group. Further ANCOVAs of the questionnaire data with 
age as a covariate indicated that the differences between the groups remained significant (See 
Appendix 2.8).  
  
-------------------------------- 
INSERT TABLE 4 HERE 
-------------------------------- 
 
3.3. Experimental data 
3.3.1. SIT 
The SIT procedure generated a score of the number of periodic leg movements in one hour of 
voluntary immobilisation, a mean sensory discomfort score and a mean mood visual analogue score 
for each of the participants. One of the participant’s experiment was cut short due to technical 
problems and the SIT index was calculated by dividing the number of PLM by the number of 
minutes of the test that were completed and multiplying by 60. It was predicted that the RLS group 
would have the highest SIT PLM index, followed by the PIs and then the controls. The data for 
each of the three groups is shown in Table 5. The results indicate that the RLS group had a mean 
SIT index approximately 2.5 times greater than both NRCs (p = .022) and PIs (p= .021) partially 
confirming the hypothesis. The results of the SIT procedure are illustrated in Figure 4 and the 
magnitude of the difference in SIT PLM index scores can be seen between the groups. Surprisingly 
the PIs and the NRCs did not differ on the level of PLM during the SIT and therefore this part of 
the hypothesis was not upheld. The PIs and NRCs did not differ in the level of movement and 
therefore suggests that the SIT PLM index is an indictor of motor disorder rather than restlessness 
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per se.  Eighty-percent of the RLS group had a SIT PLM index >12. However, only 60% of 
controls were correctly identified using a cut-off of 12, questioning the specificity of this measure. 
  
--------------------------------- 
INSERT TABLE 5 HERE 
--------------------------------- 
 
3.3.2. Visual analogue scales: sensory discomfort and mood 
It was hypothesized that the sensory discomfort experienced during the SIT would be highest in the 
RLS group and lowest in the NRC group. The results from the sensory discomfort analogue scale 
indicated that the RLS group had a significantly higher Mean Discomfort Score (MDS) than the 
NRC group (p=.003) but not the PI group (p=.262) (see Table 5 for data). However Figure 4 
illustrates a trend towards the MDS being larger in the RLS group compared to the PI group. 
Applying the MDS cut-off of 11 to the MDS data revealed that 73.3% of the RLS group were 
correctly identified. However 80% of the PI group were also in the clinical range compared with 
just 53.3% of the NRC group which suggests that the MDS might be measuring the sensory aspect 
of restlessness rather than the discomfort tied to a specific motor disorder. No specific hypotheses 
were made about the Mean Mood Score from the visual analogue during the SIT and this scale did 
not in fact show any differences between the three groups.  
 
---------------------------------- 
INSERT FIGURE 4 HERE 
---------------------------------- 
 
3.3.3 PANAS 
The PANAS was employed as a retrospective measure of affect and was completed by participants 
immediately following the SIT procedure.  The instructions asked them to rate, on a 5-point Likert 
Scale, to what extent they had felt a range of positive and negative emotions during the previous 
hour. The overall mean scores for the PANAS Positive and Negative Scales were 20.4 (SD = 6.7; 
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Range = 10-41) and 12.0 (SD = 2.6; Range = 10-20) respectively. Internal consistency of the 
Positive Scale was high (Cronbach’s α = 0.85; range: 0.82-0.86). However the Negative Scale was 
disappointing in terms of reliability (Cronbach’s α = 0.42; range: 0.24 - 0.64). This was perhaps 
related to the small variance of the measure. Two of the variables had zero variance and were 
removed automatically (Ashamed; Afraid). Following analysis of alpha if item-deleted values, two 
further variables were removed (Nervous; Guilty), improving reliability considerably (Cronbach’s 
α = 0.66; range: 0.50 - 0.68), although the coefficient remained below established minimum 
reliability criteria [55]. The two scales did correlate positively with each other, confirming that they 
are not measuring the opposite extremes of the same construct (rs=.46, p=.002). 
 
The main hypothesis predicted that the RLS group would have greater levels of negative affect and 
this prediction was upheld. Unadjusted PANAS data for each group can be seen in Table 5. In 
addition, it was predicted that the NRC would have the highest levels of positive affect. This was 
not upheld and in fact the RLS group had significantly higher levels of positive affect compared to 
the PI and NRC groups (see Table 5). Further analysis was carried out using ANCOVA (see 
Appendix 2.8 for data). In addition to age, level of pre-existing depressive symptoms were 
controlled for by adding the BDI-II mean score as a covariate. The results demonstrated that a 
significant difference remained between the groups on the Positive (F(2, 45) = 3.39, p = .044) and 
the Negative (F(2, 45) = 4.88, p =.013) scales of the PANAS when controlling for age and 
premorbid depressive symptoms.  
 
3.3.4. Actigraphy 
The sleep parameters obtained from the participants’ sleep diaries were essential to analyse the 
Actigraphy data. All included participants returned their sleep diary along with the Actiwatches. 
The PLMS indices obtained for each of the groups can be seen in Table 5. It was hypothesised that 
the RLS group would have the largest PLMS index score and the results confirmed this prediction. 
Non-parametric testing revealed that the RLS group’s PLMS index was significantly higher than 
both the PI (z=58.5; p=.025) and NRC groups (z=45; p=.005). It was also hypothesised that the PI 
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group would have a greater PLMS index than the NRCs. The results did not support this hypothesis 
– no significant difference was found between the PIs and NRCs (z=86.5; p=.280).  
 
3.4. Association between periodic leg movements, mood and sleep quality. 
The Spearman’s rank order correlation coefficient was calculated between PLMS index and BDI-II 
total score to check for an underlying associated between depression and PLMS across all 
participants. Although a positive correlation was revealed, this did not reach significance (rs= .182, 
p=.231). It was predicted, a priori, that higher PLM index scores as measured by actigraphy would 
be positively related to the level of depression reported on the BDI-II in the RLS group. The 
opposite was found using Spearman’s Rho with a non-significant negative correlation between 
PLMS index and BDI-II scores in the RLS group (rs= -.175, p=.532). This was also the case for the 
NRC group (rs= -.385, p=.156), however, interestingly for the PI group PLMS index scores were 
strongly associated with depression scores on the BDI (rs=.638, p=.01). This correlation was 
reduced and became non-significant when the analysis was repeated using the using the BDI-II 
score minus the sleep–related items (rs=.457, p=.087). 
 
It was predicted that PLMS would be positively associated with measures of sleep quality in the 
RLS group (a higher score on the PSQI indicates poorer sleep quality). There was a non-significant 
positive correlation between PLMS index and PSQI scores in the RLS group (rs=.447, p=.094). 
Furthermore the RLS group’s ratings on the IRLS correlated strongly with the PSQI (r=.573, 
p=.013) and ISI (r=.852, p<.001). 
 
3.5. Association between sensory discomfort and affect 
Possible underlying associations between affect and sensory discomfort during the SIT were 
investigated using Pearson’s product-moment correlation coefficient except where parametric 
assumptions were not met (see data analysis section above). Overall a strong positive correlation 
was found between negative affect and sensory discomfort in the legs (rs = .635, p<.001) and a 
moderate correlation between positive affect and sensory discomfort (r= .39, p = .008).  
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It was hypothesised, a priori, that the level of negative affect would be positively correlated to the 
level of sensory discomfort in the RLS group. Further analysis of the correlations in each group 
found, as predicted, that in the RLS group negative affect was strongly associated to sensory 
discomfort (rs = .853, p<.001). This association was strengthened when the unreliable items of the 
PANAS Negative Scale were removed (rs =.906, p<.001)(see Figure 5), indicating that over 80% of 
the variance in negative affect can be accounted for by sensory discomfort. In the PI (rs=.160, p = 
.569) and NRC (rs=.314, p= .255) groups, positive correlations were revealed between negative 
affect and sensory discomfort, although neither reached statistical significance. 
 
-------------------------------- 
INSERT FIGURE 5 HERE 
--------------------------------- 
 
4. Discussion 
This study investigated the previously reported relationship between RLS and depression, using a 
comparative design, comprising both clinical [primary insomnia (PI)] and good sleeper [non-
restless (NRC)] control groups. The groups were compared on a number of subjective and 
objective measures. The main hypotheses predicted how the groups would differ in their levels of 
positive and negative affect following the SIT. There were a number of secondary hypotheses 
examining the level of depressive symptoms and the subjective measures of sleep quality, as well 
objective measures of involuntary movements during sleep - PLMS. When controlling for age as a 
covariate, all of the results held.  
 
As predicted the RLS group had higher levels of negative affect following the SIT than the PI and 
NRC groups however they also had higher levels of positive affect compared to both the PI and 
NRC groups. The latter finding was unexpected. One explanation is that this was as a result of a 
rebound effect as the PANAS was completed immediately after the participants were allowed to 
move again. Another possibility is related to the positive emotions in the PANAS such as 
“interested” and “enthusiastic” which were more frequently endorsed by the RLS group. It could be 
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that the participant information sheet description (see Appendix 3.3) of the SIT as a diagnostic test 
for RLS was welcomed by these participants. Therefore the RLS group may have regarded the SIT 
as having particular relevance to them. 
 
Notwithstanding these possibilities, it should be noted that the presence of positive and negative 
affect occurring simultaneously is not unusual in itself. Watson and Tellegren’s model [56] of 
emotion proposes that positive and negative affect are orthogonal constructs, therefore high 
negative affect and high positive affect can occur at the same time. However in comparison to 
healthy undergraduate student norms, the levels of positive and negative affect in all the groups in 
the present study were below typical values [57]. Inspection of the mood terms according to 
Watson & Tellegrens’ model used to define low positive and low negative affect, such as drowsy, 
dull, sleepy for positive affect, and calm, placid and relaxed for negative affect, demonstrates that 
the PANAS could well have captured how the participants felt during an hour of inactivity. This 
may also explain the lack of variance in the negative affect scale, particularly for the control 
groups. The lack of high negative affect in the RLS group could also be in part due to the timing of 
the SIT which may have meant, depending on severity of RLS, that the sensory symptoms were not 
evoked. This issue is discussed further below.   
 
With regard to the secondary hypotheses, the predicted positive correlation between PLMS and 
level of depressive symptoms, as measured by the BDI-II, in the RLS group was not found. 
Hornyak and colleagues’ study [23] found a small positive correlation, explaining four-percent of 
the variance, between depressive symptoms and PSQI rather than subjective self report of RLS 
severity. Using actigraphy as an objective measure of RLS severity (assuming increased PLMS 
leads to increased arousals) in the present study also failed to reveal an association with level of 
depressive symptoms as measured by the BDI. Therefore it appears that neither subjective nor 
objective measures of RLS severity are associated with a subjective measure of depression.   
 
It was hypothesised that the association previously found between RLS and depression could be 
accounted for by the increased PLMS in people with RLS disturbing their sleep; and consequently 
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increasing their risk of depression. Results showed that whereas the RLS group had significantly 
higher PLMS index scores, they did not differ from the PI group on the sleep diary parameters or 
the subjective reports of sleep quality measured by the PSQI and ISI. Bearing in mind that people 
with a diagnosis of Major Depression were excluded, mild depressive symptoms were found in the 
two clinical groups.  These findings then suggest that the PLMS per se were not a causal factor in 
the levels of sleep disturbance and depressive symptoms reported by the RLS group; however this 
is speculative as these variables would have to be entered into a regression analysis in order to 
draw that conclusion. A regression analysis could not be carried out on this occasion due to a 
number of assumptions not being met.  
 
A possible explanation for the RLS group having similar levels of subjective sleep disturbance to 
the PI group despite higher PLMS is that people are not always consciously aware of PLMS and 
often have to be told by a partner about their leg movements and therefore these would not be 
reflected in their self-reported sleep quality. Alternatively, there may be another mechanism for the 
sleep disturbance in the RLS group such as the increasing sensory discomfort as they lie in bed and 
trying to resist the urge to move their legs, which would be similar to the effects of sleep effort in 
people with primary insomnia [31]. 
 
The mean level of sensory discomfort (MDS) during the SIT was higher in the RLS group 
compared to the NRC group as predicted. However there was no significant difference between the 
RLS and PI groups.  Figure 3 demonstrated a trend in the direction predicted between the RLS 
group and the PI group with higher MDS in the RLS group. Post-hoc power calculations suggest 
that 48 participants in each group would have been required for the difference in MDS between 
RLS and PI groups to reach statistical significance. As RLS patients have not previously been 
compared to people with primary insomnia on this measure, a lack of statistical power could well 
be responsible for these findings. Another factor may be, as the diagnostic criteria of RLS 
emphasize, that movement in individuals with RLS group relieves sensory discomfort and the RLS 
group have the highest SIT PLM index. The greater movement in this group may lower the level of 
sensory discomfort. However further analysis using the SIT PLM index as a covariate to control for 
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the effects of movement did not find a significant difference between the RLS and PI group on 
MDS (See Appendix 2.8 for the supplementary analysis). So why might the PI group also find the 
SIT challenging? Poor stimulus control has been proposed as a ‘setting condition’ for primary 
insomnia and given the context of the experiment - a bedroom environment - this may have 
increased their sensory discomfort. They may try to remain motionless in bed at night in a bid to 
fall asleep and the SIT may trigger both automated conditioned arousal and the behavioural 
tendency to remain still. The net effect of this could be sensory discomfort. Nevertheless despite 
higher levels of sensory discomfort in the PI compared to the NRC group, this did not appear to 
create a high negative affective response. 
 
As predicted, the level of negative affect in the RLS group was strongly associated with the level of 
sensory discomfort during the test, with the sensory discomfort explaining 80% of the variance in 
PANAS negative scores. This strong association was unique to the RLS group (sensory discomfort 
explained 2.5% of the variance in negative affect in the PI group) and could suggest that the 
experience of restlessness during the SIT differed between the groups.  There was no significant 
difference in the RLS group and PI group on measures of sleep quality suggesting that people with 
RLS are similar to people with primary insomnia in terms of level of sleep disturbance. However, 
there was a trend towards the cognitive arousal measured by the PSAS to be greater in the PI group 
than the RLS group and post-hoc power calculations predicted that a further 11 people in each 
group would be required for this trend to become significant. Whilst the PI group had the typical 
high levels of cognitive arousal before sleep, the RLS group may be more affected by the 
psychological distress that accompanies the sensations in their legs and compelling urge to move 
prior to sleep onset. The presence of a motor disorder appears to be associated with qualitative 
difference in the experience of restlessness for the RLS group, although the outcome may be 
similar – problems with arousal and initiating sleep. The negative affect in the PI group appears to 
be less influenced by being asked to stay immobile and could be due to timing of the SIT or 
negative attributions regarding arousal being related to the controllability of sleep in primary 
insomnia rather than restlessness.  
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It is plausible with such a high correlation between sensory discomfort and negative affect in the 
RLS group that these measures tap into the same construct. It appears that the RLS patients with 
higher levels of sensory discomfort responded positively to the negative and positive PANAS 
items, possibly capturing their level of arousal. These individuals possibly found it difficult to 
separate the sensory experience from the emotional impact caused by the discomfort which may 
also explain the trend towards lower PSAS cognitive arousal scores. This issue creates a dilemma 
for future measurement of the immediate affective response to RLS symptoms. In the arena of 
Chronic Pain Management the age-old view of mind and body is being replaced by a much more 
holistic view whereby pain is recognised as having cognitive, affective and behavioural 
components and RLS could also be viewed in this way [58]. The pain literature suggests that 
unpredictable pain causes anxiety and heightened vigilance, leading to an increase in pain 
sensitivity [59].  Anecdotally, people with severe RLS often describe it as painful and therefore the 
sensory RLS symptoms or the anticipation of symptoms may elicit negative affect leading to 
increased perception of motor and sensory symptoms. This raises a further issue of controllability. 
There is evidence from pain research that the perception of control over pain can increase coping 
[58]. For those with the severest forms of RLS the ability to self-regulate emotion may be crucial to 
reduce distress caused by the RLS symptoms.  
 
Finally, there was no correlation found between the objective measure of RLS severity (PLMS) and 
a subjective measure of sleep quality (PSQI) whereas the self-report measure of RLS severity 
(IRLS) correlated positively with the PSQI and the ISI. Insomnia research shows that people’s 
subjective accounts of sleep do not always correlate with objective measures [60] and therefore 
RLS patients are perhaps no different in this respect. However there is also the possibility that not 
all PLMS measured by the actigraphy caused microarousals.  Although PLMS and PLMS-arousal 
indices as measured by PSG have been found to be highly correlated with one another [51], being 
unable to verify whether PLMS were related to microarousals or wakefulness is a potential 
disadvantage to using actigraphy.  
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This study is the first to have investigated the levels of positive and negative affect in patients with 
RLS. The finding of a strong association between sensory discomfort and negative affect in the 
RLS group is an important one. The results shed some light on the possible mechanisms for the 
increased comorbidity between RLS and depression. Essentially the results indicate that the 
sensory discomfort felt by the RLS group prior to sleep onset could be associated with an increase 
in negative affect and this emotional as well as physical arousal delays sleep onset. The sleep 
disturbance caused by these experiences results in an increased risk of depression similar to the 
insomnia population as a whole [24] and may be compounded further by the increased exposure to 
negative affect.  
 
There are a number of important limitations to the present study that must be considered. Firstly, 
despite no effect of age, future studies should use age and gender matched controls. This was not 
possible in the present study due to the methods of recruitment and the people responding 
positively to the RLS advertisement tended to be older than those with sleep complaints or normal 
sleeper controls. 
 
Secondly, due to practical constraints, the SIT procedure was carried out during the day. Hening et 
al [61] found that an independent circadian factor modulates the intensity of RLS symptoms, hence 
the standard diagnostic criteria relating to the RLS symptoms occurring mostly at night. They 
measured sensory discomfort and periodic leg movements and found that both of these increased 
throughout the day and peaked in the hours after midnight in a group of people with severe RLS. 
Therefore carrying out the SIT during the day may mean there is actually a reduction in the PLM 
index and sensory discomfort for the less severely affected individuals. Nevertheless the RLS 
group did have significantly higher SIT PLM scores than the two control groups. However future 
studies, testing at night, prior to sleep onset, may produce a greater difference in levels of sensory 
discomfort, with the RLS group experiencing much more discomfort. 
 
Another potential criticism of the present study is that the SIT traces were not also scored by an 
independent rater. The main author scored all of the SIT data for every participant. Whilst this 
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ensured consistency of the scoring, no evidence of inter-rater reliability could be provided for the 
present study.  
 
Finally, the reliability of the PANAS negative subscale is disappointing, calling the results into 
question. The low internal consistency of this scale means that the items do not correlate highly 
with one another and therefore the validity of the measure is uncertain. This also reduces the 
likelihood that the findings of this study are replicable. The PANAS was chosen because of good 
face validity but on reflection this may not have been the best measure as we cannot be sure that it 
is not just tapping into the sensory discomfort. Perhaps a better approach would be to look at the 
items on the PANAS individually. Some of the items, for example “jittery” are more likely to be 
tapping into the motor and sensory symptoms than others. Another approach might be to measure 
facial EMG as an alternative measure of emotion, which would also circumvent the problem of the 
measurement of affect being retrospective. The facial EMG and leg EMG could be analysed in 
parallel showing the impact of leg movements and periods of inactivity on mood.  
 
If we consider the findings of the present study a true reflection of the impact of sensory discomfort 
on mood in those with RLS, there are obvious implications for clinical practice and future research. 
Currently RLS patients, if properly diagnosed, are treated by their GP using various medications or 
referred to Neurologists for investigation.  The Neurologist will attempt to treat the motor disorder 
and may be unaware of the problems of emotional and physiological arousal when trying to remain 
at rest. Whilst medication may help to relieve or dull down the sensory discomfort, this does not 
work for all patients and in other cases certain medications can lead to an augmentation of 
symptoms [26]. These results provide some initial evidence that the distress caused by RLS 
symptoms may have a psychophysiological basis and so be amenable to psychological treatment. 
Cognitive behavioural techniques that have been shown to be effective for treating insomnia [62] 
could also be useful for reducing the impact of RLS. Provision of information regarding RLS may 
help to alleviate the sense of being helpless. Cognitive restructuring to help tackle unhelpful beliefs 
that elicit negative affect and avoidance of situations such as going to the cinema may also prove 
beneficial. Cognitive coping strategies that have been shown to be effective in increasing pain 
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tolerance may also be useful, such as pleasant imagery or distraction techniques [58]. New 
acceptance-based approaches and mindfulness techniques which have been applied successfully to 
chronic pain may also be helpful. A recently published preliminary study evaluating an acceptance 
and mindfulness based group therapy has demonstrated promising results [63] and should be 
explored in future research. However prior to this, a number of issues need to be resolved. Further 
research comparing RLS patients with PI groups is required, using the standard SIT procedure just 
prior to sleep onset. Sleep onset should be calculated according to the individual’s circadian 
rhythm, using for example core body temperature. It would be interesting to discover whether the 
levels of positive and negative affect would be different to those found in the present study. 
Another important suggestion would be to measure subjective and objective sleep quality, affect 
and RLS severity prospectively over the same time period which would enable analyses of which 
factor or factors predicted the level of depressive symptoms.  
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5. Conclusion 
This study was the first to investigate levels of positive and negative affect in RLS and to use PI as 
a clinical control group.  Use of the PI group enabled exploration of what relationships may be 
specific to the RLS syndrome and which may be accounted for by having a sleep disorder of some 
type. Perhaps the most striking result is the high correlation between negative affect and sensory 
discomfort in the RLS group, however, the difficulties with the reliability of the scale in this case 
and the likelihood of affect and sensory discomfort being orthogonal constructs must be 
considered. Further studies are needed to establish the validity of the use of the PANAS on a sleep 
disorder population. Despite the practical limitations of the study, significant differences were 
found between the RLS group and the control groups on the objective measures of the SIT and 
actigraphy with relatively small sample sizes. This study supports the view that the increased 
comorbidity between RLS and depression is due mainly to the level of sleep disturbance and this 
sleep disturbance is not directly related to the number of PLMS. This study also underlines sensory 
discomfort experienced by RLS patients as they are trying to fall asleep and points to the resultant 
emotional arousal as having a potential role in the sleep disturbance and increased level of 
depressive symptoms. Taking into account the limitations of the study, any conclusions drawn from 
the present study must be approached with some caution. The results of this study have important 
implications for future research and clinical practice. It is important that the RLS patients’ 
experience is recognised and understood, as the excerpt at the beginning of this paper demonstrates, 
RLS can leave those with the condition with intolerable anguish and distress.  
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Table 1. Clinical Features of Restless Legs Syndrome 
 
 
Essential diagnostic criteria for restless legs syndrome 
 
1. An urge to move the legs,  usually accompanied or caused by uncomfortable and unpleasant 
sensations in the legs (Sometimes the urge to move is present without the uncomfortable 
sensations and sometimes the arms or other body parts are involved in addition to the legs) 
 
2. The urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity 
such as lying or sitting 
 
3. The urge to move or unpleasant  sensations are partially or totally relieved by movement, such as 
walking or stretching, at least as long as the activity continues 
 
4. The urge to move or unpleasant sensations are worse in the evening or night than during the day or 
only occur in the  evening or night (When symptoms are very severe, the worsening at night may 
not be noticeable but must have been previously present) 
 
 
Supportive clinical features for restless legs syndrome 
Family history 
Response to dopamingeric therapy 
Periodic limb movements (during wakefulness or sleep) 
 
 
Associated features of restless legs syndrome 
Natural clinical course, typically chronic and progressive 
Physical examination normal in primary RLS 
Sleep disturbance common in severely affected patients 
 
 
Diagnostic criteria are mandatory for a positive diagnosis of RLS. Supportive clinical features although not 
essential may help resolve diagnostic uncertainty. Associated features are typical but do not contribute to the 
diagnosis. Adapted from ref [20]. 
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Table 2. Telephone screening questions utilised in the study. 
 
 
Telephone Screening Questions 
 
1. Do you have, or have you sometimes experienced, a recurrent need or urge to move your legs 
while sitting or lying down? 
 
2. When present, do these uncomfortable feelings or this urge to move become worse when you 
are resting (either sitting or lying down), and relieved by movement? 
 
3. Are these uncomfortable feelings, or this urge to move, worse in the evening or at night, 
compared with the morning? 
 
4. During the last 12 months, have these uncomfortable feelings or sensations in your legs, or the 
need to move your legs while sitting or lying down, happened to you on average for one or 
more nights/days per week? 
 
A positive diagnosis requires that the respondent answer YES to the first 3 questions.  
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Table 3. Participant demographics within the RLS, PI and NRC groups (means with standard 
deviations in parentheses). 
 
Demographic RLS (n=15) PI  (n=15) NRC (n=15) F(2, 45)/χ2(2) p 
Age (years) 39.8 (13.7) 35.4 (9.8) 28.9 (4.2) 4.43 ‡ .018 
Gender (male/female) 6/9 5/10 8/7 1.28 .529 
BMI 25.8 (4.4) 23.6 (2.3) 23.5 (3.6) 1.98 .151 
Smoker (n) 3 3 2 .30 .859 
Alcohol 3.6 (5.4) 7.1 (9.8) 6.9 (9.7) .740 .483 
Snorer (n) 4 4 5 .213 .897 
 
 
*: indicates significant (P<.05) difference between RLS and PI with Tukey post-hoc Test 
‡: indicates significant (P<.05) difference between RLS and NRC with Tukey post-hoc Test 
†: indicates significant (P<.05) difference between PI and NRC with Tukey post-hoc Test 
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Table 4. Screening, clinical and sleep diary measures for the RLS, PI, and NRC groups (means 
with standard deviations in parentheses). 
  
Measure Overall  RLS (n=15) PI   (n=15) NRC (n=15) F(2, 45) p 
ISI 9.5 (6.8) 14.1 (5.9) 11.9 (5.2) 2.6 (1.8) 26.05‡† <.001 
PSAS COG  19.5 (7.2) 19.9 (6.1) 24.0 (8.1) 14.5 (3.3) 8.89† .001 
PSAS PHY  11.3 (4.1) 13.7 (4.1) 12.1 (4.3) 8.2 (0.6) 10.27‡† <.001 
PSQI 7.7 (4.4) 9.9 (4.2) 9.7 (3.3) 3.3 (1.4) 20.59‡† <.001 
EPWORTH 6.7 (4.4) 7.9 (4.8) 6.0 (4.1) 5.7 (4.3) 1.12 .337 
IRLS § 8.3 (10.8) 21.5 (7.5) 3.5 (5.3) N/A 7.61*‡ <.001 
SOL¶ 23.7 (14.6) 26.9 (17.1) 29.5 (12.4) 14.1 (10.0) 4.94† .013 
WAKE 2.0 (1.7) 2.4 (1.5) 2.7 (2.0) 1.0 (0.8) 5.04‡† .011 
WASO¶ 17.9 (23.0) 26.6 (23.2) 27.9 (27.0) 2.1 (1.8) 7.54‡† .002 
TST 6.7 (1.3) 6.1 (1.1) 6.3 (1.4) 7.5 (0.7) 7.24‡† .002 
TIB 7.9 (1.1) 8.1 (1.2) 7.8 (1.3) 7.9 (0.6) 0.18 .833 
SE 84.4 (13.4) 76.3 (14.0) 81.0 (12.3) 95.2 (4.3) 11.85‡† <.001 
SF36PH 81.5 (17.6) 67.3 (20.4) 85.0 (12.7) 92.0 (6.9) 11.67*‡ <.001 
SF36MH 74.9 (15.9) 64.8 (16.2) 75.0 (16.0) 84.9 (7.6) 7.90‡ .001 
BDI 7.5 (6.8) 10.6 (8.8) 7.9 (5.3) 4.1 (4.2) 3.94‡ .027 
 
§
 Independent samples t-test replaced the ANOVA as the IRLS was not relevant for the NRC group. 
¶
 Outliers removed from each group 
 
ISI: Insomnia Severity Scale; PSAS Cog: Pre-Sleep Arousal Scale Cognitive subscale; PSAS PHY: Pre-
Sleep Arousal Scale Physical Subscale; PSQI: Pittsburgh Sleep Quality Index; IRLS: International Restless 
Legs Syndrome Study Group RLS Severity Scale; EPWORTH: Epworth Sleepiness Scale; SOL: Sleep 
Onset; WAKE: Number of wakenings; WASO: Wake time after sleep onset; TST: Total Sleep Time; TIB: 
Total Time in Bed; SE: Sleep Efficiency {TST/TIB × 100}; SF36PH: Short Form 36 Version 2 Physical 
Health Subtotal; SF36MH: Short Form 36 Version 2 Mental Health Subtotal; BDI: Beck Depression 
Inventory (2nd Eds).  
 
*: indicates significant (P<.05) difference between RLS and PI with Tukey post-hoc Test 
‡: indicates significant (P<.05) difference between RLS and NRC with Tukey post-hoc Test 
†: indicates significant (P<.05) difference between PI and NRC with Tukey post-hoc Test 
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Table 5. SIT, Actigraphy and PANAS measures in RLS, PI and NRC groups (means with standard 
deviations in parentheses). 
 
Variable RLS (n=15) PI   (n=15) NRC (n=15) F(2, 45)/ 
χ²(2) p 
SIT index 51.5 (42.3) 19.7 (20.7) 19.9 (26.5) 5.15*‡ .010 
MDS 32.0 (23.6) 21.8 (15.4) 10.4 (5.0) 6.08‡ .005 
MMS 64.0 (18.8) 65.9 (18.1) 77.0 (15.9) 2.37 .106 
PLMS index§ 15.0 (14.8) 4.5 (4.9) 3.4 (3.8) 9.40*‡ .009 
PANAS pos 24.3 (7.6) 18.6 (5.6) 18.3 (5.1) 4.54*‡ .016 
PANAS neg§ 13.9 (3.5) 11.5 (1.6) 10.7 (1.1) 9.59*‡ .008 
PANAS neg 6-
item 9.6 (3.5) 7.2 (1.3) 6.6 (0.7) 7.58*‡ .023 
 
§ Kruskal Wallis Test and Mann-Whitney Tests for post-hoc pairwise comparisons 
 
SIT index: The number of PLMs during the Suggested Immobilisation Test; MDS: Mean discomfort Score; 
MMS: Mean Mood Score; PLMS index: The PLMS index for both legs combined averaged over 3 nights; 
PLMS time: The average time in minutes of PLMS in combined legs for all three nights; PANAS pos: 
Positive and Negative Affectivity Scale Positive Scale; PANAS neg: Positive and Negative Affectivity Scale 
Negative Scale. 
 
 
 
*: indicates significant (P<.05) difference between RLS and PI with Tukey post-hoc Test 
‡: indicates significant (P<.05) difference between RLS and NRC with Tukey post-hoc Test 
†: indicates significant (P<.05) difference between PI and NRC with Tukey post-hoc Test 
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Figure 1. Photograph of Suggested Immobilisation Test set up.  
 
 
 
Main photograph shows the context of the Suggested Immobilisation Test (SIT) and participant position, 
with two electrodes attached to the forehead and two electrodes attached to each leg. The photograph inset 
illustrates the positioning of the electrodes above the anterior tibialis muscles approximately 3cm apart. 
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Figure 2. Example from Stellate Harmonie Version 6 Software of Periodic Leg Movements. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure shows periodic leg movements detected by the surface electrodes above the right anterior tibialis 
muscle in a participant with RLS. Each green line represents 1 second.  
 105 
Figure 3. Positioning of AW4 Actiwatch (Cambridge Neurotechnology) on the foot. 
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Figure 4. Bar chart illustrating the results from the SIT for all three groups; RLS, PI and NRC. 
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SIT index: The number of PLMs during the Suggested Immobilisation Test; 
MDS: Mean discomfort Score; MMS: Mean Mood Score. 
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Figure 5. Scatterplot illustrating the association between negative affect and sensory discomfort in 
the RLS group. 
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ABSTRACT 
 
 
The aim of this reflective account is to chart my own professional development throughout 
training. I use excerpts from a reflection written at the beginning of my current placement to 
illustrate how my understanding of the role has grown. I discuss the usefulness of reflecting on 
learning experiences, using structured reflective models to facilitate reflection and how this 
contributes to my practice. By becoming a more reflective practitioner, I hope to always be aware 
of my internal influences that I bring to each session and therefore be a more competent therapist. 
Reflection or self-discovery can also show us the gaps in our knowledge and provide us with the 
impetus to continue life-long learning.  
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ABSTRACT 
 
Being on my last placement of my training has brought up a range of emotions – excitement, 
trepidation, and satisfaction. This account focuses on the Intended Learning Outcomes for this final 
placement; namely the ILOs concerned with working with an inter-professional and multi-agency 
approach and consultancy. A meeting with the manager of the CMHT were I am based stimulated 
my thoughts on working in partnership with Social Care. There was a clear sense that the 
psychologists in the team had been a real asset in creating a well-functioning team as is envisioned 
by the BPS document “Working Psychologically in Teams”. I then reflect on my own personal 
experiences of working in consultation with members of the CMHT, in particular a piece of work I 
carried out with a Community Psychiatric Nurse. My reflection has aided my future plans in terms 
of how I would want to improve this skill especially in view of my transition from trainee to 
qualified Clinical Psychologist approaching.    
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APPENDIX 1.1 
AUTHOR GUIDELINES FOR SUBMISSION TO MOVEMENT DISORDERS 
 
Movement Disorders Manuscript instructions 
 
Scope 
Movement Disorders publishes Reviews, Full-length Articles, Brief Reports, Clinical or Scientific Notes, and Letters. Case reports in 
which interesting diagnostic difficulties arose in which a definitive pathological or genetic diagnosis was ultimately made can be 
submitted for the Clinico-Pathological Grand Round section of the journal. The case history and the pathological findings should be 
submitted to the editors. If the editor determines that the report is appropriate for the Grand Round format two referees can be solicited 
to discuss the case and become co-authors of the report. All articles in Movement Disorders can be accompanied by a video when 
appropriate. 
Authors in Japan please note: Wiley-Japan can provide authors in Japan with a list of recommended services to check and improve the 
English in their papers before submission. Please contact Masayo Kobayashi in the Wiley-Japan office by Fax (81-3-3556-9763) or E-
mail (wileyjpn@mb.kcom.ne.jp) for more information. 
Full-Length Articles: Full-length articles present new data in any field related to movement disorders. Suggested length: Abstract up to 
200 words, text up to 2700 words, and up to 5 tables and/or figures, legends. The word count must appear on the title page.  
Reviews and Viewpoints: Clinical and basic science Reviews or Viewpoints that provide a position statement or summary are 
generally published upon request or after agreement with the editors of Movement Disorders. Authors interested in writing reviews 
should contact the respective Review Subspecialty Editor (Clinical or Basic Science). Authors interested in writing Viewpoints should 
contact the Editors-in-Chief. Suggested length will be individually discussed.  
Brief Reports: These are short reports, original studies, or evaluations. Suggested length: Abstract up to 150 words, text up to 1500 
words, and up to 2 tables, and/or figures, legends. The word count must appear on the title page. This section also includes brief video-
based reports of an interesting case or educational observations with a very brief clinical description. In addition, patient photographs or 
samples of imaging studies demonstrating a unique observation or educational point accompanied by a very brief commentary legend 
can be submitted.  
Letters allow publication of views and discussion of previously published material in the Journal or interesting observations (up to 800 
words total). This section is also the appropriate venue for single case histories without video.  
Clinical Trial Reports must be written in accordance with the Consolidated Standards of Reporting Trials (CONSORT) statement 
(Moher D et al., JAMA 2001;285:1987–1991; see also Moher D et al., Lancet 2001;357:1191–1194.) Authors should ensure that 
information on all of the critical design features listed in the CONSORT checklist is reported in the manuscript. (Reviewers are provided 
with the checklist to assess the manuscript for the relevant content.) The CONSORT flow diagram (figure) should be included with the 
manuscript, clearly outlining the flow of patients through the trial. In addition, a statement is required in the cover letter specifically 
confirming that there has been no ghost writing by anyone not named on the author list (see Editorial in Movement Disorders 
2005;20:1536). The precise financial relationship between a clinical trial sponsor and the authors must be delineated in the manuscript. 
 
Form of Manuscripts. 
The text of the manuscript should be in the following sequence: (1) Title page, (2) Abstract, (3) Introduction, (4) Methods, (5) Results, 
(6) Discussion, (7) Acknowledgment, (8) References, (9) Video Legend, (10 Figures, and (11) Tables. Pages should be numbered in 
succession, the title page being one. 
Title : Titles should be short, specific, and clear. They should not exceed 100 characters. Do not use abbreviations in the title. 
Title Page : The opening page of each manuscript should include only: (1) article title; (2) authors' names and affiliations; (3) name, 
address, and telephone and fax numbers of the person to whom proofs and reprint requests should be addressed; (4) word count; (5) 
any necessary footnotes to these items; and (6) a running title not exceeding 45 letters and spaces. Indicate the specific affiliation of 
each author by superscript, Arabic numerals. 
Abstract : The page following the title page of Full-Length Articles should include a brief abstract of up to 200 words describing the 
purpose, methods, results, and conclusions of the study. The page following the title page of a Brief Report or Clinical/Scientific Note 
should include a brief abstract of up to 100 words. 
Key words : Up to six key words or terms should be provided following the abstract. 
Introduction : Give a brief description of the background of the scientific contribution. 
Methods : Informed consent: For experimental investigation of human or animal subjects, state in this section that an appropriate 
institutional review board approved the project. For those investigators who do not have formal ethics review committees, the principles 
outlined in the “Declaration of Helsinki” should be followed. For investigations in human subjects, state in this section the manner in 
which informed consent was obtained from the subjects. A letter of consent must accompany all photographs, patient descriptions, and 
pedigrees in which a possibility of identification exists. The authors are responsible for proper anonymisation of their patients. 
Results : No specific regulations. 
Discussion : No specific regulations. 
Acknowledgment : Information concerning sources of financial support and funding should be placed in the Acknowledgement section. 
References : See “Details of Style” for the proper formatting of citations and References. 
Tables and Figure Legends : Double-space legends (use fewer than 40 words) to tables and figures. For photomicrographs, include 
the type of specimen, original magnification, and stain type. Include internal scale-markers on photomicrographs. Where applicable, 
indicate the method used to digitally enhance images. 
Tables should be typed neatly, each on a separate page, with a title above and any notes below. Explain all abbreviations. Do not 
repeat the same information in tables and figures or tables and text. 
Figures and Illustrations : Adapt any figures to an appropriate size of art and letters to make them readable in the printed version. 
Illustrations in full color are accepted at additional charge from the publisher. Any illustration or figure from another publication must be 
acknowledged in the figure legend, and the copyright holder’s written permission to reprint in print and online edition of Movement
Disorders must be submitted to the editors. 
 
Digital Artwork Preparation 
For best reproduction, electronic artwork files must be in TIFF or EPS format, at a resolution of 600 dpi or higher, sized to print. 
Movement Disorders offers Rapid Inspector ™ to help ensure that your electronic graphics files are suitable for print purposes. This 
free, stand-alone software application will help you to inspect and verify illustrations right on your computer. Go to 
http://rapidinspector.cadmus.com/wi/index.jsp and select Movement Disorders. 
 
Details of Style 
No patient identifiers (e.g., patient initials) are to be included in the manuscript or videotape (e.g., case reports, tables, figures, etc.). 
Units of measure : Conventional units of measure according to the Systeme International (SI) are preferred. The metric system is 
preferred for length, area, mass, and volume. Express temperature in degrees Celsius. 
Drug Names : Use generic names only in referring to drugs, followed in parentheses after first mention by any commonly used generic 
variant. 
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Abbreviations : Follow the list of abbreviations given in "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" (see 
section on References). For additional abbreviations, consult the CBE Style Manual (available from the Council of Biology Editors, 9650 
Rockville Pike, Bethesda, Maryland 20814, USA) or other standard sources. 
Spelling : American spelling is used throughout the Journal. 
 
References 
Movement Disorders complies with the reference style given in "Uniform Requirements for Manuscripts Submitted to Biomedical 
Journals". (See Annals of Internal Medicine 1982;96:766-771, or British Medical Journal 1982:284:1766-1770.) 
References are to be cited in the text by number, and in the list of References they are to be numbered in the order in which they are 
cited. The reference section should be double-spaced at the end of the text, following the sample formats given below. Provide all 
authors' names when fewer than seven; when seven or more, list the first three and add et al. Provide article titles and inclusive pages. 
Accuracy of reference data is the responsibility of the author. For abbreviations of journal names, refer to List of Journals Indexed in 
Index Medicus (available from the Superintendent of Documents, U.S. Government Printing Office, Washington DC 20402, USA, DHEW 
Publication No. (NIH) 83-267; ISSN 0093-3821). 
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3. Patrono C, Ciabattoni G, Pugliese F, et al. Effect of dietary variation in linoleic acid content on platelet aggregation and the major 
urinary metabolites of the E prostaglandins and (PGE-M) in infants. In: Hegyeli RJ, editor. Prostaglandins and cardiovascular disease. 
New York: Raven Press; 1981. p 111–122. (Atherosclerosis reviews; vol. 8). 
 
 
 115 
APPENDIX 2.1 
AUTHOR GUIDELINES FOR SUBMISSION TO SLEEP MEDICINE 
 
Manuscript Preparation 
Use double spacing throughout, including the reference section. Manuscripts should be organized as 
follows: Title page, Abstract, Introduction, Methods, Results, Discussion, References, Legends, and 
Tables and Figures. 
 
Title Page 
Authors' full names, academic or professional affiliations, and complete addresses must be included 
on the title page. The corresponding author must be indicated by an asterisk, and his/her full contact 
details must be included (telephone and fax numbers and e-mail address). 
 
Abstract 
A structured abstract of approximately 200 words is mandatory at the beginning of each article. The 
abstract should be organized by: Objective or Background, Methods, Results, and Conclusions. 
Review articles and case reports do not need a structured abstract. 
 
Keywords 
6-8 items must be included on the title page. Authors are encouraged to choose their own key words, 
but Medical Subject Headings (issued with the January Index Medicus, latest edition) may be used as 
a guideline. 
 
References 
References to literature must be indicated by Arabic numerals which run consecutively through the 
paper. Where a reference is cited more than once in the text the same number should be used each 
time. Reference style should follow the "Vancouver" style described in the "Uniform Requirements for 
Manuscripts Submitted to Biomedical Journals" (published in N Engl J Med 1997;336:309-315). The 
titles of journals should be abbreviated in conformity with Index Medicus. The following are sample 
styles: 
[1] Bondi M, Kaszniak A. Implicit and explicit memory in Alzheimer's disease and Parkinson's disease. 
J Clin Exp Neuropsychol 1991;13:339-358. 
[2] Wechsler D. Wechsler Adult Intelligence Scale. New York: Grune & Stratton, 1976. 
[3] Hirst W, Volpe B. Automatic and effortful encoding in amnesia. In: Gazzaniga M, editor. 
Handbook of cognitive neuroscience. New York: Plenum Press, 1984; p. 369-386. 
Please ensure that references are complete, i.e. that they include, where relevant, the author's name, 
article or book title, volume and issue number, publisher and publisher's location, and page reference. 
This journal should be abbreviated as Sleep Med. 
 
Figure and Table Legends 
Legends should be typed double spaced on a separate page and numbered with Arabic numerals 
corresponding to the illustrations. When symbols, arrows, numbers or letters are used to identify parts 
of the illustrations, each should be explained clearly in the legend. The legends should permit the 
figures to be understood with reference to the text. If the figure has been published previously a credit 
line should be included. 
 
Figures 
Figures of good quality should be submitted online as a separate file. Letters, numbers and symbols 
should be clear throughout and should be large to permit photographic reduction. 
Be sure that all spelling is correct, that there are no broken letters or uneven type, and that 
abbreviations used are consistent with those in the text. Use a label on the back of each figure to 
indicate the article's running title and the top of the figure. Do not write directly on the back of 
photographs. Do not trim, mount, clip or staple the illustrations. Submit photomicrographs in the final 
desired size. The colour transparency or negative should be supplied, in addition to colour prints. 
Photographs of recognizable persons should be accompanied by a signed release from the patient or 
legal guardian authorizing publication. Masking eyes to hide identity is not sufficient. 
 
Colour Reproduction 
For colour reproduction in print, a limited number of colour figures may be printed in the Journal 
without cost, at the discretion of the Editor, who will make the judgement based on the academic 
necessity of the colour illustrations. Otherwise you will receive information regarding the costs from 
Elsevier after receipt of your accepted article. For further information on the preparation of the 
electronic artwork, please see http://www.elsevier.com/artworkinstructions 
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Tables 
Tables should be submitted online as a separate file and should bear a short descriptive title. If a 
table must exceed one typewritten page, duplicate all headings on the second sheet. Number tables 
in the order in which they are cited in the text. Every column in the table should have an abbreviated 
heading. Define all abbreviations and indicate the units of measurements for all values. Explain all 
empty spaces or dashes. Indicate footnotes to the table with the superscript symbols cited in order as 
you read the table horizontally. 
 
Preparation of Supplementary Material (MultiMedia Components) 
Elsevier now accepts electronic supplementary material to support and enhance your scientific 
research. Supplementary files offer the author additional possibilities to publish supporting 
applications, movies, animation sequences, background datasets, sound clips and more. 
Supplementary files supplied will be published online alongside the electronic version of your article in 
Elsevier web products, including ScienceDirect (http://www.sciencedirect.com). In order to ensure that 
your submitted material is directly usable, please ensure that data is provided in one of our 
recommended file formats. Files can be stored on diskette, ZIP or Jaz-disk, or CD or DVD (either MS-
Windows or Macintosh). Authors should submit the material in electronic format together with the 
article and supply a concise and descriptive caption for each file. For more detailed instructions 
please visit http://elsevier.com/authors. 
 
Language Editing 
We have successfully negotiated with eight language editing companies to provide language editing 
services to our authors at competitive rates. American Journal Experts, Asia Science Editing, 
Diacritech Language Editing Services, Edanz Editing, International Science Editing, ScienceDocs 
Editing Services and SPI Publisher. 
Services provide language and copy editing services globally to authors who wish to publish in 
scientific, technical and medical peer-reviewed journals and would like assistance either before they 
submit an article for peer review or before it is accepted for publication. 
Use of an English-language editing service listed here is not mandatory, and will not guarantee 
acceptance or preference for publication in an Elsevier journal. Please note: Elsevier neither endorses 
nor takes responsibility for any products, goods or services offered by outside vendors through our 
services or advertised on this website. 
Please go to: http://www.elsevier.com/wps/find/authors.authors/languagepolishing for more 
information. 
 
Proofs 
Proofs will be sent to the first-named author of an article unless an alternative is requested on the title 
page of the manuscript. They should be checked carefully and returned to the publisher by airmail 
within 2 days of receipt. Only typesetting errors may be corrected: no changes in or additions to the 
edited original manuscript will be allowed at this stage. 
 
Reprints 
Reprints may be ordered by completing and returning to the Publisher the order form sent with the 
proofs. 25 free reprints per contribution will be made available. 
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Queries about a manuscript after its acceptance, especially those relating to proofs, publication and 
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APPENDIX 2.2 
 
 
 
 
Restless? 
 
 
 
Can’t sit still? 
Uncomfortable sensations in your legs? 
Does moving your legs help? 
 
You may be suffering from  
Restless Legs Syndrome (RLS) 
 
Do you find yourself walking or pacing, moving your legs and 
feet or tossing and turning in bed to stop the RLS?  
 
We are looking at the impact of a condition called RLS and 
require volunteers to take part. 
 
Although research shows that many people suffer with this 
difficult condition, it is often under recognised. We need to 
know more about the impact this condition has on people, 
for example, their sleep and mood.  
 
If you have answered yes to the above questions, or just 
consider that you are restless and that this can affect your 
sleep we are interested in hearing from you. 
 
If you would like more information about what is involved in 
participation in this research study, please contact: 
 
Lisa Galloway 
Mobile: 07514 404516 
Email: restlesslegssyndrome@googlemail.com 
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 SALETU ET AL EFFECT SIZE CALCULATION 
   
   
  
 
ƒ = φ' 
 
 
 
 
φ' =         ∑ (µ j - µ)²/k 
    σ²e 
  
  
 
 
 
φ' =         (29.6 – 34.9)² + (39.9 – 34.9)² + (35.1-34.9)²/ 3 
    4.6² + 8.5² + 7.3² /3 
 
 
 
 
φ' =   17.71 
  48.9 
 
 
 
φ' = 0.602 
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SLEEP DIARY 
 
 
 
 
Sleep Diary 
 
Name __________________________   ID#______________________ 
This diary helps both us and yourself to find out your sleep pattern and how you feel about your 
sleep. In order to get a precise picture of your night-by-night sleep and your feelings about it, it is 
essential that you fill in the diary every morning. Please remember that there is not a right or wrong 
answer but just the way you slept each night.  
 
Date started: Night 1 Night 2 Night 3 
1. What time did you rise from your 
bed this morning? 
   
2. At what time did you go to bed last 
night? 
   
3. How long did it take you to fall 
asleep? 
 
   
4. How many times did you awake 
during the night? 
   
5. How long were you awake during 
the night (in total)? 
   
6. About how long did you sleep 
altogether (hours/mins)? 
   
7. How many units of alcohol did you 
take last night? 
   
8. Did you take any sleeping tablets? 
(Y/N) 
 
   
Measuring the Quality of your sleep 
1. How was your sleep? 
0          1         2          3        4 
very   bad    so so   good   very  
bad                                    good 
   
2. How rested do you feel this 
morning? 
0          1         2          3         4 
not     little   so so    quite    very 
at all                                    good 
   
 
 
 
The 
RLS  
Project 
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BIOCALIBRATION  
 
 
 
 
Movement     Time 
 
Left foot toes back       :    :   .  
 
Right foot toes back      :    :   . 
 
Left foot toes forward      :    :   . 
 
Right foot toes forward      :    :   . 
 
Both feet toes back      :    :   . 
 
Both feet toes forward      :    :   . 
 
Lift left leg just off the bed     :    :   . 
 
Lift right leg just off the bed     :    :   . 
 
Both legs just off the bed      :    :   . 
 
PEN      :    :   . 
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ACTIWATCH INSTRUCTIONS 
 
 
 
 
 
 
 
 
Thank you for agreeing to take part in this study. Your participation is 
essential for future understanding of Restless Legs Syndrome.  
 
What to do: 
 
Each night: 
 
1. Each night just before you go to bed strap each actiwatch to each 
foot, with the monitor just below the big toe. Each watch is labelled on 
the back, either left or right. Please ensure you have put the watch on 
the correct leg.  
 
2. Make sure that the monitor is 
secure and will not slip from its 
position. You can use the tape 
provided to secure the actiwatch. 
 
3. Keep the actiwatches on throughout 
the night. 
 
4. When you get up in the morning 
remove the Actiwatches. 
 
 
 
 
 
Each morning:  
 
1. Please remember to fill in your sleep diary as soon as you get up 
when it is fresh in your mind. 
2.  This should only take 5 minutes or so. 
 
After the 3 nights please return the equipment and diary to the 
Sleep Research Centre, or we can arrange collection from your 
work or home. 
 
THANK YOU VERY MUCH FOR YOUR ASSISTANCE!!! 
The 
RLS  
Project 
 
Restless Legs Syndrome Project 
Actiwatch Instructions 
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ANOVAS WITH TRANSFORMED DATA 
 Descriptives
15 .5473 .40341 .10416 .3239 .7707 .00 1.11
15 .8462 .35581 .09187 .6492 1.0432 .00 1.26
15 .9175 .41314 .10667 .6887 1.1463 .00 1.49
45 .7703 .41556 .06195 .6455 .8952 .00 1.49
15 .6141 .14717 .03800 .5326 .6956 .30 .85
15 1.0127 .12851 .03318 .9415 1.0839 .85 1.23
15 1.0022 .19789 .05109 .8926 1.1118 .48 1.30
45 .8763 .24453 .03645 .8029 .9498 .30 1.30
15 .5107 .20079 .05184 .3995 .6219 .30 .85
15 1.0702 .20265 .05232 .9580 1.1825 .60 1.34
15 1.1284 .26247 .06777 .9830 1.2737 .30 1.41
45 .9031 .35656 .05315 .7960 1.0102 .30 1.41
15 1.9627 .03478 .00898 1.9435 1.9820 1.86 2.00
15 1.9245 .07036 .01817 1.8855 1.9634 1.77 2.00
15 1.8071 .14581 .03765 1.7263 1.8878 1.52 1.99
45 1.8981 .11493 .01713 1.8636 1.9326 1.52 2.00
15 .9130 .02745 .00709 .8978 .9282 .90 1.00
15 1.0582 .14409 .03720 .9784 1.1380 .90 1.30
15 1.1202 .12767 .03297 1.0495 1.1909 .95 1.34
45 1.0305 .14053 .02095 .9882 1.0727 .90 1.34
15 .0000 .00000 .00000 .0000 .0000 .00 .00
15 .3490 .51391 .13269 .0644 .6336 .00 1.18
15 1.3268 .15642 .04039 1.2402 1.4134 1.04 1.56
45 .5586 .64371 .09596 .3652 .7520 .00 1.56
15 .9025 .69282 .17889 .5188 1.2862 .00 1.92
15 1.0835 .53547 .13826 .7870 1.3800 .00 1.86
15 1.5247 .48571 .12541 1.2557 1.7937 .70 2.14
45 1.1702 .62358 .09296 .9829 1.3576 .00 2.14
15 .9986 .25577 .06604 .8569 1.1402 .40 1.26
15 1.1881 .51893 .13399 .9007 1.4754 .00 1.79
15 1.3840 .36233 .09355 1.1834 1.5847 .78 1.91
45 1.1902 .41665 .06211 1.0650 1.3154 .00 1.91
Controls
Restless controls
RLS
Total
Controls
Restless controls
RLS
Total
Controls
Restless controls
RLS
Total
Controls
Restless controls
RLS
Total
Controls
Restless controls
RLS
Total
Controls
Restless controls
RLS
Total
Controls
Restless controls
RLS
Total
Controls
Restless controls
RLS
Total
TRANSBDI
TRANSPSQI
TRANSISI
TSF36PHY
TPSASphy
TIRLS1
TSITPLM1
TMDS1
N Mean Std. Deviation Std. Error Lower Bound Upper Bound
95% Confidence Interval for
Mean
Minimum Maximum
ANOVA
1.158 2 .579 3.775 .031
6.440 42 .153
7.598 44
1.548 2 .774 30.034 .000
1.083 42 .026
2.631 44
3.490 2 1.745 34.839 .000
2.104 42 .050
5.594 44
.197 2 .099 10.794 .000
.384 42 .009
.581 44
.339 2 .170 13.465 .000
.529 42 .013
.869 44
14.192 2 7.096 73.770 .000
4.040 42 .096
18.232 44
3.073 2 1.536 4.597 .016
14.037 42 .334
17.110 44
1.114 2 .557 3.587 .036
6.524 42 .155
7.638 44
Between Groups
Within Groups
Total
Between Groups
Within Groups
Total
Between Groups
Within Groups
Total
Between Groups
Within Groups
Total
Between Groups
Within Groups
Total
Between Groups
Within Groups
Total
Between Groups
Within Groups
Total
Between Groups
Within Groups
Total
TRANSBDI
TRANSPSQI
TRANSISI
TSF36PHY
TPSASphy
TIRLS1
TSITPLM1
TMDS1
Sum of
Squares df Mean Square F Sig.
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Post Hoc Tests 
 
Multiple Comparisons
Tukey HSD
-.29895 .14299 .104 -.6463 .0484
-.37027* .14299 .034 -.7177 -.0229
.29895 .14299 .104 -.0484 .6463
-.07133 .14299 .872 -.4187 .2761
.37027* .14299 .034 .0229 .7177
.07133 .14299 .872 -.2761 .4187
-.39864* .05863 .000 -.5411 -.2562
-.38815* .05863 .000 -.5306 -.2457
.39864* .05863 .000 .2562 .5411
.01049 .05863 .983 -.1319 .1529
.38815* .05863 .000 .2457 .5306
-.01049 .05863 .983 -.1529 .1319
-.55956* .08172 .000 -.7581 -.3610
-.61770* .08172 .000 -.8162 -.4192
.55956* .08172 .000 .3610 .7581
-.05814 .08172 .758 -.2567 .1404
.61770* .08172 .000 .4192 .8162
.05814 .08172 .758 -.1404 .2567
.03825 .03491 .522 -.0466 .1231
.15563* .03491 .000 .0708 .2404
-.03825 .03491 .522 -.1231 .0466
.11738* .03491 .005 .0326 .2022
-.15563* .03491 .000 -.2404 -.0708
-.11738* .03491 .005 -.2022 -.0326
-.14526* .04100 .003 -.2449 -.0457
-.20725* .04100 .000 -.3068 -.1076
.14526* .04100 .003 .0457 .2449
-.06198 .04100 .296 -.1616 .0376
.20725* .04100 .000 .1076 .3068
.06198 .04100 .296 -.0376 .1616
-.34897* .11325 .010 -.6241 -.0738
-1.32681* .11325 .000 -1.6019 -1.0517
.34897* .11325 .010 .0738 .6241
-.97784* .11325 .000 -1.2530 -.7027
1.32681* .11325 .000 1.0517 1.6019
.97784* .11325 .000 .7027 1.2530
-.18101 .21110 .670 -.6939 .3319
-.62220* .21110 .014 -1.1351 -.1093
.18101 .21110 .670 -.3319 .6939
-.44119 .21110 .104 -.9540 .0717
.62220* .21110 .014 .1093 1.1351
.44119 .21110 .104 -.0717 .9540
-.18951 .14391 .394 -.5391 .1601
-.38545* .14391 .028 -.7351 -.0358
.18951 .14391 .394 -.1601 .5391
-.19595 .14391 .370 -.5456 .1537
.38545* .14391 .028 .0358 .7351
.19595 .14391 .370 -.1537 .5456
(J) Group
Restless controls
RLS
Controls
RLS
Controls
Restless controls
Restless controls
RLS
Controls
RLS
Controls
Restless controls
Restless controls
RLS
Controls
RLS
Controls
Restless controls
Restless controls
RLS
Controls
RLS
Controls
Restless controls
Restless controls
RLS
Controls
RLS
Controls
Restless controls
Restless controls
RLS
Controls
RLS
Controls
Restless controls
Restless controls
RLS
Controls
RLS
Controls
Restless controls
Restless controls
RLS
Controls
RLS
Controls
Restless controls
(I) Group
Controls
Restless controls
RLS
Controls
Restless controls
RLS
Controls
Restless controls
RLS
Controls
Restless controls
RLS
Controls
Restless controls
RLS
Controls
Restless controls
RLS
Controls
Restless controls
RLS
Controls
Restless controls
RLS
Dependent Variable
TRANSBDI
TRANSPSQI
TRANSISI
TSF36PHY
TPSASphy
TIRLS1
TSITPLM1
TMDS1
Mean
Difference
(I-J) Std. Error Sig. Lower Bound Upper Bound
95% Confidence Interval
The mean difference is significant at the .05 level.*. 
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SUPPLEMENTARY ANALYSES  
 Questionnaire Data Analysis with Age as a Covariate 
 
Tests of Between-Subjects Effects 
 
Dependent Variable: SF36PHtotal  
Source 
Type III Sum 
of Squares df Mean Square F Sig. 
Corrected Model 4887.315(a) 3 1629.105 7.666 .000 
Intercept 23258.069 1 23258.069 109.442 .000 
Age 29.706 1 29.706 .140 .710 
Group 3846.953 2 1923.476 9.051 .001 
Error 8713.107 41 212.515     
Total 312254.777 45       
Corrected Total 13600.421 44       
a  R Squared = .359 (Adjusted R Squared = .312) 
 
 Tests of Between-Subjects Effects 
 
Dependent Variable: SF36MHtotal  
Source 
Type III Sum 
of Squares df Mean Square F Sig. 
Corrected Model 3659.701(a) 3 1219.900 6.746 .001 
Intercept 12368.292 1 12368.292 68.395 .000 
Age 631.311 1 631.311 3.491 .069 
Group 3659.701 2 1829.850 10.119 .000 
Error 7414.326 41 180.837     
Total 263603.877 45       
Corrected Total 11074.027 44       
a  R Squared = .330 (Adjusted R Squared = .281) 
 
 
 
 Tests of Between-Subjects Effects 
 
Dependent Variable: Insomnia Severity Index Total Score  
Source 
Type III Sum 
of Squares df Mean Square F Sig. 
Corrected Model 1120.295(a) 3 373.432 16.957 .000 
Intercept 310.449 1 310.449 14.097 .001 
Age 
.162 1 .162 .007 .932 
Group 944.779 2 472.389 21.451 .000 
Error 902.905 41 22.022     
Total 6113.000 45       
Corrected Total 2023.200 44       
a  R Squared = .554 (Adjusted R Squared = .521) 
 
 
 
 127 
APPENDIX 2.8 
 
 Tests of Between-Subjects Effects 
 
Dependent Variable: Pittsburgh Sleep Quality Questionnaire Global score  
Source 
Type III Sum 
of Squares df Mean Square F Sig. 
Corrected Model 445.254(a) 3 148.418 14.887 .000 
Intercept 86.394 1 86.394 8.666 .005 
Age 22.454 1 22.454 2.252 .141 
Group 295.085 2 147.543 14.800 .000 
Error 408.746 41 9.969     
Total 3499.000 45       
Corrected Total 854.000 44       
a  R Squared = .521 (Adjusted R Squared = .486) 
 
 
 
 Tests of Between-Subjects Effects 
 
Dependent Variable: Pre-sleep Arousal Scale Cognitive total  
Source 
Type III Sum 
of Squares df Mean Square F Sig. 
Corrected Model 690.677(a) 3 230.226 5.972 .002 
Intercept 1514.021 1 1514.021 39.275 .000 
Age 14.944 1 14.944 .388 .537 
Group 678.221 2 339.110 8.797 .001 
Error 1580.523 41 38.549     
Total 19324.000 45       
Corrected Total 2271.200 44       
a  R Squared = .304 (Adjusted R Squared = .253) 
 
 Tests of Between-Subjects Effects 
 
Dependent Variable: Pre-sleep Arousal Scale Physical Total  
Source 
Type III Sum 
of Squares df Mean Square F Sig. 
Corrected Model 242.074(a) 3 80.691 6.698 .001 
Intercept 396.977 1 396.977 32.952 .000 
Age 
.340 1 .340 .028 .867 
Group 193.382 2 96.691 8.026 .001 
Error 493.926 41 12.047     
Total 6516.000 45       
Corrected Total 736.000 44       
a  R Squared = .329 (Adjusted R Squared = .280) 
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Tests of Between-Subjects Effects 
 
Dependent Variable: EPWORTH test Total Score  
Source 
Type III Sum 
of Squares df Mean Square F Sig. 
Corrected Model 43.308(a) 3 14.436 .727 .542 
Intercept 146.243 1 146.243 7.368 .010 
Age 
.064 1 .064 .003 .955 
Group 38.682 2 19.341 .974 .386 
Error 813.803 41 19.849     
Total 2791.000 45       
Corrected Total 857.111 44       
a  R Squared = .051 (Adjusted R Squared = -.019) 
 
  
 Tests of Between-Subjects Effects 
 
Dependent Variable: RLS Rating Scale for Severity Total  
Source 
Type III Sum 
of Squares df Mean Square F Sig. 
Corrected Model 2437.530(a) 2 1218.765 28.175 .000 
Intercept 303.704 1 303.704 7.021 .013 
Age 7.530 1 7.530 .174 .680 
Group 2295.456 1 2295.456 53.066 .000 
Error 1167.936 27 43.257     
Total 8268.000 30       
Corrected Total 3605.467 29       
a  R Squared = .676 (Adjusted R Squared = .652) 
 
 Tests of Between-Subjects Effects 
 
Dependent Variable: Pre-sleep Arousal Scale Physical Total  
Source 
Type III Sum 
of Squares df Mean Square F Sig. 
Corrected Model 21.291(a) 2 10.646 .587 .563 
Intercept 404.031 1 404.031 22.290 .000 
Age 
.458 1 .458 .025 .875 
Group 18.985 1 18.985 1.047 .315 
Error 489.409 27 18.126     
Total 5503.000 30       
Corrected Total 510.700 29       
a  R Squared = .042 (Adjusted R Squared = -.029) 
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Tests of Between-Subjects Effects 
 
Dependent Variable: Beck Depression Inventory v.2 Total Score  
Source 
Type III Sum 
of Squares df Mean Square F Sig. 
Corrected Model 493.829(a) 3 164.610 4.334 .010 
Intercept 685.226 1 685.226 18.040 .000 
Age 170.096 1 170.096 4.478 .040 
Group 475.009 2 237.504 6.253 .004 
Error 1557.371 41 37.985     
Total 4605.000 45       
Corrected Total 2051.200 44       
a  R Squared = .241 (Adjusted R Squared = .185) 
 
 Tests of Between-Subjects Effects 
 
Dependent Variable: PANAS Positive Affect 
Source 
Type III Sum 
of Squares df Mean Square F Sig. 
Corrected Model 559.241(a) 4 139.810 3.979 .008 
Intercept 622.039 1 622.039 17.702 .000 
Age 88.525 1 88.525 2.519 .120 
BDItotal 56.636 1 56.636 1.612 .212 
Group 238.475 2 119.237 3.393 .044 
Error 1405.559 40 35.139     
Total 20692.000 45       
Corrected Total 1964.800 44       
a  R Squared = .285 (Adjusted R Squared = .213) 
 
 Tests of Between-Subjects Effects 
 
Dependent Variable: PANAS Negative Affect 
Source 
Type III Sum 
of Squares df Mean Square F Sig. 
Corrected Model 83.795(a) 4 20.949 3.755 .011 
Intercept 336.402 1 336.402 60.292 .000 
Age 
.335 1 .335 .060 .808 
BDItotal 
.799 1 .799 .143 .707 
Group 54.501 2 27.250 4.884 .013 
Error 223.183 40 5.580     
Total 6811.000 45       
Corrected Total 306.978 44       
a  R Squared = .273 (Adjusted R Squared = .200) 
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Tests of Between-Subjects Effects 
 
Dependent Variable: PANASneg6item  
Source 
Type III Sum 
of Squares df Mean Square F Sig. 
Corrected Model 78.076(a) 4 19.519 3.961 .008 
Intercept 161.116 1 161.116 32.693 .000 
Age 1.631 1 1.631 .331 .568 
BDItotal 
.223 1 .223 .045 .833 
Group 56.992 2 28.496 5.782 .006 
Error 197.124 40 4.928     
Total 3013.000 45       
Corrected Total 275.200 44       
a  R Squared = .284 (Adjusted R Squared = .212) 
 
 Tests of Between-Subjects Effects 
 
Dependent Variable: PANASneg6item  
Source 
Type III Sum 
of Squares df Mean Square F Sig. 
Partial Eta 
Squared 
Corrected Model 77.923(a) 4 19.481 3.950 .009 .283 
Intercept 173.644 1 173.644 35.208 .000 .468 
Age 1.827 1 1.827 .370 .546 .009 
BDIminusSleep 
.070 1 .070 .014 .906 .000 
Group 59.216 2 29.608 6.003 .005 .231 
Error 197.277 40 4.932       
Total 3013.000 45         
Corrected Total 275.200 44         
a  R Squared = .283 (Adjusted R Squared = .211) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Pairwise Comparisons 
 
Dependent Variable: PANASneg6item  
(I) Group (J) Group 
Mean 
Difference 
(I-J) Std. Error Sig.a 
95% Confidence Interval for 
Difference(a) 
Upper Bound Lower Bound 
Controls Restless controls -.719 .878 1.000 -2.913 1.476 
RLS 
-3.196* 1.003 .008 -5.702 -.689 
Restless controls Controls 
.719 .878 1.000 -1.476 2.913 
RLS 
-2.477* .850 .017 -4.600 -.354 
RLS Controls 3.196* 1.003 .008 .689 5.702 
Restless controls 2.477* .850 .017 .354 4.600 
Based on estimated marginal means 
*  The mean difference is significant at the .05 level. 
a  Adjustment for multiple comparisons: Bonferroni. 
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Differences between groups on Mean Sensory Discomfort with SIT PLM index as a covariate. 
 
 
 
Estimated Marginal Means 
Group 
 
 
Tests of Between-Subjects Effects
Dependent Variable: Sensory Discomfort Rating Average
3650.666a 3 1216.889 4.458 .008 .246
7650.484 1 7650.484 28.027 .000 .406
319.793 1 319.793 1.172 .285 .028
2250.071 2 1125.036 4.122 .023 .167
11191.568 41 272.965
35035.924 45
14842.234 44
Source
Corrected Model
Intercept
SITPLMindex
Group
Error
Total
Corrected Total
Type III Sum
of Squares df Mean Square F Sig.
Partial Eta
Squared
R Squared = .246 (Adjusted R Squared = .191)a. 
Estimates
Dependent Variable: Sensory Discomfort Rating Average
11.275a 4.350 2.490 20.060
22.742a 4.354 13.948 31.536
29.534a 4.601 20.242 38.827
Group
Controls
Restless controls
RLS
Mean Std. Error Lower Bound Upper Bound
95% Confidence Interval
Covariates appearing in the model are evaluated at the following
values: SITPLMindex = 30.3556.
a. 
Pairwise Comparisons
Dependent Variable: Sensory Discomfort Rating Average
-11.467 6.033 .193 -26.527 3.592
-18.260* 6.560 .024 -34.634 -1.886
11.467 6.033 .193 -3.592 26.527
-6.792 6.568 .921 -23.188 9.603
18.260* 6.560 .024 1.886 34.634
6.792 6.568 .921 -9.603 23.188
(J) Group
Restless controls
RLS
Controls
RLS
Controls
Restless controls
(I) Group
Controls
Restless controls
RLS
Mean
Difference
(I-J) Std. Error Sig.a Lower Bound Upper Bound
95% Confidence Interval for
Differencea
Based on estimated marginal means
The mean difference is significant at the .05 level.*. 
Adjustment for multiple comparisons: Bonferroni.a. 
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SUMMARY 
 
 
 
 
 
Restless legs Syndrome is a sensorimotor disorder characterised by unpleasant sensations in the 
legs when at rest that are only relieved by movement. RLS is associated with deterioration in 
quality of life. Depression is a common comorbid affective disorder found in those with RLS. 
Possible mechanisms for this association are described, including the impact of periodic leg 
movements during sleep (PLMS). The present study aims to establish whether RLS is an 
independent risk factor for depressive symptoms by comparing 3 groups of RLS suffers, restless 
controls (a primary insomnia group), and normal controls. There will be 10-15 participants 
recruited to each group.  There are 3 primary dependent measures of mood with differing time 
periods. The Beck Depression Inventory (BDI-II), Positive and Negative Affect Schedule 
(PANAS), and a visual analogue scale (VAS). The PANAS will relate to affect during a suggested 
immobilization test (SIT) which will be used to provoke and measure RLS symptoms. The VAS 
will be concurrent with the SIT ad the BDI-II will measure depressive symptoms over a two week 
period. New actigraphy techniques will be used to measure PLMS over 4 nights at home. Between 
group differences will be analysed using ANOVAs for each of the 3 dependent variables. Initial 
analyses will reveal whether there are any covariates, whereby an ACOVA will be necessary.  
Bonferroni correction for multiple comparisons will be applied. 
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APPENDIX 3.1 
MRP Proposal 
 
Investigating the Link between Depression and Restless Legs Syndrome: A 
Controlled Comparison of Mood and Motor Restlessness in Restless Legs Syndrome, 
with Restless and Normal Controls 
 
Restless legs syndrome (RLS) is described by sufferers as creeping or tingling sensations mostly 
occurring deep within the legs, coupled with an inescapable desire to move the affected limbs. 
Movement brings only momentary relief and symptoms appear to get worse when at rest. Many 
people with RLS also complain of sleep disturbance related to the RLS symptoms occurring at 
night. It is usually the impact of the insomnia that leads people to seek treatment. 
 
However, at present there is no cure for this condition and the aetiology has not yet been 
established. Current treatments include diet, exercise, iron supplement, and drug therapy such as 
dopamine antagonists and benzodiazepines. There are two kinds of RLS: primary and secondary. 
Primary or idiopathic RLS can have a childhood onset and slowly progresses, worsening with age. 
Secondary RLS usually occurs late in life and linked to medical conditions or side-effects of 
medication. 
 
Phillips et al (2000) found a 10% prevalence rate of at least weekly RLS symptoms amongst adults 
in their population sample in North America. Hening et al (2004) estimated a prevalence of 9.6% of 
weekly occurring RLS symptoms in a large multi-national primary care population. Even so RLS 
remains under diagnosed and there is increasing research evidence demonstrating the negative 
impact of the condition on the sufferer’s quality of life.  
 
RLS can cause insomnia in sufferers of the condition. However this differs from primary insomnia 
or classic insomnia which is a psychophysiological disorder. With primary insomnia, people have 
mainly been conditioned not to sleep by sleep-preventing habits and this is then maintained by 
excessive worry about sleep (Morin & Espie, 2003). The proposed mechanism by which RLS 
sufferers have disturbed sleep is the increasing sensory discomfort as they lie at rest in bed and the 
compelling need to move their legs. Whilst those with primary insomnia may complain of 
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restlessness and hyper-arousal whilst trying to get to sleep this is quite separate from the specific 
symptoms of RLS which is a sensorimotor disorder. However is not yet known if the experience of 
restlessness in these two groups differs. A control group consisting of people with primary 
insomnia who complain of restlessness is therefore a useful comparison to decipher whether the 
impact of RLS on sleep, and consequently mood, is similar to that found in primary insomnia, or 
whether the motor restlessness compounds the difficulties common to RLS. The present study will 
therefore recruit three distinct groups: people with RLS; people with primary insomnia; and normal 
good-sleeper matched controls. 
 
It is also thought that periodic leg movements during sleep (PLMS) may reduce the quality of sleep 
in RLS sufferers even if they are not occurring when the person is awake. PLMS are described as 
extensions of the big toe followed by dorsiflexions of the foot sometimes with flexion of the knees 
and hips (Michaud et al, 2001) and occur in 80% of RLS sufferers (Montplaisir et al, 1997). These 
movements can also be observed whilst awake during periods of inactivity. PLMS and periodic 
legs movements during wakefulness (PLMW) are usually measured by surface electromyogram 
(EMG) channels placed on the right and left anterior tibialis muscle. According to the scoring 
method, these movements last 0.5-10 seconds and are separated by intervals ranging from 4 to 90 
seconds.  
 
As with many other conditions, including sleep disorders, the rate of depression is higher in people 
with RLS compared to control groups (Sevim et al, 2004). Winkelmann et al (2005) compared rates 
of depression between people with RLS and a community sample of people suffering from other 
somatic conditions. The results suggested that RLS sufferers are at increased risk of psychological 
distress. This finding is important as it demonstrates that people with RLS could be more at risk of 
developing depressive symptomatology than people with other somatic conditions such as diabetes 
or cardiovascular disorders. The elevated rate of depression in RLS creates a problem for the 
clinical management of this group as antidepressants can aggravate restless leg symptoms. There is 
conflicting research in the literature, as well as expert opinion, about the effects of anti-depressant 
medication on RLS symptom severity and the use of dopamine agonists as antidepressants. 
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Depression is the mood disorder predominantly associated with RLS and therefore the impact of 
RLS symptoms on mood and positive and negative affect will be explored.  
 
A clinical and neurophysiological study by Saletu and Colleagues (2002) looked at daytime brain 
function in RLS and Periodic Limb Movement Disorder (PLMD) compared to matched-controls 
and also investigated objective and subjective sleep and awakening quality in a subset of the 
sample versus controls. The EEG mapping revealed neurophysiological correlates of depression in 
RLS which was verified by self-report data. The greatest differences between RLS patients and 
controls occurred in the EEG measures that in depression showed the highest correlation to the 
Hamilton Depression score (the centroid of the delta/theta and alpha power and the dominant 
frequency and relative alpha 1 and alpha 2 power). They also revealed decreased sleep efficiency in 
the RLS group compared to controls, but there was no increased daytime sleepiness.  
 
Hornyak et al (2005) investigated the relationship between RLS symptom severity, sleep 
disturbances, and depressive symptoms. They used questionnaire data from 100 people with 
idiopathic RLS who had attended their sleep clinic in order to compare self-reported sleep quality 
and depressive symptoms (measured by the PSQI and BDI respectively) with the International RLS 
Study Group Rating Scale (IRLS). They found that depressive symptoms in patients with RLS 
seemed to be related to subjective impairment of sleep (r = 0.281, p = 0.007) rather than to 
subjective reports of RLS severity (r = 0.119, p = 0.237). However it would be interesting to 
investigate whether introducing a more objective measure of RLS severity during the night would 
further explain the RLS-depression pathway. Also the use of a control group would help 
circumvent the problem of the overlapping sleep items on the BDI and IRLS.  
 
The reason or reasons for the observed increased comorbidity of RLS and Depression is currently 
unknown. There are a number of possibilities.  
 
Firstly, the Overlap in the symptoms of depression and RLS could lead to people being 
misdiagnosed. Of the nine symptoms of depression listed in DSM-IV, four of them could be a 
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consequence of RLS: insomnia/hypersomnia; fatigue; psychomotor agitation or retardation; and 
diminished ability to concentrate or indecisiveness. Only the presence of five out of nine 
symptoms, including depressed mood or anhedonia, for over two weeks, are required for a 
diagnosis of depression.  
 
Secondly it could be that being depressed makes a person more sensitive to mild RLS symptoms 
and heightens the impact of RLS on the individual, but depression as a direct cause of RLS is 
questionable. More likely is that RLS is an independent risk factor for depression just as other sleep 
disorders have been found to be, due to the consequences of disturbed sleep and in severe cases a 
restriction on their lifestyle.  
 
Lastly, another possibility is a neurological deficit that causes both symptoms of RLS and 
depression to happen simultaneously. Dopamine deficiency has been suggested to play a part in the 
aetiology of RLS and selective serotonin uptake inhibitor (SSRI) anti-depressant medication has 
been shown to worsen RLS, whilst a low dose dopamingeric agonist has improved symptoms 
(Teiv, Quadros, Barros & Wernech; 2002). It is unclear whether RLS and Depression comorbidity 
is a consequence of a common pathophysiological pathway. 
 
The present study approaches the area of RLS and depression from the viewpoint of RLS being 
potentially an independent risk factor for depression. Below is an excerpt from a comprehensive 
book on RLS which provides insight into a RLS sufferer’s experience: 
“As I pass a window I peer at the outer, unfriendly impenetrable darkness. I wonder how 
many miles I’ve walked since sundown. A 26 mile marathon? I feel like it. Whatever is 
plaguing me holds tightly and does not want to let me go. What have I done to cause this? 
What is stealing my sleep every night and why? Like a slow, dreamy sleep walker, I crawl 
into bed. Tears seep from the corners of eyes. Maybe I do have witches blood in my veins 
like Jack says.”                    
 (From Wilson; 1996; p35) 
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This qualitative account clearly demonstrates the impact of RLS on this individual’s mood and 
indicates some of the negative cognitions surrounding locus of control and helplessness.  In order 
to investigate the association of RLS with depression, one of the possible mechanisms, sleep 
disturbance will be investigated, specifically, the role of periodic limb movements during sleep 
(PLMS). To further our understanding of the influence of motor restlessness on psychological 
distress, the level of positive and negative feelings will be explored by comparing those with RLS 
to restless controls and non-restless controls during an experimental procedure designed to elicit 
symptoms. The Suggested Immobilization Test (SIT) is used as a diagnostic test for RLS. 
Electromyogram (EMG) recordings are taken from both legs during a one hour period of voluntary 
immobility. RLS sufferers show three times more leg movements during the SIT than controls (76 
± 9.6 vs. 29.9 ± 16.6) (Montplaisir et al, 1998). In addition to being a useful assessment of the 
validity of our group allocation procedure, this test will be used to create the sensory experience of 
RLS in our participants in order to observe the direct impact on affect. 
 
Watson et al (1987) found a significant correlation between the severity of depression and the 
number of apnoeas/hypopnoeas per hour of sleep. This is an important potentially confounding 
factor, as many people with obstructive sleep apnoea (OSA) have also been found to have elevated 
levels of depression and PLMS (Schröder & O'Hara, 2005). The focus of the present study is 
related to the influence of PLMS on levels of depression in RLS and therefore people suffering 
from OSA will be excluded.  
 
By measuring the periodic leg movements in individuals with RLS during sleep we can explore 
what impact this has on subjective quality of sleep and level of depressive symptomatology. 
Hornyak et al (2004) investigated whether periodic leg movements in sleep (PLMS), measured by 
polysomnography (PSG), were associated with subjective quality of sleep in people with RLS, 
primary insomnia and secondary insomnia. They found a significant correlation between PLMS 
and subjective sleep quality in those with RLS (n=33) on the first night. It was not significant on 
the second night and they concluded that the first night result may be due to more superficial sleep 
as a result of being in the laboratory environment. However the night-to-night variability of the 
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PLMS index has been well-documented (Montplaisir et al, 1997). Monitoring PLMS over more 
than 2 nights and within the person’s home environment may elucidate whether such an association 
exists.  
 
Owing to new actigraph technology it is now possible to measure PLMS in a person’s home 
environment. A new technique has developed by Cambridge Neurotechnology Ltd that measures 
Periodic Limb Movement (PLM) in both legs simultaneously by an actiwatch device on each foot, 
which is then combined to give an index of PLM (PLM per hour). This gives a direct objective 
measurement of movement in the lower limbs. Using actigraphy as apposed to polysomnography 
and EMG means that you can obtain measurements over a longer period of time, assessing of the 
night-to-night variability of PLMs, without the need for lengthy inpatient investigation.  
 
In order to elucidate further the link between RLS and depression this study will measure positive 
and negative affect following a Suggested Immobilization Test (SIT) and whether there is a 
relationship to RLS severity. Assuming that sleep disturbance modulates the level of depression in 
people with RLS, this study postulates that PLMS play a role in the sleep disturbance in those with 
RLS and is correlated with severity of RLS and therefore with the level of depression.  
 
AIMS AND HYPOTHESES 
The aim of the present study is to compare levels of depressive symptoms, positive and negative 
affect in three groups: RLS group (RLS), restless control group (RC) and non-restless control 
group (NRC). In order to establish whether RLS is an independent risk factor for depression, taking 
into account PLMS, which may influence the level of sleep disturbance. The main hypothesis 
postulates that the groups will differ in levels of positive and negative affect following the SIT. The 
RLS group is expected to have higher levels of negative affect than RC group and NRC group. The 
NRC group will have higher levels of positive affect than the RLS and RC groups. There are a 
number of secondary hypotheses: a) higher PLM index scores as measured by actigraphy will be 
positively related to the level of depression reported on the BDI in the RLS group; b) the mean 
level of sensory discomfort score (MDS) during the SIT will be highest in the RLS group and 
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lowest in the NRC group and will be positively correlated with level of negative affect; c) 
participants with RLS will have a greater SIT PLM and PLMS index than RCs and NRCs. The RCs 
will have a greater SIT PLM and PLMS index than NRCs; and d) the PLM index will be negatively 
correlated with subjective reports of sleep quality in the RLS group. 
 
In addition a subset of the sample will be examined using objective laboratory based tests to check 
that the methodology for separating those with and without RLS has been reliable.  
 
METHOD 
Design 
The study employs a between-groups design. It will compare three groups: RLS group (RL), 
restless control group (RC) and a non-restless control group (NRC). The independent variables will 
be the presence or absence (depending on the group) of: (1) sleep disturbance, (2) “Restlessness”, 
(3) motor disorder, and (4) primary psychiatric disorder. There are three primary dependent 
variables which consist of three different measures of psychological distress over different time 
periods: a retrospective measure, the BDI, will be used as a standard measure of depressive 
symptomatology over the previous two weeks; an attributional measure, the PANAS, looking at the 
feelings related to the 60 minutes duration of the SIT; and a concurrent measure of mood, a visual 
analogue scale, taken throughout the SIT. 
 
Participants 
The participants will be recruited for the study from the general population by advertisements 
inviting people fulfilling certain criteria to contact the researcher (see appendix for a flowchart of 
participant flow through the study). A telephone screening will establish those meeting the minimal 
diagnostic criteria as outlined by the International RLS study group, which state that RLS is 
characterised by (1) an urge to move accompanied by unpleasant sensations in the legs and 
symptoms that (2) occur mostly in the evening and at night, (3) worsen during periods of rest, and 
(4) are relieved by movement (Allen et al, 2003). Volunteers who provide written informed consent 
will enter the study and be allocated to one of three groups based on the outcome of the face-to-
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face interview and their responses to the screening questionnaires: RLS group (RLS); restless 
control group (RC); or non-restless control group (NRC).  Exclusion criteria screened for include: 
age, <18years old or >80years old; diagnosis of major depression or bipolar disorder; prescribed 
medication to aid sleep; sleep apnoea, kidney disease; and pregnancy. Those in the restless control 
group will complain of restlessness that affects the quality of their sleep but will not fulfil criteria 
for RLS (verified by a high score on the Pre-Sleep Arousal Scale; PSAS; Nicassio et al, 1985). The 
normal control or non-restless control group must have no motor problems or movement disorders 
and a score < 8 on the Insomnia Severity Index (ISI; Morin; 1993). A subset of the sample will be 
randomly selected for review by the Director of the University of Glasgow Sleep Research 
Laboratory to ensure that the grouping criteria are reliable. 
 
Sample Size Estimation 
Given that the relationship between SIT-PLM (as a measure of RLS severity) and psychological 
distress has not been directly compared in previous studies the effect size is unknown. The power 
of the present study will be increased by strict adherence to the grouping protocol in order to 
reduce within-group variability. Using data from the study by Saletu et al (2002) a very large effect 
size is found (f = 0.6) for the difference between PLS, PLMD and controls on measures of anxiety 
and depression. Therefore a priori sample size calculations for a one-way ANOVA design, using 
an effect size of 0.5 (a more conservative estimate), significance level set at 0.05 and standard 
power of 0.8, suggests a sample size of 14 per group. It is proposed that at least 15 participants will 
be recruited to each of the three groups and with a maximum of 20 in each group. These numbers 
are also similar to that in the study by Montplaisir et al (1998) who recruited 16 people with RLS 
with 16 age-matched controls, and detected a significant difference in SIT PLM (28.4 vs. 5.0; p< 
0.01) and PLMS index (76.1 vs. 26.9; p <0.001).  
 
Measures 
Screening and Group Allocation 
Potential participants will be screened using the following measures: 
- The IRLSSG essential criteria for RLS. 
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- Pre-Sleep Arousal Scale (PSAS; Nicassio et al; 1985)  
- Insomnia Severity Index (ISI; Morin;1993)  
- Sleep history questionnaire 
For each participant the following data will be collected and reviewed before the groups are 
allocated. 
- RLS severity (IRLSSGRS; The International Restless Legs Syndrome Study Group 
rating scale; 2003)  
- Subjective sleep quality (PSQI Pittsburgh Sleep Quality Index ; Buysse et al; 1988) 
Descriptive Measures 
- Quality of life (SF-36) 
- Other important information gathered at interview will include Alcohol, smoker/non-
smoker, medical history, medications, BMI etc. 
Hypotheses Testing 
- Positive and Negative Affect (Positive and Negative Affectivity Schedule; PANAS; 
Watson et al; 1988) 
- Depression (The Beck Depression Inventory Second Edition; BDI-II; Beck et al; 
1996). Although the BDI has a strong somatic component, it has been commonly used 
in studies of RLS. However for the present study it shall be used as a secondary 
measure, with the PANAS being the primary measure. 
- Visual Analogue Scales (VAS) as a measure of sensory discomfort in their legs 
throughout the SIT. 
 
Experiment 
Participants will be asked to complete a daytime Suggested Immobilization test (SIT) in which they 
will be instructed to sit on a bed at a 45º angle and not to voluntarily move their legs for a period of 
one hour.  Every 5 minutes participants will be asked to rate the discomfort in their legs on a visual 
analogue scale (VAS). The descriptors on the 100mm horizontal  line will be taken from an 
established VAS that was added to the standard SIT procedure by Michaud et al (2002a); ranging 
from “no discomfort” on the left to “extreme discomfort” on the right.. The 12 discomfort scores 
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will then be averaged to give a mean discomfort score (MDS). The MDS has been found to 
correctly classify 82.7% of all subjects in a RLS group and a control group with a sensitivity of 
82% and a specificity of 84% (Michaud et al, 2002b). Periodic Leg movements (PLM) will be 
measured using electromyogram channels attached to the anterior tibialis muscles of both legs. The 
SIT PLM will be calculated in accordance with recent criteria defined by Michaud et al (2001). 
Criteria for scoring PLMS are appropriate for the SIT apart from leg movement duration which has 
been increased from 0.5-5s to 0.5-10s. A cut-off score for SIT PLM  of 12 was found to have a 
sensitivity of 62% and a specificity of 84% and is recommend when testing people with varying 
levels of symptom severity (Michaud et al, 2002b). Participants will then be asked to rate their 
performance on the test on another VAS and current level of positive and negative feelings on the 
PANAS (Watson et al, 1988). The test will be taken by the participants in a 3 hour time period, to 
minimise the affects of individual differences in circadian rhythm.  
 
Actigraphy 
The participants’ leg movements during sleep will be measured at home using the Actiwatch, 
produced by Cambridge Neurotechnology which is taped to each foot at the base of the big toe. The 
analysis software allows movements that occur simultaneously in both legs to be scored as a single 
movement. The adaptations made by Moorish et al (2002) to the American Sleep Disorders 
Association (ASDA) criteria for scoring PLMS normally measured by EMG during PSG will also 
be used in the present study in order to reduce the chance of artificially inflating the number of 
PLMS due to the lowest epoch being two seconds. Participants will be given instructions to wear 
the actiwatch devices on both feet for four nights and fill out a sleep diary each morning. Four 
nights will enable an average PLM index to be produced within a limited timeframe.  
 
Confirmatory Measures 
- Daytime Sleepiness (Epworth Sleepiness scale) 
- The SIT PLM index, PLMS index and the MDS will also contribute to the 
confirmation of group allocation. NRCs should have a PLMS index < 10. RLS 
sufferers should have a SIT index > 12 and a MDS >11 
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- Those not meeting the above criteria will be excluded from the study. 
 
Procedure 
Volunteers will be screened by telephone using information regarding sleep history, medical 
history and restlessness. Potential participants who do not meet any of the exclusion criteria will be 
invited to attend the University of Glasgow Sleep Laboratory, where they will be given more 
information about the study and provide informed written consent before proceeding to the next 
stage - a face-to-face interview with the researcher and completion the self-report measures. At this 
stage any evidence of a sleep-related breathing disorder will require further assessment and review 
by the clinical team and will be withdrawn from the study. They will be either placed in the RLS 
positive group or the RLS negative group. A group of good sleeper controls will also be recruited 
in a similar way. Participants from all three groups will be asked to complete the Suggested 
Immobilization Test (SIT).  The researcher will then set up the EMG equipment and carry out the 
necessary biocalibration procedure. Participants will rate their sensory discomfort and mood on a 
visual analogue scale every 5 minutes throughout the 1 hour duration of the test. After the test they 
will be asked to rate their affect during the SIT using the Positive and Negative Affect Schedule 
(PANAS; Watson et al; 1988). If the data from the self-report questionnaires indicate that they do 
not meet criteria for the allocated group, they will be re-allocated or excluded from the study. 
Following the SIT, participants will be given instructions regarding the use of the Actiwatches. 
They will be required to wear the Actiwatches on both legs for a period of four nights. They will 
also be required to fill in a sleep diary during this period. Following the actigraph measurement 
they will be asked to return with the monitors and diaries, when they will be given the opportunity 
to discuss and any problems.  The actiwatch data will be electronically summed using PLM 
software designed by Cambridge Neurotechnology. The average PLM index for each participant 
will be calculated from all four nights’ data. Data from the SIT and actigraphy will be used to 
confirm that the group allocation was accurate. 
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PRACTICAL ISSUES: SETTING, TIMING AND EQUIPMENT 
Setting 
Contact details will include a mobile number and an email address. The mobile will have answer 
machine set to ask for a name and phone number for those times when it cannot be answered. The 
appointments will take place at the University of Glasgow Sleep Laboratory at the Southern 
General Hospital. The participants will be able to use the actiwatch to monitor their sleep/leg 
movements at home. 
 
Timing 
The timing for the study once the main recruitment has taken place is estimated to be 
approximately 4 months based on recruiting 3 participants per week. This will largely depend on 
the number of Actiwatches we are able to obtain for the study and therefore how many participants 
may be going through the monitoring stage of the study.  
 
Equipment 
- EMG equipment and monitor 
- Mini actiwatch from Cambridge Neurotechnology Ltd. 
- PLM Software also from Cambridge Neurotechnology Ltd.  
 
DATA ANALYSIS 
Preliminary analysis will be conducted on the demographic data to check that the groups are 
similar. Any differences will be added as a covariate in the main analysis. Confirmatory analysis 
will be carried out on the screening measures to check that groups differ as appropriate on each of 
the independent variables. The main hypotheses will be tested by analysing the differences between 
the groups using three univariate ANOVAs for each of the 3 dependent variables. If a significant 
difference is found a Bonferroni correction for multiple comparisons will be applied to the analysis 
and the ANOVAs repeated. Also correlation analyses of the actigraph data in the form of the PLM 
index and subjective sleep quality, RLS severity and depression will be performed. If found to 
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significantly correlate with either of the dependent variables, PLMS will be introduced to the 
analysis and the ANOVAs will be modified to ANCOVAs were necessary. 
 
ETHICS 
• Informed Consent  
• Confidentiality and data protection – anonymised data and secure data storage.    
• Evidence of a severe affective disorder will be reviewed by the clinical team and 
appropriate referrals made. 
• Evidence of a sleep-related breathing disorder e.g. sleep apnoea will necessitate further 
assessment which will be carried out by Prof. Espie.  
• Ensure good instructions re actiwatch to prevent failure and wasting participants time 
• Participant time kept to a minimum 
• This is not an intervention study, however if there are concerns regarding any of the 
participants scores on the BDI their General Practitioner will be contacted. 
• A feedback mechanism will be put in place to enable participants to gain more knowledge 
about the nature of their condition and its impact on sleep.  
 
HEALTH AND SAFETY ISSUES 
• Lone working: local NHS policy will be followed at all times. 
• EMG electrodes are adhesive and may cause minor skin irritation.  
o Care will be taken when applying and removing the EMG electrodes.  
• The Suggested Immobilization Test is expected to be challenging but not distressing for the 
RLS group. 
 
FINANCIAL ISSUES 
• A full costing checklist will be submitted separately for the study.  
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Appendix: Flowchart of Participant flow through the study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
START Recruitment: 
Advertisement via posters, 
emails and leaflets 
(Health Centres) 
Contact details given 
Telephone screening:  
Quick checklist 
 
Those with 
exclusion criteria 
RLS positives and 
restless control group 
FINISH 
Appointment (1hour 30mins) 
• Go over information and Consent sheet (e.g. 
right to withdraw, Confidentiality) 
• Fill in questionnaires 
• Provide and go through written instructions for 
actiwatch and sleep diary 
• Complete SIT and affect measures 
Information sheet sent with 
confirmation of appointment 
time and location (inc map 
and travel details) 
Return appointment: 
• Actiwatch returned 
• Any problems discussed 
• Make arrangements to give feedback 
if requested 
FINISH 
1 WEEK LATER 
Those with 
exclusion criteria 
FINISH 
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APPENDIX 3.3 
 
PARTICIPANT INFORMATION SHEET 
 
 
Investigation of the Link between Restless Legs Syndrome and Mood.  
 
Introduction 
You are invited to take part in a research study that is being carried out by the University of 
Glasgow.  Before you decide, it is important for you to understand why the research is being 
carried out and what is involved.  Please take some time to read the following carefully and 
discuss it with friends and relatives if you wish.  Please ask if you would like more 
information or if there is anything that is not clear. 
 
What is the purpose of the study?   
Restless legs syndrome (RLS) can impact sufferers in a number of ways. We want to 
investigate further the impact of RLS on sleep quality and mood. It is important to understand 
how this condition affects sleep and mood. We want to find out whether people with RLS 
differ from others suffering from insomnia in their levels of positive and negative feelings. It 
is hoped that this study may increase awareness of the difficulties faced by sufferers of RLS. 
 
Why have I been Chosen? 
People who complain of the symptoms of RLS are invited to take part in the study. These are 
defined as: (1) an urge to move accompanied by unpleasant sensations in the legs and 
symptoms that (2) occur mostly in the evening and at night, (3) worsen during periods of rest, 
and (4) are relieved by movement. 
 
We will also need some people to take part in the study who do not have any of the above 
symptoms in order to compare results.  
 
Do I have to take part? 
It is entirely up to you whether you take part or not.  If you decide to take part you will be 
given this information sheet to keep and asked to sign a consent form.  If you decide to take 
part you are still free to withdraw at any time without giving a reason.  A decision to 
withdraw at any time or a decision not to take part will not affect the standard of care you 
receive.  
 
What will happen to me if I take part? 
If you decide to take part, you will be contacted by the main researcher by telephone. 
Whether you are selected to take part in the study will depend on your answers to a number 
of questions. If selected at this stage you will be invited to the University of Glasgow Sleep 
Research Laboratory (Southern General Hospital) for a short interview and asked to fill out 
some questionnaires. We will then carry out a test (Suggested Immobilization Test; SIT) that 
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would be helpful to wear baggy clothing so that you are more comfortable. We will ask you 
to rate your discomfort and mood during and immediately following the test. The final stage 
of the study involves wearing a small device called an actiwatch at the base of the big toe for 
three nights and filling in a sleep diary each morning. You will be given full instructions 
before taking the device home. You will be asked to return the device and diaries to the sleep 
laboratory and given the opportunity to discuss any queries or problems.  
 
What will the researcher do with the information? 
The researcher will write a research dissertation on the effects of RLS on mood and sleep for 
the University of Glasgow, and will also aim to publish the results of the study in a relevant 
scientific journal. If you would like a summary of the results of the study, the researcher will 
provide you with one.   
Will my taking part in the study be kept confidential?  
Your identity and personal information will be completely confidential and known only to the 
researcher. 
 
What are the possible disadvantages or risks of taking part? 
There are no risks or disadvantages of taking part. However you might experience some 
discomfort when the electrodes are removed, much in the same way as removing a plaster. 
 
What are the potential benefits of taking part? 
The Suggested Immobilization Test is a reliable diagnostic test for RLS. Taking part in the 
study will provide further assessment of the condition and give an objective measure of 
symptom severity.  
 
Who is organizing and paying for the research? 
This research study is organised by Lisa Galloway, Doctoral Research Student (University of 
Glasgow), and funded by University of Glasgow.  Educational supervision of this research is 
provided by Professor Colin Espie, University of Glasgow.   
 
 
Contact for further information 
If you have any questions about the study please contact Lisa Galloway at the: 
University of Glasgow Sleep Research Laboratory 
Sackler Institute of Psychobiological Research 
Southern General Hospital  
1345 Govan Road 
Glasgow  
G51 4TF 
Email: restlesslegssyndrome@googlemail.com 
Telephone: 07514 404 516 
 
 
                                                                                                                  
Thank you for your time and co-operation.                        
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